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Intrauterine growth restriction (IUGR) increases risks of perinatal death >5-fold, and 
has lifelong adverse effects on health. There is currently no treatment to prevent or 
cure IUGR, although animal studies have shown promising effects of maternal growth 
hormone (GH) treatment on fetal and placental growth. The overall aim of this project 
was to test a novel approach to stimulate the mother’s own production of GH, to 
promote placental function and fetal growth in normal and IUGR pregnancies, and 
hence develop a therapy to prevent IUGR which is acceptable to patients.  
My first aim was to investigate whether the abundance or activation of the GH 
secratagogue, ghrelin, increased during pregnancy or in response to dietary 
supplementation with octanoic acid, which is required for activation (acylation) of 
ghrelin. Maternal circulating total and acyl-ghrelin and GH profiles were measured in 
late pregnant mice and in aged-matched non-pregnant females, fed a diet 
supplemented with octanoic or palmitic (control) acid. However, dietary 
supplementation did not increase the activation of ghrelin in female mice, whilst the 
pregnancy-associated increase in maternal GH secretion occurred without elevated 
circulating acyl-ghrelin concentrations.  
The second aim was to develop a novel method to measure placental function, a major 
determinant of fetal growth, using non-radioactive tracers in mice. A dye containing 
fluorescently-labelled glucose was injected into pregnant dams near term, and its 
maternal, placental and fetal uptake were characterised. Although the results indicated 
that this tracer was not specific for placental glucose uptake, its uptake provided a 
good indication of overall placental function and fetal nutrient uptake.  
Lastly, in order to test potential interventions, a murine model of IUGR in multiple 
pregnancies was established. Mouse pregnancies were generated by transferring 
XII 
variable numbers of embryos into pseudo-pregnant mice, generating litters with varying 
degrees of maternal constraint near term. Fetuses from the largest litters were ~25% 
lighter as well as thinner and with evidence of brain-sparing, compared to fetuses from 
smaller litters. Interestingly, the relationship between viable litter size and fetal weight 
differed between sexes, such that fetal weights of males, but not females, correlated 
negatively with litter size. However, this sex difference was not explained by 
morphological and functional changes in the placenta. The results of this experiment 
suggested that male fetuses grew as fast as permitted by nutrient supply, whereas the 
female maintained placental reserve capacity. This strategy, likely reflecting sex-
specific gene expression, would be expected to place the male fetus at greater risk of 
death in the face of any additional intrauterine stressors.  
In conclusion, the dietary supplementation trialled in this project did not promote fetal 
growth in normal pregnancies or stimulate responses in the mother that would promote 
fetal growth in growth restricted pregnancies. However, this project has generated 
valuable new tools to help investigate and ultimately address the major clinical 
challenge of poor growth before birth. The development and optimisation of this IUGR 
model will now allow us to combine genetic models in mice with testing of intervention 
strategies to prevent IUGR due to chronic restriction. 
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Chapter 1 Literature review  1 
1.1 Maternal adaptations to pregnancy  2 
A female undergoes significant anatomical and physiological adaptations in order to 3 
support the developing conceptus while still being able to cope with the increased 4 
metabolic and physical demands of pregnancy. Changes in maternal physiology occur 5 
progressively throughout pregnancy, as the metabolic demands of the conceptus 6 
increase [1-3]. Most of the information below is derived from investigations in human 7 
pregnancies, however, similar maternal adaptations during pregnancy are also 8 
observed in rodents.   9 
During early pregnancy, maternal systemic vascular resistance decreases by 25-30%, 10 
which in turn contributes to a decrease in maternal diastolic blood pressure during the 11 
first and second trimesters [4, 5]. In response, cardiac output increases by ~30-50% 12 
and the renin-angiotensin-aldosterone system (RAAS) is activated early in pregnancy, 13 
thereby promoting sodium and water retention and contributing to the progressive 14 
increase in plasma volume [6-8]. The resulting increase in total maternal blood volume, 15 
as well as cardiac output allows enhanced blood flow to the uterus and placental 16 
perfusion to promote its growth and development [5, 9, 10]. Besides adaptations to the 17 
cardiovascular system, a number of other maternal systems also undergo significant 18 
changes during pregnancy. These include mechanical alterations to the chest wall and 19 
diaphragm to accommodate the enlarging uterus and increased maternal ventilation to 20 
meet the significant increase in oxygen demand [11, 12]. Pregnancy-associated 21 
increases in circulating progesterone concentrations are associated with decreased 22 
gastric contractility and delayed gastrointestinal transit time, possibly to allow a longer 23 
time for absorption of nutrients [13-15].  24 
2 
In order to cope with the increased energy demands of pregnancy, significant 25 
alterations occur to the maternal metabolic and endocrine state. Hyperplasia of insulin-26 
secreting pancreatic β-cells in early pregnancy results in increased maternal insulin 27 
secretion compared to the non-pregnant state. Maternal insulin resistance develops in 28 
skeletal, adipose and hepatic tissues during mid-late pregnancy by the actions of 29 
placental hormones like human placental lactogen, progesterone, cortisol and prolactin, 30 
and this ensures availability of maternal glucose to maintain an adequate fetal glucose 31 
supply [16, 17]. In addition to effects on glucose metabolism, early human pregnancy is 32 
associated with increased insulin sensitivity in white adipose tissue, giving rise to 33 
adipocyte hypertrophy, increased lipogenesis and lipid storage [16, 18, 19]. An average 34 
pregnant woman gains ~2.5 kg of fat mass [20], while abdominal fat mass doubles by 35 
late pregnancy in rats [21]. Hepatic glycogen storage also increases and hepatocytes 36 
undergo hypertrophy and hyperplasia to meet the demands of pregnancy in both 37 
humans and mice [22, 23].  38 
The maternal insulin-resistant state also contributes to increased lipolysis and hepatic 39 
gluconeogenesis in the latter part of pregnancy. This in turn allows the mother to 40 
preferentially use fat for fuel, while preserving glucose and amino acids for the fetus 41 
[24]. Pregnancy-associated increases in maternal food intake and decreases in energy 42 
expenditure, observed in humans and rodents, allow maintenance of a positive energy 43 
balance and supply of nutrients to the fetus [3, 20, 25, 26]. Collectively, these 44 
adaptations minimise maternal protein catabolism to supply the nutrients required for 45 
accelerating fetal growth. The increase in maternal weight during pregnancy occurs 46 
predominantly during the second and third trimesters, and in addition to fat deposition 47 
and increase in maternal blood volume, reflects growth of the fetus, placenta and fetal 48 
membranes, amniotic fluid, as well as expansion of uterine tissue and mammary 49 
glands (Figure 1.1) [2, 3, 27]. In litter-bearing species, including mice, the gravid uterus 50 
accounts for approximately 30% of maternal weight at term. However, in species like  51 
3 
 52 
Figure 1.1 Comparison of changes in fetal (green line), placental (purple dashes) and 53 
maternal weight (black dots) during pregnancy in humans (top figure) and mice (bottom 54 
graph) and periods of conceptus development. Term in humans is  typically 37-41 55 
weeks from the last menstrual period (LMP), implantation occurs around 6 days post-56 
ovulation, and the embryonic period with developmental events such as gastrulation 57 
and organogenesis is completed by 10 weeks of gestation/ since LMP, or the end of 58 
the first trimester. Fetal growth and maturation then continues from 11 weeks’ gestation 59 
until birth. In mice, gestation lasts for approximately 20 days post conception, 60 
implantation occurs around gestational day (GD)4.5, at the beginning of the embryonic 61 
period. Gastrulation occurs on ~GD6.5 and is shortly followed by organogenesis on 62 
~GD8.5, and the fetal growth phase begins by GD14.5 and continues until birth. 63 
4 
Maternal, fetal and placental weight data extracted from [3, 28-30];mouse fetal and 64 
placental weight data are from CD-1 mice [28]; mouse maternal weight data is from 65 
C57BL/6J mice [3].  66 
humans and sheep, that typically only bare one fetus at a time, about 6-9% of maternal 67 
weight is attributable to the fully developed conceptus (Figure 1.1) [2]. 68 
1.2 Fetal growth 69 
The process of growth and development within the uterus from fertilisation until birth 70 
can be categorised into three phases: the pre-implantation phase, the embryonic phase 71 
and the fetal phase (Figure 1.1). Prior to implantation, the fertilised zygote undergoes 72 
rapid cell cleavage without increasing in size to form a blastocyst, which implants into 73 
the maternal uterine decidua (endometrium) and where subsequent development takes 74 
place. Post-implantation, organ primordia form during the embryonic phase and 75 
undergo further extensive expansion and remodelling during the fetal phase (Figure 76 
1.1). In humans, the pre-implantation and embryonic stages take place during weeks 1-77 
2 and 2-8 weeks post conception (2-4 weeks and 4-10 weeks since the first day of the 78 
last menstrual period; LMP), respectively. The fetal period begins from the 9th week of 79 
development (11 weeks LMP) and continues until term (typically 37-41 weeks LMP) 80 
[31] although women are usually told their estimated date of delivery is 40 weeks’ LMP. 81 
Mice have a much shorter gestation than humans (typically 19-21 days post-82 
conception, depending on the strain [32]). Therefore, stage of development is usually 83 
indicated by gestational age, with the night of mating designated as gestational day 84 
(GD)0, and the following morning, when the copulation plug is detected in the female, 85 
marked as GD0.5. Implantation in mice occurs around GD4.5, and gastrulation 86 
(~GD6.5) is shortly followed by organogenesis (~GD8.5), and by GD14.5, the fetal 87 
growth phase begins and continues until birth (Figure 1.1). Hence, mice spend 88 
approximately two-thirds of gestation (up to GD14.5) undergoing important 89 
development events such as gastrulation and organogenesis and spend a 90 
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comparatively shorter period of time in utero undergoing fetal maturation and growth. 91 
Consequently, a significantly greater proportion of these maturational events and 92 
growth continue into the postnatal period in mice. Conversely, humans only spend 93 
around one-fifth of the gestation in the embryonic phase and a significantly longer 94 
period is spent in the fetal period [33]. As a result, human infants are more 95 
developmentally mature than mouse pups at birth [34, 35].  96 
1.2.1 Fetal sex  97 
It is now well established in humans, sheep and rodents that males grow faster in utero 98 
and on average, are heavier than females at an equivalent gestational age [36-39]. 99 
Since fetal growth is largely dependent on the capability of the placenta to facilitate 100 
materno-fetal exchange, sex-specific developmental disparities are likely in part 101 
orchestrated by the placenta, which shares the same sex as the fetus [40-42]. The 102 
rapid growth observed in male fetuses is associated with a higher fetal to placental 103 
weight ratio than for females, and may mean that male fetuses have limited placental 104 
reserve capacity to draw upon in the event of perturbations experienced later in 105 
gestation [43]. This in turn, is believed to put them at a higher risk of inadequate 106 
nutrient supply and growth restriction, hence increasing their risk of developing adult-107 
onset disorders like cardiovascular disease [44, 45]. In contrast, females appear to 108 
invest more in placental development, and have a better chance of survival in the face 109 
of suboptimal intrauterine conditions [46, 47]. As a result of their different growth 110 
strategies, the incidence of pregnancy complications differs between sexes; while 111 
intrauterine growth restriction (IUGR) is more prevalent in females [48], males have 112 
higher rates of severe placental dysfunction, spontaneous preterm birth and perinatal 113 
death if they experience an intrauterine perturbation [44, 49-53]. As an example, in the 114 
presence of maternal asthma, female fetuses slow their growth and are therefore 115 
protected from adverse fetal outcomes and stillbirth in the face of an exacerbation of 116 
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maternal asthma in late gestation [54]. In contrast, male fetuses of asthmatic women 117 
maintain normal growth across gestation, and are therefore at increased risk of 118 
intrauterine death, stillbirth and being born SGA [55].  119 
There is now good evidence indicating that differences in fetal outcomes in response to 120 
the same intrauterine challenge are likely to be associated with sex-specific 121 
morphological and/or functional adaptations made by the placenta. RNA sequencing 122 
analyses of sex differences in placental gene expression indicate that almost half are 123 
X-linked [56, 57]. Placental global gene microarray conducted on placentas from non-124 
asthmatic and asthmatic women revealed that the number of genes whose expression 125 
was significantly impacted by maternal asthma was 10-fold higher in female placentas 126 
compared to male placentas [58]. Furthermore, the changes in placental gene 127 
expression in females were associated with the suppression of immune and growth 128 
factor pathways, and would thus be expected to lower fetal growth rate [58]. 129 
Conversely, the relatively conserved placental gene expression in males may account 130 
for the maintenance of fetal growth in an adverse maternal environment [58]. 131 
Furthermore, genes of the VEGF signalling pathway, implicated in placental 132 
development and angiogenesis, also demonstrate general sex-bias [41]. Such sex-133 
specific expression of genes involved in placental development pathways may 134 
influence key placental processes, such as establishment of the placental vascular 135 
architecture [41, 59].Consistent with this hypothesis, uterine artery Doppler 136 
measurements from uncomplicated singleton pregnancies show higher pulsatility index, 137 
and higher prevalence of notching, in women carrying a male fetus, reflecting higher 138 
utero-placental resistance [60]. 139 
As a result of sex differences in the placenta and fetal growth rates, the male fetus is 140 
more susceptible to suboptimal placentation and less capable of adapting to adverse 141 
conditions than the female fetus [41, 44, 61]. This has clinical implications, since it 142 
implies that male and female fetuses may respond differently to the same intervention. 143 
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Therefore, it is also crucial for studies evaluating mechanisms contributing to fetal 144 
growth or growth restriction, and testing interventions, to analyse feto-placental 145 
outcomes separately within each sex [40, 61].  146 
 147 
1.3 Placental development  148 
The placenta is the interface between the mother and fetus and performs a number of 149 
crucial functions that are essential for the maintenance of a successful pregnancy. It 150 
mediates exchange of nutrients and gases between the maternal and fetal 151 
compartments, prevents the semi-allogeneic fetus from being rejected by the mother’s 152 
immune system and produces a range of peptide and steroid hormones that mediate 153 
the changes in maternal physiology and metabolism described above [62].  154 
Both humans and mice have haemochorial placentas, where the tissue separating the 155 
maternal blood from fetal circulation consists of only fetal tissues (chorionic trophoblast 156 
and allantoic mesenchyme and vasculature) [63]. Additionally, both species have a 157 
haemochorial placental interface, as interactions between the materno-fetal blood 158 
circulations involves the direct contact of maternal blood and chorionic trophoblast [63]. 159 
However, the pattern of branching of these trophoblast layers to form the area of 160 
materno-fetal exchange differs between the two species.  161 
In humans, chorionic villi form a complex, highly branched villous tree structure, and 162 
each villus is bound by a single syncytiotrophoblast layer in contact with maternal 163 
blood. Inside the villus is a layer of cytotrophoblast and the basement membrane, while 164 
the central part of the villus contains fetal mesenchyme and vessels. Maternal blood 165 
flows in from the decidual spiral arteries into the intervillous space and flows around 166 
these terminal villi. This requires the modification of uterine spiral arteries from tight 167 
spirals with high-resistance, low-flow, to wide conduits with low-resistance high-flow 168 
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blood vessels [64]. Spiral artery remodelling occurs during the first few weeks of 169 
pregnancy when maternal vascular endothelial and smooth muscle cells are lost from 170 
the spiral arteries and replaced by fetal trophoblast cells, resulting in at least 10-fold 171 
increase in their diameter [65]. This is also accompanied by a reduction in the 172 
responsiveness of the vessels to vasoconstrictors [65]. The exchange of gases and 173 
metabolic products between the materno-fetal circulations hence takes place across 174 
the chorionic membrane [66]. Oxygen and nutrients are transported across the 175 
chorionic membrane into fetal blood and carried to the fetal circulation via the umbilical 176 
vein, maternal blood in the intervillous space leaves via the decidual veins and uterine 177 
vein [67].  178 
The maternal side of the murine placenta comprises of the maternal decidua, a layer of 179 
maternal tissue similar to the human decidua basalis. It also comprises of maternal 180 
vessels that traverse it to supply the placenta [63]. A layer of trophoblast giant cells 181 
separates the decidua from the junctional zone, which structurally supports the 182 
labyrinth throughout its development and comprises spongiotrophoblasts, trophoblast 183 
giant and glycogen cells. These cells have endocrine and invasive properties and can 184 
also provide an energy source for the developing fetus. This layer is discontinuous due 185 
to the presence of trophoblast-lined arterial and venous channels but does not contain 186 
any fetal blood vessels. Distal to the junctional zone, the labyrinth forms the interface 187 
for materno-fetal nutrient and gas exchange in the murine placenta. Compared to the 188 
human placenta, the branches of the main chorionic projections of the mouse placenta 189 
are much more interconnected, giving rise to the maze-like or labyrinthine structure. 190 
Three layers of trophoblast cells separate the maternal blood spaces from fetal 191 
endothelium. Maternal blood spaces are lined by a discontinuous layer of cuboidal, 192 
mononuclear cytotrophoblast cells, while the middle and third layers comprise of 193 
elongated and multinucleated syncytiotrophoblast cells [68, 69]. Maternal blood enters 194 
the maternal blood spaces of the labyrinth through amuscular spiral arteries that 195 
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converge together at the trophoblast giant cell layer into a central arterial canal that 196 
passes through to the base or fetal side of the placental labyrinth. Similar to the pattern 197 
of placental development in humans, remodelling of murine spiral arteries to permit 198 
increased blood flow occurs in the first third of pregnancy [70]. Blood then percolates 199 
back to the maternal side of the placenta through tortuous, highly interconnected, 200 
trophoblast lined sinusoids in the labyrinth [70]. These sinusoids join to form larger 201 
channels that traverse the junctional and giant cells layers and lead into large, 202 
endothelial cell-lined, maternal venous sinuses in the decidua [70]. Fetal blood passes 203 
through the labyrinth in a counter-current direction to the maternal blood. Feto-204 
placental arterioles pass through the apical side of the labyrinth before branching into 205 
capillaries that course back towards the base of the placenta. This allows fetal blood to 206 
equilibrate with maternal and arterial blood through the trophoblast layers, thereby 207 
maximising the umbilical venous nutrient and oxygen delivery to the fetus [70].  208 
 209 
1.4 Placental function  210 
1.4.1 Placental nutrient transport  211 
A sufficient supply of nutrients from the mother, including glucose, amino acids and 212 
fatty acids, is important for optimal fetal growth and development. However, the 213 
transfer of substances between the maternal and fetal circulations requires them to 214 
pass through the placental barrier [71]. In humans, transplacental transfer involves 215 
nutrient transport across the maternal facing microvillous membrane (MVM) of the 216 
syncytiotrophoblast, across the cytoplasm and exit to the fetal circulation via the fetal 217 
facing basal membrane (BM) [72]. In mice, on the other hand, the mononuclear 218 
trophoblast cell layer is highly permeable to solutes with a small molecular weight and 219 
hence the second syncytial layer is the initial barrier to materno-fetal exchange [73, 74]. 220 
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The second and third membranes of the mouse placenta are connected through gap 221 
junctions, with the third layer being in close proximity to the fetal endothelium. Studies 222 
of isolated apical membrane of the second syncytial layer in mice have shown that it is 223 
highly analogous to human MVM [75], while the third placental layer in mice is 224 
suggested to be analogous to human BM [76].  225 
The placental transfer of individual substances is dependent on a number of factors 226 
including the size of the molecule, its lipophilicity, the rate of blood flow and its 227 
transplacental concentration gradient [75]. Small, lipophilic molecules such as 228 
respiratory gases diffuse readily across the placenta, and their concentration gradients 229 
rapidly equilibrate across the membranes [77]. However larger, hydrophilic and 230 
charged molecules cannot readily cross the placenta and hence require membrane 231 
transporters, which can transport molecules either down their concentration gradient 232 
(facilitated transport) or against their concentration gradient (active transport) [77]. 233 
These processes are discussed in greater depth in the following sections, with respect 234 
to transport of glucose, amino acids and fatty acids, the main substrates utilised by the 235 
fetus. 236 
1.4.1.1 Glucose transport  237 
Transfer of glucose from the maternal to fetal circulations is critical to allow the fetus to 238 
meet its energy needs. Glucose concentrations are lower in the fetus than in the 239 
mother and thus  materno-fetal transfer of glucose across the placenta occurs down a 240 
concentration gradient via facilitated diffusion through a family of glucose transporters 241 
(GLUTs), primarily GLUT1 (encoded by Slc2a1) and GLUT3 (encoded by Slc2a3) [78]. 242 
GLUT1 is expressed in both the MVM and BM of the human placenta, with 243 
approximately 3-fold higher abundance in the MVM compared to the BM [79-81]. 244 
GLUT3 is mainly localised to the MVM and its expression decreases across gestation 245 
[82, 83].  246 
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GLUT1 and GLUT3 are also the primary glucose transporter isoforms expressed in the 247 
mouse placenta [84]. Compared to humans, fewer studies in mice have characterised 248 
placental localisation of GLUT proteins across gestation. GLUT1 and GLUT3 are co-249 
localised in the placental labyrinth, predominantly in the maternal facing 250 
syncytiotrophoblast cell layer [78]. GLUT1 deletion results in embryonic loss at GD12 in 251 
mice, while the deletion of GLUT3 results in growth arrest of the embryo around GD8.5 252 
[85]. This suggests that the two isoforms have a dynamic role in supporting fetal and 253 
placental growth throughout gestation in both humans and mice, with GLUT1 254 
supporting placental, as well as fetal, growth throughout gestation but GLUT3 255 
predominantly playing a role in the growth of the placento-fetal unit during early 256 
gestation [86].    257 
1.4.1.2 Amino acid transport  258 
In contrast to glucose, concentrations of virtually all amino acids are greater in the fetus 259 
than in the mother, suggesting that the transfer of amino acids across the placenta is 260 
an active process [87]. A range of transporters are utilised, including Na+ dependent 261 
co-transporters which generate an electrochemical gradient via activity of Na+/K+ 262 
ATPase, which in turn drives these energy demanding processes [88]. One such 263 
system is the sodium-coupled neutral amino acid transporter (SNAT) family, involved in 264 
the transport of small, neutral amino acids such as alanine, serine and glycine. The 265 
family comprises three highly homologous isoforms, SNAT1, SNAT2 and SNAT4, 266 
encoded by the genes Slc38a1, Slc38a2 and Slc38a4 [89], and all three isoforms are 267 
expressed in both the human and mouse placenta [90-92]. Protein expression of 268 
SNAT1 and SNAT2 is abundant in the rat labyrinth [91] with studies in isolated mouse 269 
placental vesicles further localising SNAT2 and SNAT4 to syncytiotrophoblast layer II, 270 
the maternal-facing plasma membrane [92, 93]. Similarly, all three isoforms are 271 
expressed in the placental MVM and BM in humans [90].  272 
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The system L transporters, consisting of large neutral amino acid transporter (LAT)1 273 
and LAT2, are also active amino acid transporters, and are sodium-independent [94-274 
96]. In the human placenta, LAT1 is predominantly localised to the MVM, and its 275 
expression is higher at term compared to mid-gestation [94, 97]. LAT2 is mainly 276 
localised in the BM and facilitates the exchange of non-essential amino acids in the 277 
fetal circulation with essential amino acids in the cytoplasm of the syncytium [94]. It has 278 
been more difficult to determine the presence and localisation of these amino acid 279 
transporters in rodent placentas, and the mode of transfer of amino acids across the 280 
two syncytial layers remains to be elucidated [86]. However, one study identified LAT1 281 
and 2 protein expression in the maternal-facing plasma membrane of the second 282 
trophoblast layer of the mouse placenta [98].  283 
1.4.1.3 Fatty acid transport 284 
Fatty acids are essential precursors of bioactive molecules such as eicosanoid lipid 285 
mediators, and an important source of energy and building blocks for the fetus, with a 286 
particularly important role in supporting the developing brain and central nervous 287 
system [99, 100]. Although maternal circulating concentrations determine the fatty acid 288 
composition delivered to the fetus, the placenta preferentially transfers physiologically 289 
important long chain polyunsaturated fatty acids (LC-PUFAs), in particular the omega-3 290 
fatty acids [101, 102]. Fatty acids can diffuse across the placenta down their 291 
concentration gradient but their movement is facilitated through a series of transport 292 
systems [99].These transporters include fatty acid binding protein of the plasma 293 
membrane (FABPpm), fatty acid translocase (FAT/CD36) and fatty acid transport 294 
proteins (FATP). FAT/CD36 and FATP transporters are localised in the MVM and the 295 
BM of human placental syncytiotrophoblast, suggesting their role in lipid transfer to the 296 
fetal circulation [103, 104]. FAT is a multifunctional protein and can bind to free fatty 297 
acids, collagen, thrombospondin and oxidized low density lipoproteins [100]. Similar to 298 
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the FATP proteins, FABPpm shows higher affinity for LC-PUFAs than other fatty acids, 299 
but is only localised to the maternal facing membranes of the human placenta [105]. 300 
Several of these fatty acid transport systems have also been identified in the rodent 301 
placenta. FABPpm, FAT and FATP are expressed in the rodent placental labyrinth and 302 
junctional zones, along with another transporter known as heart-type fatty acid binding 303 
protein (hFABP) [106]. Predominant expression of hFABP and FAT in the labyrinth 304 
suggests their involvement in the trans-placental movement of fatty acids from the 305 
mother to the fetus while FABPpm, FAT and FATP may also have a role in placental 306 
fatty acid uptake [106, 107]. The precise localisation of fatty acid systems in the rodent 307 
placenta and how lipids pass through the two syncytial layers is, however, still unclear 308 
[86]. 309 
1.4.2 Placental hormone production  310 
The placenta orchestrates the maternal metabolic adaptations of pregnancy by 311 
secreting a variety of hormones, including members of the growth hormone (GH) and 312 
prolactin (PRL) family, steroid hormones and neuroactive hormones. 313 
1.4.2.1 Growth hormone-prolactin family  314 
One of the major hormone families expressed by the placenta is the growth hormone-315 
prolactin (GH-PRL) family, which comprise structurally-similar genes that are 316 
expressed in a species-specific manner [108]. Humans only express a single PRL 317 
gene, but have an expanded GH locus (discussed in later sections), consisting of five 318 
genes, including a placentally-expressed GH variant (GH-V) [109]. Conversely, rodents 319 
only have a single pituitary-expressed Gh gene, but have a large Prl locus, consisting 320 
of approximately 26 genes that include placental lactogens (PLs), PRL-like hormones, 321 
proliferins, and proliferin-related proteins [108, 110]. The rodent placenta expresses 322 
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around 22 members of the Prl gene family, in the trophoblast giant cells, 323 
spongiotrophoblast cells, and invasive trophoblast cells [110-114].  324 
The GH-PRL family promotes maternal metabolic adaptation to pregnancy by inducing 325 
β-cell mass expansion by increasing β-cell proliferation and reducing apoptosis in 326 
maternal pancreatic islets [115, 116]. These hormones also enhance the expression of 327 
glucokinase, hexokinase, and glucose transporter-2 (Slc2a2), and activate the 328 
serotonin biosynthesis pathway in pancreatic islets to mediate an increase in insulin 329 
secretion during pregnancy [1, 115, 117, 118]. This physiological state is essential for 330 
adequate glucose transport down a concentration gradient from maternal to fetal 331 
circulations [119]. In humans, pituitary GH secretion is diminished by mid-pregnancy 332 
when placental production of GH begins to dominate, [120, 121]. An increase in 333 
endogenous maternal GH secretion also occurs in rodent pregnancy, but in the 334 
absence of the placental growth hormone variant this is derived from the pituitary and 335 
is likely driven by a placentally derived factor (discussed in later sections) [122, 123]. 336 
1.4.2.2 Steroidogenesis  337 
Early in human pregnancy, the corpus luteum (maintained by the placental hormone 338 
human Chorionic Gonadotropin; hCG) synthesises progesterone and oestrogens, until 339 
the placenta takes over production of these steroid hormones at about 8 weeks 340 
gestation, with increasing production until term [124]. In rodents, the corpus luteum 341 
remains the source of these hormones throughout pregnancy [125, 126]. The function 342 
of the corpus luteum is regulated by PRL-like or lactogen hormones in mice. Prolactin 343 
is secreted by the maternal pituitary until mid-pregnancy in rodents, and is inhibited by 344 
the placental secretion of placental lactogens 1 and 2 during mid-late pregnancy 345 
(Figure 1.2) [126-131]. Prolactin stimulates expression of oestrogen and luteinising 346 
hormone receptors, which increases the sensitivity of the corpus luteum to these 347 
hormones [132-134]. Prolactin also promotes differentiation of follicular cells into non-348 
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dividing, progesterone-producing luteal cells, establishing the ongoing progesterone 349 
secretion necessary for the inhibition of ovulation, implantation and maintenance of 350 
pregnancy (along with oestrogen) [132, 135]. Although a transient increase in 351 
oestradiol (produced by follicular and luteal tissue) is observed at the time of embryo 352 
implantation, a substantial increase in maternal serum oestradiol concentrations occurs 353 
from mid-pregnancy until late pregnancy, with concentrations decreasing rapidly before 354 
delivery (Figure 1.2) [136]. 355 
 356 
Figure 1.2 Schematic representation of hormonal profiles during pregnancy in the 357 
mouse and rat. During early pregnancy, maternal pituitary derived prolactin (PRL) is 358 
secreted in twice-daily surges. During early mid-gestation, the placenta secretes PL-I 359 
and then PL-II, which also play roles in inhibiting maternal PRL secretion. This 360 
inhibition is lost near the end of gestation resulting in a surge in circulating maternal 361 
pituitary PRL. As the overall result of these coordinated events in mice, serum 362 
progesterone levels increase with the progression of pregnancy and peak at GD16, 363 
rapidly decreasing before parturition [137]. A substantial increase in maternal serum 364 
oestradiol (a form of oestrogen) concentrations occurs from mid-pregnancy until late 365 
pregnancy, with concentrations decreasing rapidly before delivery [136]. Figure taken 366 
from [138].  367 
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 368 
Oestrogen (oestradiol in rodents) and progesterone have crucial roles in pregnancy in 369 
humans and rodents.  Progesterone induces expression of genes that increase uterine 370 
receptivity, maintain myometrial quiescence and contributes to maternal immune 371 
tolerance through its anti-inflammatory properties. The fall in progesterone prior to 372 
parturition allows the ratio of oestradiol to progesterone to increase, which initiates gap 373 
junction formation between myometrial smooth muscles cells and permits coordinated 374 
contractions during labour [139-142]. Oestrogen also increases uterine receptivity and 375 
promotes endometrial growth and differentiation, placental angiogenesis, vasodilation, 376 
uteroplacental blood flow and nutrient transport [143-145]. Both hormones also 377 
contribute to maternal metabolic adaptations to pregnancy, including facilitating shifts in 378 
glucose and insulin homeostasis, lipid handling and appetite regulation [16, 124, 146, 379 
147]. They also promote the development of the mammary gland through proliferation 380 
of mammary epithelium by promoting production and secretion of prolactin [148, 149]. 381 
 382 
1.5 IUGR 383 
1.5.1 Overview  384 
Intrauterine growth restriction (IUGR), in which a suboptimal fetal environment prevents 385 
the fetus from attaining its genetically determined growth potential, affects 6-12% of 386 
babies in developed countries [150]. A lack of international consensus on the 387 
diagnostic criteria for IUGR makes the identification of growth restricted fetuses difficult 388 
in clinical settings. Recently, the Delphi procedure was used to establish consensus-389 
based definitions for early (>32 weeks) and late (>32 weeks) onset IUGR due to 390 
placental insufficiency. Three parameters, abdominal circumference (AC) <3rd 391 
percentile, estimated fetal weight (EFW) <3rd percentile or absent end-diastolic flow in 392 
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the umbilical artery, were accepted as solitary parameters – i.e. any of these 393 
characteristics is sufficient to diagnose early onset IUGR, even if all other parameters 394 
are normal. Additionally, AC or EFW <10th percentile combined with a pulsatility index 395 
>95th percentile in either the umbilical or uterine artery were identified as contributory 396 
parameters, which require other abnormal parameter(s) to be present for the diagnosis 397 
of IUGR. For late onset IUGR, AC or EFW <3rd percentile were identified as solitary 398 
parameters. Three contributory parameters were defined: AC or EFW <10th percentile, 399 
AC or EFW crossing centiles by > two quartiles on the growth charts and cerebero-400 
placental ratio <5th centile or uterine artery pulsatility index >95th percentile. Presence 401 
of at least two out of the three contributory parameters was agreed as defining late 402 
onset IUGR.  However, these definitions require information that may not be available 403 
in all pregnancies, if repeated ultrasound data is not available. Low birth weight (LBW, 404 
<2.5 kg) or small for gestational age (SGA, birth weight <10th percentile for gestational 405 
age) as well as ultrasound assessments of fetal growth (abdominal circumference 406 
<2.5th percentile) are therefore often used in clinical studies as markers of IUGR in 407 
human infants [151]. It must be noted, however, that not all SGA babies are 408 
pathologically growth restricted and some may be constitutionally small, while LBW can 409 
be the result of prematurity without IUGR [152].  410 
LBW and IUGR amplify risks of perinatal mortality more than 5-fold, including a 411 
substantial increase in the risk of stillbirth [153]. For those infants who survive, the 412 
adverse effects of IUGR persist throughout the life-course, with increased risks of 413 
multiple adult diseases including type 2 diabetes and cardiovascular disease [154]. In 414 
developed countries, where maternal nutrition is usually not a limiting factor, placental 415 
dysfunction is the most common contributor of IUGR and currently cannot be prevented 416 
or treated.  417 
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1.5.2 Classification of IUGR 418 
IUGR can be classified into three types: asymmetric, symmetric and mixed [155-157]. 419 
Asymmetric IUGR is associated with a reduced fetal abdominal circumference but 420 
normal biparietal diameter, head circumference and femur length. It is the most 421 
common type of IUGR and is typically associated with utero-placental insufficiency 422 
[158]. This phenotype occurs as a result of redistribution of cardiac output to maintain 423 
the growth of essential organs, including the brain and heart, resulting in compromised 424 
growth of organs like the kidneys, gut and liver [159, 160]. Symmetric IUGR, where all 425 
morphological measures are similarly reduced, was believed to be typically due to 426 
genetic disorders or infection intrinsic to the fetus. However, recent work has shown 427 
that markers of poor maternal health during early pregnancy, such as low and high 428 
body mass index, low socioeconomic status were strong risk factors associated with 429 
symmetric SGA [161]. Contrary to asymmetric IUGR, where the onset of growth 430 
restriction usually occurs later in gestation, symmetric IUGR is associated with insults 431 
that occur during early gestation [157]. This is due to the fact that this stage of fetal 432 
development is associated with rapid cellular hyperplasia, as opposed to cellular 433 
hypertrophy, and thus insults tend to result in proportionally small fetuses with reduced 434 
cell numbers but normal cell size [162]. Fetuses from mixed IUGR, most commonly 435 
observed in developing countries, have clinical features of both asymmetric and 436 
symmetric IUGR and usually reflect an insult that occurs in early gestation that is 437 
further exacerbated later in gestation by placental dysfunction [163].  438 
1.5.3 IUGR diagnosis 439 
Measurement of fundal height (in centimetres) between 24-38 weeks of gestation 440 
provides an approximation of gestational age and is also used to screen for fetal 441 
growth less than or greater than the 10th percentile for gestational age [164]. However, 442 
this method has limited accuracy when identifying abnormally grown fetuses, with 443 
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maternal obesity further complicating this clinical estimate [165-167]. More appropriate 444 
assessment of growth restriction is obtained by biometric measures of fetal biparietal 445 
diameter, head circumference, abdominal circumference and femur length by 446 
ultrasound [167, 168]. Ultrasonography is also used to obtain an estimate of fetal 447 
weight and, if estimated to be below the 10th percentile, further evaluations are 448 
considered, including ultrasound assessment of amniotic fluid index and umbilical 449 
artery blood flow [169]. Increased umbilical artery resistance may suggest that the 450 
pregnancy is complicated by underlying placental insufficiency. Furthermore, absent or 451 
reversed end-diastolic flow in the umbilical artery is associated with increased risk of 452 
perinatal mortality and will therefore influence clinical decisions about timing of 453 
interventions including early delivery [170-174]. 454 
1.5.4 Causes of IUGR  455 
IUGR can be caused by a number of maternal, placental and fetal factors, including 456 
maternal immaturity (adolescent pregnancy) or advanced maternal age, smoking, 457 
infections and genetic/chromosomal abnormalities [175-177]. Although the underlying 458 
pathophysiological mechanisms in these conditions are different, they often share the 459 
same final pathway of suboptimal utero-placental perfusion and fetal supply of oxygen 460 
and nutrients [178].  461 
1.5.4.1 Maternal causes  462 
Maternal demographic factors including age, weight, socio-economic status and 463 
ethnicity can influence the risk for IUGR in their babies. Women at extremes of 464 
reproductive age, especially younger mothers, have a higher risk of experiencing 465 
complications like IUGR, while advanced maternal age has been associated with an 466 
increased risk of delivering a LBW baby [179, 180]. Due to factors like poor nutritional 467 
status, maternal anaemia, lack of access to prenatal care, lower pre-pregnancy weight 468 
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and weight gain, women from developing countries have a higher risk of LBW and 469 
IUGR compared to women living in developed countries [181-183]. Women living in 470 
high altitude areas also experience a chronically hypoxic environment, which probably 471 
explains their higher incidence of LBW offspring compared to women living at sea level 472 
[184-186]. Substance use and abuse in pregnancy, including maternal smoking, 473 
increases the risk of LBW, SGA, preterm birth and perinatal death and is also 474 
associated with a greater risk of Sudden Infant Death Syndrome (SIDS) [187, 188]. 475 
Similarly, maternal alcohol consumption during pregnancy can cause Fetal Alcohol 476 
Spectrum Disorder which is associated not only with reduced fetal growth, but also 477 
birth defects and growth and neurodevelopmental issues that persist into adulthood 478 
[189]. Maternal medical conditions that alter utero-placental blood flow, including pre-479 
gestational diabetes mellitus, pregnancy-related hypertensive diseases, and cyanotic 480 
cardiac disease, as well as autoimmune diseases, can also lead to IUGR [190]. 481 
1.5.4.2 Fetal causes 482 
Fetal factors that may cause IUGR include genetic abnormalities, congenital 483 
malformations, and fetal infections. Fetal genetics including chromosomal 484 
abnormalities account for 5-20% of IUGR cases, and in the majority of these, the 485 
growth restriction has an early onset [191, 192]. Fetal infections can result in restricted 486 
fetal growth, but this is relatively rare, only accounting for <5% of IUGR cases. Both 487 
viral infections, including rubella, cytomegalovirus, herpes and human 488 
immunodeficiency virus, and parasitic infections, like toxoplasmosis and malaria, are 489 
associated with reduced fetal growth [193, 194]. Malaria is a common cause of LBW 490 
and IUGR in developing countries as it reduces uterine and umbilical artery blood flows 491 
as well as placental oxygen and nutrient transport capacity [195-197]. Although 492 
bacterial infections are less likely to cause IUGR, some reports have linked syphilis, 493 
chlamydia, mycoplasma, listeria and tuberculosis with impaired fetal growth [192, 198].  494 
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1.5.4.3 Placental causes 495 
Placental dysfunction or placental insufficiency is the most common pathology 496 
associated with IUGR, and is broadly defined as alterations in placental oxygen and 497 
nutrient transfer capacity which adversely impact fetal growth [199]. Although maternal 498 
undernutrition and hypertension can contribute to the development of placental 499 
insufficiency, in more than half of the cases placental dysfunction is due to abnormal 500 
remodelling of uterine and placental spiral arteries which reduces utero-placental 501 
perfusion [200, 201]. Placental insufficiency is often characterised by fetal redistribution 502 
of blood flow to vital organs over peripheral organs, in response to hypoxia, and can be 503 
detected through altered umbilical, uterine and middle cerebral artery Doppler flows 504 
[169, 202]. Certain placental complications, including placental abruption, infarction, 505 
circumvallate shape, haemangioma and chorioangioma, although more rare, can also 506 
impair the normal function of the placenta and contribute to IUGR or mortality in severe 507 
cases [203-207].  508 
1.5.4.4 Placental nutrient transport in IUGR 509 
Facilitated glucose transport across the human placenta through the second half of 510 
gestation is primarily mediated by GLUT1 (product of the Slc2a1 gene). Although fetal 511 
hypoglycaemia is associated with IUGR, GLUT1 protein expression, as well as activity 512 
in syncytiotrophoblast membranes, is normal in placentas of these fetuses [79, 208]. 513 
However, compared to normal placentas, placentas from pregnancies complicated by 514 
late-onset IUGR have higher Slc2a3 mRNA and GLUT3 protein expression on the 515 
maternal side of the placental barrier [209]. This may reflect increased placental 516 
glucose consumption at the expense of glucose availability for fetal growth [79, 208].  517 
Activity of the System A transporters (SNATs), which mediate the uptake of neutral 518 
amino acids (glycine/serine/alanine), is reduced in the MVM of IUGR placentas [208, 519 
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210-212]. This decrease in activity is likely due to reduced MVM protein expression of 520 
SNAT1 and SNAT2 [212]. Furthermore, the degree of reduction in System A activity is 521 
related to the severity of IUGR, as assessed by abnormal pulsatility index in the 522 
umbilical artery and fetal heart rate monitoring [213]. In another study, the reduction in 523 
placental System A activity is especially notable in IUGR babies who were delivered 524 
preterm (28-36 weeks) compared to IUGR babies delivered at term [208]. Additionally, 525 
the placental uptake of essential amino acids including leucine, lysine (system L 526 
transporters) and taurine (system β transporters) is reduced in MVM and/or BM 527 
vesicles isolated from IUGR pregnancies compared to those from uncomplicated 528 
pregnancies [214, 215]. Similarly, reduced placental transfer of essential amino acids 529 
leucine and phenylalanine in term IUGR pregnancies has been demonstrated in vivo 530 
using stable isotope techniques [216]. Reductions in activity of placental amino acid 531 
transporters are likely associated with decreases in placental amino acid uptake, and 532 
contribute to lower plasma concentrations of several amino acids in IUGR fetuses 533 
[217].  534 
The characteristically low subcutaneous fat depots and thin appearance of the IUGR 535 
fetus are thought to be attributed to reduced fetal fat synthesis and/or placental transfer 536 
of free fatty acids [218]. An important first step in the transplacental transfer of free fatty 537 
acids to the fetus involves placental lipoprotein lipase. The activity of this enzyme is 538 
reduced in the MVM from human IUGR placentas compared to age-matched controls 539 
[219, 220] and corresponds to lower fetal/maternal ratios of LC-PUFAs in IUGR 540 
pregnancies [221]. Higher protein expression of receptors involved in placental 541 
cholesterol uptake (low density lipoprotein-receptor and scavenger receptor class B 542 
type-I) [222], as well as placental fatty acid transporters (FATP6 and CD36) [223], 543 
provide further evidence of alterations in fetal lipid uptake in IUGR. These appear to be 544 
compensatory mechanisms to maintain delivery of cholesterol and vital LC-PUFAs to 545 
support processes like placental steroid hormone synthesis and brain development in 546 
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the IUGR fetus [223, 224]. However, further studies are required to confirm these 547 
associations.  548 
1.5.4.5 Multiple gestation 549 
Multiple gestation is another cause of IUGR, which can reflect maternal (ovulation rate) 550 
and fetal (embryo division) factors and leads to placental insufficiency. In these 551 
pregnancies, the degree of growth restriction increases in proportion with fetal number, 552 
as approximately 55% of twins and 99% of higher-order multiples are LBW compared 553 
with 5.2% of singletons [188]. Similarly, the incidence rate of IUGR in singleton 554 
pregnancies is around 10% but this increases to 15-41% in twin pregnancies and 50-555 
60% in higher order pregnancies [150, 225-227]. Besides number of fetuses, the risk of 556 
IUGR in multiple pregnancies is also influenced by other factors like chorionicity, 557 
prevalence of a congenital anomaly or umbilical cord abnormalities, twin-twin 558 
transfusion syndrome and maternal nutrition [228]. Poor fetal growth contributes to 559 
poor health outcomes in multiple compared to singleton human pregnancies. Twin 560 
pregnancies make up only 2-5% of all livebirths but they account for 10-15% of all 561 
adverse neonatal outcomes [229, 230]. As a result, twin and triplet neonates have 3 562 
and 9 times longer hospital stay, respectively, compared to singletons [231], and a 563 
large proportion of twin (78.2%) and triplet (97.1%) gestations result in Caesarean 564 
delivery [231]. One of the major contributors to perinatal mortality in multiples is 565 
believed to be the high prevalence of preterm births in this population (~63% in twins 566 
and 100% in higher-order pregnancies compared with ~7% in singletons) [188, 232]. 567 
As a result, fetuses in multiple pregnancies are also more likely to have respiratory 568 
complications immediately after delivery and are more likely to die due to related 569 
complications within the first year of life, compared to singletons [231].  570 
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1.5.5 Consequences of IUGR 571 
1.5.5.1 Short-term consequences of IUGR  572 
IUGR has a number of short-term consequences for the infants. These include a higher 573 
risk of preterm delivery, asphyxia and related neonatal complications including 574 
respiratory distress syndrome, need for intubation, acidosis, stillbirth and neonatal 575 
death [233, 234]. In the early neonatal period, IUGR infants have a higher incidence of 576 
low Apgar scores, seizures, polycythemia, hyperbilirubinemia, hypoglycaemia, 577 
hypothermia, sepsis, intraventricular haemorrhage, and necrotising enterocolitis [234-578 
236].  As a result of the higher incidence of neonatal complications, growth restricted 579 
fetuses often require prolonged support in a neonatal intensive care unit (NICU) and 580 
have higher health care costs than babies born at an appropriate weight for gestational 581 
age (AGA) [235, 237, 238]. 582 
1.5.5.2 Long-term consequences of IUGR  583 
Epidemiological studies have consistently reported associations between LBW and risk 584 
of developing a number of complications, including coronary artery disease, type 2 585 
diabetes, central obesity and the metabolic syndrome, later in life [239-243]. IUGR, 586 
LBW and SGA babies characteristically exhibit accelerated neonatal growth, known as 587 
catch-up growth, during the first two years of life [244, 245]. This period of accelerated 588 
growth is associated with preferential deposition of fat (particularly visceral fat), altered 589 
insulin secretion, glucose intolerance, hypertension and raised plasma triglyceride 590 
concentrations, and is hence a major factor predisposing this population to the 591 
development of chronic disease later in life [45, 246-251]. Furthermore, children 592 
exposed to a suboptimal intrauterine environment also have reduced head 593 
circumference and brain volume due to grey matter loss, as well as impaired white 594 
matter development. This is accompanied by microstructural changes that are 595 
indicative of reduced myelination and axon injury, often due to inflammation [252-256]. 596 
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Although reductions in head circumference, a proxy for brain size, are somewhat offset 597 
by accelerated post-natal growth, this recovery is often incomplete compared to 598 
normally grown infants of the same age [253]. As a result of impaired 599 
neurodevelopment, IUGR children often have poorer cognitive and academic outcomes 600 
compared to AGA children, with higher incidence of cerebral palsy and behavioural 601 
disorders [234, 257-262]. Therefore, the origin of a number of complications associated 602 
with IUGR appear to be due to effects of a sub-optimal perinatal environment on the 603 
development of fetal organs and systems, including adaptations to survive the 604 
intrauterine insult, and these can have life-long impacts [263]. 605 
1.5.6 Treatment of IUGR  606 
To date, a number of approaches for treating IUGR have been trialled in both pre-607 
clinical and clinical studies. The following section will summarise some of these 608 
approaches including those aimed at directly increasing fetal nutrient availability, 609 
decreasing fetal oxidative stress and enhancing utero-placental blood flow.  610 
1.5.6.1 Nutrition  611 
As placental insufficiency is associated with reduced supply of nutrients and oxygen to 612 
the fetus, a number of animal studies have tested whether direct or indirect nutrient 613 
supplementation can improve fetal growth and long-term outcomes. In a hyperthermia-614 
induced sheep model of IUGR, chronic fetal infusion with branched and essential 615 
amino acids during late gestation restored fetal insulin secretion and pancreatic islet 616 
size [264], but had variable effects on protein accretion rates [265] without any 617 
improvements in fetal or placental weights [264, 265]. Direct glucose infusion to growth 618 
restricted ovine fetuses, however, was not well-tolerated, as the resulting fetal 619 
hyperglycemia resulted in increased fetal oxygen consumption in the absence of an 620 
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increased fetal oxygen supply, giving rise to fetal hypoxia and acidosis, in the absence 621 
of any effects on fetal growth [266].  622 
Results of nutrient supplementation are also mixed in human studies. Intra-umbilical 623 
supplementation with glucose and amino acids causes an imbalance of amino acids in 624 
the fetal plasma and no significant improvements in severely growth restricted fetuses 625 
[268]. Later studies combined this method of nutrient supplementation with hyperbaric 626 
oxygenation, to increase oxygen diffusion across the placenta. This technique was only 627 
tested in two women and results are mainly based on fetal survival, which was only 628 
achievable in one of these women [269]. Therefore, attempts to promote fetal growth 629 
by increasing nutrient availability appear to result in variable degree of success across 630 
species with side effects that may further impair fetal development.  631 
1.5.6.2 Antioxidants  632 
Maternal antioxidant administration using a range of agents, including allopurinol, 633 
vitamin C and melatonin, has been applied in human studies in an attempt to reduce 634 
oxidative stress. Of these agents, melatonin is the most well studied and has an 635 
established safety profile, strong antioxidant properties and can be easily administered 636 
orally. Treatment with melatonin improves vascular endothelial integrity of cultured 637 
human umbilical vein cells [270], likely due to the combined effect of melatonin’s anti-638 
oxidant and anti-inflammatory properties [271-274]. In rodents and sheep pregnancies 639 
complicated by IUGR, maternal melatonin treatment increased fetal oxygenation, 640 
uterine blood flow and/or fetal weight [275-278]. Melatonin administration also 641 
improved brain development and neuro-behavioural outcomes in growth restricted 642 
lambs [218]. However, other studies in sheep found that treatment with melatonin 643 
either resulted in no improvement in birthweight [271] or worsened the hypoxia-induced 644 
IUGR with further reductions in fetal weight and size [279]. Melatonin is also being 645 
assessed as a treatment for IUGR and preeclampsia in human clinical trials. 646 
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Preliminary results suggest that melatonin may prolong pregnancy duration and 647 
possibly improve fetal growth, but these trials are still ongoing, and therefore clinical 648 
efficacy and safety profile remain to be defined [270, 280, 281].  649 
1.5.6.3 Treatments to increase utero-placental blood flow 650 
A technique that improves utero-placental blood flow is the use of vasodilators, with 651 
sildenafil citrate being the most widely studied example. Sildenafil inhibits 652 
phosphodiesterase type 5, the main enzyme responsible for nitric oxide clearance, and 653 
hence prolongs elevation of nitric oxide, leading to vasodilation and relaxation of 654 
smooth muscle [282]. The vasodilatory effects of sildenafil on human myometrial 655 
vessels from normal and growth restricted placentas have been confirmed in vitro as 656 
well as in vivo [283, 284]. Experimental animal studies have been conducted in a wide 657 
range of species, including sheep, rabbits, rats and mice, and sildenafil increased 658 
utero-placental blood flow and fetal delivery of nutrients and oxygen, resulting in 659 
improved fetal growth in these species, with improved maternal blood pressure also 660 
reported in preeclampsia models in rodents [285-288]. However, sildenafil treatment 661 
only improves fetal and maternal outcomes in compromised and not normal 662 
pregnancies, with its effects being greatest when given orally and continuously [289]. 663 
Furthermore, in some animal studies sildenafil treatment caused adverse fetal 664 
outcomes [290, 291]. For example, in a sheep IUGR model of single umbilical artery 665 
ligation (SUAL), sildenafil was administrated over 24 hr to pregnant ewes between 105-666 
110 days’ gestation (term is 150 days) [290]. Outcomes measured over 48 hr after 667 
sildenafil administration were indicative of a significant deterioration in fetal well-being, 668 
as evidenced by decreased fetal oxygenation, increased fetal CO2, hypotension, and 669 
tachycardia [290]. Maternal administration of sildenafil from mid-late pregnancy in the 670 
placental-specific Igf2 knockout mouse model of IUGR also did not improve fetal 671 
growth and was associated with increased blood pressure in adult mouse offspring 672 
[292].   673 
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In light of the positive effects obtained in in vitro and in some experimental animal 674 
studies, sildenafil citrate was tested as a potential treatment for IUGR in human 675 
pregnancies in a multicentre, randomised, placebo-controlled, double-blind trial, the 676 
Sildenafil Therapy in Dismal prognosis Early‐onset intrauterine growth Restriction 677 
(STRIDER) study. This trial only included severely growth restricted babies who had a 678 
very low chance of survival without any intervention and may not have been 679 
representative of more typical cases of IUGR. Fetal outcomes did not improve in the 680 
cohort based in Australia and New Zealand, but no evidence of harm was observed 681 
[293]. The STRIDER trial has since been suspended, however, due to the deaths of a 682 
number of babies, associated with pulmonary dysfunction [294-296].  683 
Nutritional approaches to increase the abundance of nitric oxide and increase utero-684 
placental blood flow have also been investigated in animal and human studies.  685 
Providing protein-restricted pregnant rats drinking water supplemented with L-citrulline, 686 
a precursor to the amino acid L-arginine and in turn nitric oxide synthesis increased 687 
fetal weight near term by 8%, without changing placental weight [267]. This was 688 
attributed to a combination of increased muscle synthesis and the vasodilatory effects 689 
of increased nitric oxide in the dam [267]. Similarly, intravenous and/or oral L-arginine 690 
supplementation for 7 days to women with pregnancies complicated with IUGR 691 
improved fetal weight by up to 6.4% [297]. In another study, intravenous L-arginine to 692 
hospitalised pregnant women increased fetal weight by 3.9%, and reduced utero-693 
placental vascular resistance, although the timing and duration of treatment are unclear 694 
[298]. In women with gestational hypertension with or without proteinuria, oral L-695 
arginine supplementation reduced diastolic blood pressure and prolonged pregnancy 696 
duration [299]. However, no improvements were found in birthweight in the latter study 697 
or when oral L-arginine supplements were given to women with severe IUGR [299, 698 
300].  699 
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Another interesting approach to increasing utero-placental blood flow and thereby fetal 700 
growth is through overexpression of VEGF in uterine arteries, using an adenovirus 701 
vector [301]. Preclinical work has shown promising results with improved uterine artery 702 
blood flow [301] and fetal weight gain in growth restricted sheep [302, 303], due to 703 
improved placental vascularisation. This approach was also tested in guinea pigs, and 704 
resulted in a more modest (3%) improvement in weight of growth restricted fetuses 705 
compared to non-treated controls [304]. Different methods were used to induce growth 706 
restriction between these studies, as the sheep study over nourished adolescent ewes, 707 
whereas guinea pig dams were undernourished to restrict fetal growth. Further studies 708 
need to be performed to determine whether the effectiveness of this approach is 709 
dependent on the experimental model and/or the degree of IUGR. Therefore, there 710 
remains a lack of safe and effective strategies for treating IUGR, and animal models 711 
are needed to test other possible interventions. 712 
1.5.7 Animal models of IUGR 713 
Several different animal models have been developed in order to better understand the 714 
complex mechanisms and molecular events that contribute to an adverse intrauterine 715 
environment and the alterations in placental physiology leading to growth restricted 716 
offspring. These models allow researchers to study the effects of various types and 717 
durations of ‘insults’ on maternal and fetal outcomes and hence better understand the 718 
multifactorial nature of IUGR. However, due to species differences in placental 719 
anatomy, gestation length, maturation stage at birth, and rate of fetal development, the 720 
same type of insult can result in different fetal and maternal outcomes depending on 721 
the experimental model.  722 
As discussed earlier, the primary cause of IUGR in developed countries is placental 723 
dysfunction, which results in a sub-optimal supply of oxygen and nutrients to the 724 
developing fetus. This, in turn, can be influenced by a number of factors, including 725 
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alterations in maternal or fetal blood flow and/or inability of the placenta to sufficiently 726 
alter its morphology (vascularity, barrier thickness/surface area etc.) and function 727 
(nutrient transporters) to meet fetal growth demands [200, 305, 306]. Several different 728 
approaches to experimentally induce placental insufficiency, and thereby IUGR, have 729 
been applied in both small and large animal models, and the most widely used of these 730 
models will be described briefly below.  731 
1.5.7.1 Uterine artery ligation 732 
Uterine artery ligation is a commonly used method to experimentally induce placental 733 
insufficiency in animals with bicornuate uteri. This process reduces utero-placental 734 
blood flow and hence reduces oxygen and nutrition delivery to the fetus, a feature 735 
commonly present in clinical IUGR secondary to placental insufficiency [307, 308]. In 736 
guinea pigs, rabbits and sheep, SUAL produces asymmetrically growth restricted 737 
fetuses [309-312]. Using this model, the average growth restriction relative to controls 738 
is 24% in rats [310, 313, 314] and sheep [309, 315, 316], 30% in rabbits [312, 317] and 739 
44% in guinea pigs [318, 319]. SUAL also reduces materno-fetal transfer of glucose, an 740 
observation first made in sheep studies and induces fetal hypoxaemia, both of which 741 
contribute to reduced fetal growth [320]. Similarly, SUAL in late gestation of rats and 742 
guinea pigs decreases placental capacity to transfer glucose and amino acids in 743 
conjunction with reduced fetal growth [321, 322].  744 
1.5.7.2 Carunclectomy  745 
Another model of IUGR in sheep is caruncletomy, which involves the surgical removal 746 
of the majority of the discrete endometrial implantation sites (caruncles) prior to mating 747 
[323, 324]. Limited number of placentomes are formed from the beginning of 748 
pregnancy, which constrains placental growth and function, and restricts placental 749 
capability to deliver oxygen and nutrients to the fetus [325-327]. Fetuses of 750 
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carunclectomised ewes are hypoxemic and hypoglycaemic, with higher cortisol 751 
concentrations and lower concentrations of insulin, thyroid hormone and prolactin 752 
compared to controls [325, 328, 329]. Furthermore, fetal circulating concentrations of 753 
the key promoters of fetal growth, insulin-like growth factor (IGF)1 and IGF2, are 754 
decreased during late gestation in these fetuses. Ultimately, the restricted nutrient 755 
supply and altered hormone concentrations induced by caruncelectomy reduces fetal 756 
survival by 14%. Asymmetric growth restriction is observed in the surviving fetuses,  757 
with an average of 25% reduction in birth weight relative to control fetuses [330, 331]. 758 
In addition to the effects outlined above, the increased exposure to glucocorticoids 759 
during late gestation in carunclectomised fetuses likely attenuates the activation and 760 
regulation of the hypothalamic pituitary adrenal (HPA) axis and impairs fetal glucose-761 
mediated insulin secretion [325, 327, 332].  Enhanced insulin action on glucose and 762 
amino acids has been linked to the catch up growth in one-month old IUGR lambs, 763 
while increased insulin sensitivity of circulating free fatty acids (FFAs) contribute 764 
towards enhanced visceral adiposity, similar to observations in some cases of human 765 
IUGR [248, 331, 333]. The period of accelerated growth which occurs after birth is, 766 
however, often followed by the gradual development of insulin resistance in these 767 
individuals and may contribute to the development of metabolic syndrome and its 768 
associated complications (including impaired β-cell function) [334-336], particularly in 769 
males [337, 338]. Indeed, by one year of age, the elevated insulin sensitivity observed 770 
in IUGR male sheep at one month, is lost and insulin action is actually impaired in 771 
these young adult sheep [338].  772 
1.5.7.3 Maternal undernutrition 773 
Although most cases of IUGR in developed countries are due to impaired placental 774 
function rather than maternal undernutrition, the effects of both of these insults on 775 
placental signalling and function are similar, suggesting common final pathways of 776 
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placental responses that are independent of the cause of IUGR. Similar to SUAL, 777 
maternal undernutrition in rats, guinea pigs, rabbits and sheep produces growth 778 
restricted fetuses near term with evidence of brain sparing [339-342]. Additionally, 779 
maternal undernutrition during pregnancy has been associated with several postnatal 780 
complications in the offspring, including hypertension, glucose intolerance, increased 781 
fat mass and reduced organ weights [342-344]. A large number of studies have 782 
investigated the timing and effect of mild (~20-30% less than ad libitum), moderate 783 
(~50%) and severe (~70%) maternal caloric restriction in a number of animal models 784 
[345]. Depending on the timing, duration and severity of the nutrient restriction, 785 
decreases in fetal weight compared to controls range from 13-49% in rats [50, 342, 786 
346], 11-17% in sheep [317, 347], 10-35% in guinea pigs [339, 348] and 7-10% in 787 
rabbits [341, 349].  788 
Many of the effects of nutrient restriction are likely mediated through the placenta. In 789 
guinea pigs, maternal undernutrition not only reduces fetal and placental weights, but 790 
also induces structural modifications in the placenta. Roberts and colleagues found the 791 
mean placental barrier thickness for diffusion was higher, and total placental area 792 
available for exchange lower, in dams subjected to caloric restriction during pregnancy 793 
compared to ad libitum fed controls, likely further restricting the delivery of nutrients to 794 
the fetus [348]. Reductions in placental functional capacity have also been 795 
demonstrated in rats after maternal caloric restriction through reduced trans-placental 796 
transfer of radiolabelled isotopes measuring neutral amino acid and glucose transport 797 
in late gestation [350]. Consistent with these measures of impaired function, placental 798 
GLUT3, SNAT1 and SNAT2 are lower, although SNAT4 protein abundance is higher in 799 
pregnant rats during late gestation in response to 50% maternal caloric restriction [351, 800 
352]. Although maternal undernutrition in mice has been associated with reduced fetal, 801 
as well as placental, weights in some studies, only limited data are available on its 802 
effect on murine placental function [353, 354]. In contrast to the studies in rats, 20% 803 
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maternal caloric restriction in mice from GD3 onwards did not change placental 804 
capacity for glucose transport at GD16 or GD19, although the transport capacity for 805 
neutral amino acids was increased at GD19 [354]. Given the discrepancies in the 806 
literature, further studies are needed to clarify the effects of different timing and degree 807 
of restriction in placental nutrient transport, and to determine whether these are 808 
species-specific.  809 
1.5.7.4 Maternal protein restriction  810 
Restriction of maternal protein intake during pregnancy is also associated with 811 
modifications in placental function that vary depending on gestational age and species. 812 
Jansson and colleagues fed pregnant rats protein restricted (4% protein) or control 813 
diets (18% protein) starting from GD2 [355]. They reported lower placental System A 814 
transporter activity at GD19 and 21 and lower SNAT2 protein at GD21 compared to 815 
dams fed an isocaloric, protein-sufficient diet [355]. However, fetal and placental 816 
weights were not reduced in the low protein group until GD21, leading the researchers 817 
to conclude that placental transporter changes were a cause, rather than a 818 
consequence of IUGR [355]. The group also demonstrated decreased protein 819 
expression of SNAT1 and System L transporter activity measured by radioisotopes 820 
during late gestation in rat dams fed a low-protein diet compared to control dams [356]. 821 
This decrease was linked to inhibition of placental insulin, IGF1, mammalian target of 822 
rapamycin (mTOR), and signal transducer and activator of transcription (STAT)3 823 
signalling, positive regulators of placental amino acid transporters [356]. Therefore, 824 
these results suggest that maternal protein restriction disturbs placental signalling 825 
pathways, which in turn reduces placental capacity for amino acid uptake through 826 
downregulation of multiple transporter systems, ultimately reducing fetal weight [355, 827 
356].   828 
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Placental adaptations in response to alterations to maternal dietary protein content 829 
(casein content 23%, 18% or 9%) have also been reported in mice. In contrast to rat 830 
studies, maternal protein restriction (18% or 9% casein in comparison with 23% in the 831 
control diet) throughout gestation in mice, resulted in heavier placentas compared to 832 
controls [357]. However, in the 18% casein diet, the volume of the placental labyrinth 833 
zone, responsible for nutrient exchange was smaller, while that of the endocrine 834 
junctional zone was larger compared to controls. In contrast, labyrinth volume was 835 
maintained at control values in the 9% casein group, at the expense of junctional zone 836 
growth, suggesting that different strategies were employed to match nutrient availability 837 
with fetal growth demands between the low protein groups. Furthermore, compared to 838 
controls, both protein restricted groups showed increased placental capacity for 839 
glucose transport at GD16 but this increase was only sustained until GD19 in the 9% 840 
group. Placental capacity for amino acid transport increased at GD16 but decreased at 841 
GD19 in the 18% group relative to controls, with no changes observed in the 9% casein 842 
group. Given that fetal weight was similar in all groups at GD16 and was only reduced 843 
(by 9%) in the 9% casein group at GD19, these data suggest that amino acid 844 
availability appears to be more important for fetal growth in mice during late gestation 845 
compared to glucose availability [357]. If the protein content of the maternal diet was 846 
reduced to 6% (compared with 20% protein diet in controls), from mid-pregnancy in 847 
mice, fetuses had lighter placentas compared to fetuses from control dams with 848 
evidence of brain sparing near term [358], similar to effects of maternal protein 849 
restriction in rats. Although placental function was not measured in this study, maternal 850 
protein restriction was associated with a smaller junctional zone relative to controls, 851 
possibly to allow the preferential growth of the substrate exchange, labyrinth area 852 
[358]. Taken together, these studies demonstrate that changes to maternal diet induce 853 
alterations in placental function and capacity to meet fetal growth demands. 854 
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1.5.7.5 Hyperthermia-induced placental restriction 855 
Environmental factors such as elevated temperatures can also cause IUGR. 856 
Hyperthermia was developed as an IUGR model after observations that sheep in hotter 857 
climates have a higher incidence of LBW delivery compared those in more temperate 858 
climates [359]. In this model, commencing around day 40 of gestation, pregnant ewes 859 
are housed in an environment where the ambient temperature is raised to 40 °C for 12 860 
h, and then decreased to 35 °C for 12 h of each 24 h period with moderate humidity 861 
[360]. These conditions raise maternal core body temperature from ~39 °C to 40 °C 862 
and results in redistribution of blood flow towards the peripheral vascular system, 863 
thereby reducing umbilical and uterine blood flows [361-364]. As a result, fetuses have 864 
smaller placentas with reduced glucose and oxygen transport capacity, leading to fetal 865 
hypoxaemia and hypoglycaemia, and asymmetrical growth restriction [365-369]. Fetal 866 
outcomes in the model are heavily dependent on the timing of insult. Maternal 867 
exposure to heat-stress during early pregnancy (~GD0-40) leads to embryonic loss 868 
and, consequently, the majority of studies using this model of IUGR expose ewes to 869 
high temperatures after GD45 for variable durations [359, 360]. The highest degree of 870 
fetal restriction is achieved if maternal exposure to elevated temperature occurs from 871 
~GD40 until late gestation or term (fetal weight ~50% of controls). However, less 872 
severe growth restriction is achieved if maternal heat exposure only occurs during mid 873 
or late gestation (~30% reduction compared to controls) [369].  874 
1.5.7.6 Genetic models of IUGR  875 
Genetic manipulation of specific genes in murine models have allowed researchers to 876 
better understand underlying mechanisms associated with compromised fetal growth in 877 
IUGR. A well-studied example in mice is the placental-specific insulin-like growth factor 878 
2 (Igf2) knockout model. In this model, deletion of the labyrinth specific IGF2P0 879 
promoter leads to Igf2 deficiency specifically in the placental nutrient exchange area 880 
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[93, 370].The weight of P0 mutant placentas is significantly reduced compared to wild-881 
type placentas from GD13.5 onwards and this precedes the onset of IUGR [93, 370]. 882 
As a possible adaptation to reduced placental weight, System A amino acid transport is 883 
initially upregulated in IGF2P0 knockout placentas at GD16, allowing fetal growth to be 884 
maintained through increased efficiency of secondary active transport compared to 885 
wild-type placentas [93, 370]. However, by late pregnancy, the adaptations of the 886 
IGF2P0 knockout placentas are insufficient to meet the nutrient demands of the rapidly 887 
growing fetus, resulting in growth restriction [370]. Additional stereological analysis 888 
revealed further abnormalities in the IGF2P0 knockout placentas, including a 50% 889 
reduction in surface area of the trophoblast layers and increase in barrier thickness by 890 
28% compared to wild-type placenta, contributing to reduced diffusional permeability 891 
[371]. Together, this causes a 20-25% reduction in weight of IGF2P0 knockout fetuses 892 
compared to their wild-type littermates [370, 372]. The reduction in fetal weight 893 
becomes even more severe (~50%) if the Igf2 gene is completely knocked out. Unlike 894 
the IGF2P0 knockout mouse, where placental growth restriction precedes fetal growth 895 
restriction, placental and fetal growth restriction occur concurrently in the Igf2 null mice. 896 
The placentas from mice with complete Igf2 ablation support less fetus per gram of 897 
placenta with significant reductions in placental amino acid transport compared to their 898 
wild-type littermates by term [373]. Thus, both fetal as well as placental Igf2 appear to 899 
be important for facilitating optimal fetal growth through their effects on placental 900 
development and function [373].  901 
In another genetic murine model of IUGR, the endothelial nitric oxide synthase (eNOS) 902 
gene is globally knocked out [374]. As the encoding enzyme coverts arginine to nitric 903 
oxide, and ultimately promotes vasodilation, the deficiency of eNOS results in 904 
dysfunctional responses of uterine arteries to vasodilators as well as vasoconstrictors 905 
in vitro [374, 375]. Furthermore, spiral artery remodelling and impaired feto-placental 906 
vascular development associated with reduced VEGF expression are evident in eNOS-907 
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/- mice [376, 377]. Placental System A amino acid transporter activity is also reduced, 908 
ultimately contributing to approximately 10% reduction in fetal weight at term compared 909 
to wildtype fetuses [374]. These genetic models of IUGR hence highlight the roles of 910 
specific genes as important modulators of optimal placental function and fetal growth 911 
and allow researchers to better understand and investigate the multifactorial nature of 912 
IUGR.   913 
1.5.7.7 Large litter size  914 
In rodents, as in other litter-bearing species such as pigs and rabbits, placental and 915 
fetal weight decreases with increasing litter size [378-385]. In twin-bearing sheep, 916 
reduction from a twin to singleton pregnancy after implantation results in lambs with 917 
birth weight intermediate between that of singleton and twin pregnancies [386, 387]. 918 
This suggests that constraint of fetal growth due to increasing litter size likely reflects 919 
both reduced placental growth and function and competition for maternal nutrients. 920 
Furthermore, similar to humans, the growth trajectory of twin fetal sheep diverges from 921 
that of singletons early in gestation [388-391]. Therefore, events that occur around the 922 
time of conception or during early pregnancy are likely to play an important part in 923 
causing the reduced fetal and placental growth observed in multiple pregnancies [392]. 924 
Consequently, improving fetal growth in multiple pregnancies is likely to require 925 
different interventions than in singleton IUGR pregnancies, where the primary cause is 926 
likely to be poor placental function. However, testing interventions in natural 927 
pregnancies in litter-bearing animals is complicated, because the spontaneous 928 
variation in litter size is also dependent on maternal factors that determine ovulation 929 
rate, which increases with maternal weight, parity and age across multiple species 930 
[393-398]. Therefore, there is a need to develop animal models that reflect the 931 
intrauterine environment of multiple pregnancies but are not confounded by these 932 
maternal factors. This will allow researchers to test potential intervention strategies to 933 
prevent or treat IUGR in multiple pregnancies, such as promotion of maternal metabolic 934 
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adaptations and placental function through elevated maternal growth hormone (GH) 935 
and or IGFs.  936 
 937 
1.6 Growth hormone/insulin-like growth factor axis  938 
1.6.1 Overview of the axis 939 
GH is a peptide hormone that promotes cell division, regeneration and growth. It is 940 
secreted from the somatotrophs of the anterior pituitary in a pulsatile manner due to the 941 
alternating stimulatory and inhibitory influence of hypothalamic hormones GH-releasing 942 
hormone (GHRH) and somatostatin (SRIF), respectively (Figure 1.3) [399, 400]. The 943 
gastric peptide hormone ghrelin, once acylated, also stimulates GH secretion by acting 944 
at the level of the hypothalamus and pituitary through the GH secretagogue receptor 945 
(GHSR)1-a [401]. GH secretion is further influenced by a broad range of factors, 946 
including concentrations of sex steroids (puberty, sex), age, sleep, exercise, stress, 947 
insulin, glucose, amino acids and fatty acid concentrations, visceral fat mass and 948 
pregnancy (discussed in detail later in this thesis) [402, 403]. 949 
GH mediates several important physiological processes, including somatic growth and 950 
development, carbohydrate and lipid metabolism, by binding to the growth hormone 951 
receptor (GHR). Binding of GH to the GHR induces intracellular signalling through a 952 
phosphorylation cascade involving the Janus Kinase/Signal Transducing Activators of 953 
Transcription (JAK/STAT) pathway [404]. JAK-STAT activation in turn activates a 954 
number of different intracellular signalling pathways which regulate cellular processes 955 
including transcription, proliferation and metabolism [405]. GH can also act indirectly by 956 
inducing the synthesis of the potent growth and differentiation factor, IGF1, which 957 
mediates many of GH’s metabolic and growth-promoting effects through endocrine, 958 




Figure 1.3 The non-pregnant GH-IGF1 axis: Pulsatile GH secretion is the result of 962 
alternating input from GH releasing hormone (GHRH; stimulatory) and somatostatin 963 
(SRIF; inhibitory). The acylated gastric peptide ghrelin can also stimulate GH secretion 964 
indirectly, by positively inducing GHRH neuronal activity and suppressing SRIF activity 965 
and directly, by stimulating the somatotrophs of the anterior pituitary. Once in the 966 
circulation, GH has direct actions in several organs and tissues, including the liver, 967 
which is also the major site of GH-mediated production of IGF1. IGF1 can exert its 968 
actions on tissues in an autocrine or paracrine manner. A number of feedback 969 
mechanisms exist to modulate GH secretion. GH suppresses its own secretion by 970 
acting on somatotrophs and at the hypothalamus to inhibit GHRH activity and promote 971 
SRIF release, which in turn inhibits ghrelin secretion. IGF1 also suppresses GH 972 
secretion by inhibiting GHRH and stimulating SRIF secretion.  973 
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1.6.2 GH releasing hormone (GHRH) 974 
GHRH is a peptide hormone that positively stimulates pulsatile growth hormone 975 
synthesis and secretion by binding to the GHRH receptor [407]. GHRH is produced by 976 
neurosecretory cells that originate from the arcuate nucleus of the hypothalamus [408]. 977 
The axons of these GHRH neurons project to the median eminence and terminate on 978 
the capillaries of the portal system of the pituitary and are hence optimally positioned to 979 
regulate GH release [409]. GHRH released from the hypothalamus binds to GHRH 980 
receptor on somatotroph membranes. This binding initiates G protein mediated 981 
pathways that induce membrane depolarisation and release of GH from secretory 982 
granules [410-412].  983 
1.6.3 Somatostatin (SRIF) 984 
SRIF is a cyclic tetradecapeptide that has a broad range of actions, including inhibition 985 
of GHRH-mediated GH release [413-416]. Within the hypothalamus, the peptide is 986 
predominantly synthesised in the anterior periventricular nucleus [417, 418]. These 987 
neurons have axonal projections to the median eminence with nerve terminals at the 988 
hypophyseal portal vessels [417, 418]. Elevated circulating GH activates these neurons 989 
and promotes release of SRIF into the portal vasculature, where it acts on the 990 
somatotrophs by binding to membrane-bound high-affinity somatostatin receptors 991 
(SSTR) [419].These transmembrane G-protein coupled receptors have 5 subtypes 992 
(SSTR1-5) and mediate SRIF’s inhibitory action on GH release by inhibiting adenylyl 993 
cyclase via Gi [420]. SRIF binding also results in membrane hyperpolarisation [421, 994 
422], which inhibits GHRH-induced exocytosis of GH vesicles but not their biosynthesis 995 
[423, 424]. IGF1 mediated stimulation of SRIF and inhibition of GHRH can also 996 
contribute towards the suppression of GH release [425]. 997 
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1.6.4 Ghrelin 998 
In addition to the two hypothalamic hormones, GHRH (stimulatory) and SRIF 999 
(inhibitory), GH is regulated by the acylated form of the peptide hormone ghrelin which 1000 
acts at the hypothalamus and pituitary to stimulate GH secretion (Figure 1.3, 1.5). 1001 
Following its transcription, mature ghrelin mRNA is enzymatically processed into 1002 
preproghrelin and then proghrelin. Proteolytic cleavage of proghrelin by the enzyme 1003 
prohormone convertase (PC1/3) gives rise to mature ghrelin, a 28-amino acid peptide 1004 
[426]. Cleavage of proghrelin also produces a 66-amino acid long carboxyterminal 1005 
peptide, known as C-ghrelin [427-429], which is further cleaved to generate the 23-1006 
amino acid-long peptide, obestatin [430]. This is also biologically active, but since 1007 
pathways are not the focus of this thesis, these will not be discussed further here. 1008 
Although acyl-ghrelin has multiple stimulatory actions, including adrenocorticotropic 1009 
hormone (ACTH) and prolactin release, appetite regulation, gastric acid secretion, 1010 
gastric motility and cell proliferation, the following sections will focus on its role in GH 1011 
secretion [431, 432].  1012 
1.6.4.1 Tissue distribution of ghrelin  1013 
Ghrelin is expressed mainly in the gastric mucosa and gastrointestinal (GI) tract [401, 1014 
433], where its abundance gradually decreases from the duodenum to the colon [434-1015 
436]. This peptide hormone is produced and secreted predominantly by the X/A-like 1016 
entero-endocrine cells in the oxyntic glands of the gastric fundus [434, 436-438]. 1017 
Ghrelin is also found in the pancreas, where it co-localises with a range of cell types 1018 
including α, β, ε, and acinar cells [439-443], suggesting its potential role in regulating 1019 
endocrine pancreatic activity [444]. Low-level expression of ghrelin has also been 1020 
identified in the central nervous system [434], as well as the pituitary and hypothalamic 1021 
neurons of the arcuate nucleus where ghrelin acts to regulate food intake [401, 445-1022 
447]. Other tissues including kidney, adrenal and thyroid glands, breast, ovary, 1023 
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placenta, testis, prostate, liver, gallbladder, lung, skeletal muscle, myocardium, skin 1024 
and bone also express ghrelin [448, 449].   1025 
1.6.4.2 Ghrelin secretion  1026 
Under normal physiological conditions, ghrelin secretion exhibits a circadian rhythm 1027 
with a pre-prandial rise and a post-prandial fall [450, 451]. Due to this secretion pattern, 1028 
ghrelin was initially believed to act as a meal initiation signal [451]. However, further 1029 
investigations established that ghrelin secretion actually rises in anticipation of a meal 1030 
rather than to elicit feeding [452].  1031 
1.6.4.3 Ghrelin acylation  1032 
In order to mediate a number of its functions, ghrelin undergoes a post-translational 1033 
modification in the endoplasmic reticulum, catalysed by the enzyme membrane bound 1034 
O-acyl transferase-4 (MBOAT4, also known as ghrelin O-acyl transferase), which is 1035 
predominantly co-localised with ghrelin in the GI tract [453]. During acylation, a 1036 
medium-chain fatty acid (MCFA), typically n-octanoic acid (C8:0), is covalently bonded 1037 
to the hydroxyl group of serine, the third amino acid in the ghrelin peptide (Figure 1.4) 1038 
[454, 455]. The addition of an octanoyl (8-carbon) group, or octanoylation, is necessary 1039 
for ghrelin to bind to the widely expressed GHSR1-a, as this activates downstream 1040 
pathways, including stimulation of GH secretion in humans and rodents [401, 456, 1041 
457].  1042 
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Figure 1.4 Octanoylation of ghrelin: In order to bind to growth hormone secratagogue 1044 
receptor 1a (GHSR-1a), ghrelin is n-octanoylated through the addition of an 8-carbon 1045 
fatty acid to its third (serine) residue. This process is catalysed by the enzyme 1046 
Membrane-Bound O-acyltransferase 4 (MBOAT4), also referred to as ghrelin O-acyl 1047 
transferase (GOAT). The unacylated or des-acyl form of ghrelin lacks the fatty acid 1048 
group and cannot bind or activate GHSR1-a. Figure taken from [458].  1049 
 1050 
Acyl-ghrelin has a half-life of approximately 9-13 minutes while that of des-acyl ghrelin 1051 
is approximately 30 minutes [459, 460]. Furthermore, acyl-ghrelin is rapidly de-acylated 1052 
in circulation [461, 462]. In human sera, butyrylcholinesterase is believed to mediate 1053 
ghrelin deoctanoylation/deacylation, while in rodents, carboxylesterase may be 1054 
responsible for this process [461]. However, many other proteins in human serum, 1055 
including platelet activator factor, paraoxonase, carboxypeptidase, alpha 2-1056 
macroglobulin, acyl-protein thioesterase 1 also show ghrelin esterase activity and may 1057 
also potentially deacylate circulating ghrelin [461, 463-465]. Together, rapid clearance 1058 
and de-acylation of acyl-ghrelin mean that the ratio of des-acyl ghrelin to acyl-ghrelin in 1059 
the circulation is usually high [461, 462].  1060 
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1.6.4.4 Ghrelin O-acyl transferase; Membrane-Bound O-acyltransferase-4 (MBOAT4) 1061 
The enzyme MBOAT4 is one of 16 enzymes that form part of the acyltransferase 1062 
family, but MBOAT4 is the only member of the family able to acylate ghrelin [466]. This 1063 
membrane bound enzyme has eleven transmembrane helices and one entrant loop. 1064 
The C-terminus of the enzyme is located in the cytosol and the N-terminus is in the 1065 
lumen of the endoplasmic reticulum, where the catalytic activity likely occurs [453, 467]. 1066 
This enzyme has a broad substrate specificity for fatty acids, and can acylate ghrelin 1067 
with fatty acids between acetic acid (C2:0) to tetradecanoic acid (C16:0) [453]. The 1068 
composition of dietary fatty acids is therefore an important determinant of the carbon 1069 
chain length of the acyl group attached to nascent ghrelin molecules. In mice, the 1070 
lengths of carbon chains attached to ghrelin correspond to those of the ingested 1071 
MCFAs or medium-chain triglycerides (MCTs) [468]. However, in the stomach, the 1072 
majority of ghrelin is acylated with n-octanoic acid (C8:0) [469]. This suggests that 1073 
octanoic acid has greater enzyme affinity and/or concentration near X/A-like entero-1074 
endocrine cells than other MCFAs and MCTs present in the typical human diet [455].  1075 
1.6.4.5 Ghrelin-mediated GH secretion  1076 
Acyl-ghrelin can promote GH secretion directly by stimulating somatotrophs of the 1077 
anterior pituitary, and indirectly by acting at the hypothalamus to inhibit SRIF and 1078 
stimulate GHRH-neuronal activity (Figure 1.5) [431]. Binding of acyl-ghrelin to GHSR1-1079 
a activates Gαq/11 signalling, resulting in activation of phospholipase C (PLC), which in 1080 
turn hydrolyses phosphatidylinositol 4,5 bisphosphate (PIP2) located in the cell 1081 
membrane, contributing to the generation of diacylglycerol (DAG) and inositol 1,4,5- 1082 
trisphosphate (IP3) [431, 432, 470-472]. IP3 then binds to its receptor (IP3-R) in the 1083 
endoplasmic reticulum which releases calcium into the cell, increasing intracellular 1084 
calcium ion concentrations. IP3 also enables GH secretion by facilitating mobilisation of 1085 
GH secretory granules to fuse with the plasma membrane [473]. Elevated intracellular 1086 
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Ca+ mobilises DAG-activated protein kinase C to the plasma membrane, where it 1087 
inhibits potassium ion channels, thereby causing membrane depolarisation. Opening of 1088 
L-type voltage dependent calcium channels is then triggered, which further increases 1089 
intracellular calcium ion concentration and induces GH secretion [431, 474]. 1090 
Ghrelin-stimulated GH release is also mediated via ghrelin’s interactions with the 1091 
hypothalamic feeding circuits, particularly through neuropeptide-Y (NPY) / Agouti-1092 
related protein (AgRP) expressing neurons in the arcuate nucleus, a region with high 1093 
density of GHSR1-a (Figure 1.5) [475, 476]. Connection of these neurons with those 1094 
that express somatostatin in the periventricular nucleus provides a potential pathway of 1095 
action in the regulation of acyl-ghrelin induced GH secretion [477]. The vagus nerve 1096 
also appears to play an important role in mediating ghrelin’s GH releasing effects, 1097 
because disruptions of vagal connections in animal models impair GH release in 1098 
response to central and peripheral ghrelin injections [478]. The endocannabinoid 1099 
system is likely involved in relaying ghrelin’s effects on GH secretion via the vagus 1100 
nerve, since blockade of peripheral cannabinoid receptor subtype 1 with rimonabant 1101 
decreases ghrelin-induced, but not GHRH-induced GH secretion but the inhibitory 1102 
effect of rimonabant on GH secretion is lost in vagotomised animals (Figure 1.5) [477, 1103 
479].  1104 
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Figure 1.5 Established and potential pathways of acyl-ghrelin-stimulated GH secretion: 1106 
Acyl-ghrelin can travel via the bloodstream to stimulate GH indirectly through 1107 
stimulating GHRH neuronal activity (arcuate nucleus) or directly, by acting on 1108 
somatotrophs in the anterior pituitary. Additionally, the vagus nerve is necessary for the 1109 
full GH-releasing activity of ghrelin. Some data suggest that the peripheral cannabinoid 1110 
receptor subtype 1 (CB1) may be important for relaying ghrelin’s action on GH 1111 
secretion but this receptor does not alter GHRH induced GH secretion, suggesting that 1112 
it is not involved in ghrelin’s activity in the hypothalamus. The NPY/AgRP neurons in 1113 
the arcuate nucleus, typically involved in mediating ghrelin’s orexigenic effects have 1114 
connections to somatostatin (SRIF) neurons in the periventricular nucleus, and hence 1115 
may also be involved in regulation of ghrelin-mediated GH secretion through unknown 1116 
mechanisms. Figure based on information from [431, 475-479]. 1117 
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1.6.4.6 Des-acyl ghrelin  1119 
Due to its inability to bind to GHSR-1a, unacylated or des-acyl ghrelin was originally 1120 
thought to be an inactive degradation product. However recent work suggests that des-1121 
acyl ghrelin is also a hormone, which can either act synergistically with, antagonise the 1122 
actions of, or work independently from, acyl-ghrelin [480-488]. Furthermore, des-acyl 1123 
ghrelin can suppress acyl-ghrelin secretion in both humans and animals and therefore 1124 
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has the potential to inhibit GHSR-1a activation [489]. It has been speculated that des-1125 
acyl ghrelin mediates its functions by binding to an unknown receptor and that it may 1126 
also interact with acyl-ghrelin at this receptor but further studies are required to 1127 
investigate this directly [486, 490].  1128 
1.6.5 Growth hormone (GH) 1129 
Regulation by GHRH, SRIF and acyl-ghrelin results in episodic, high amplitude bursts 1130 
of GH secretion, separated by troughs of low-level or basal secretion throughout each 1131 
24 h period. Each episode of GH secretion is initiated by a burst of GHRH released into 1132 
the hypophyseal portal system, preceded by a withdrawal of SRIF’s inhibitory input on 1133 
GHRH neurons and somatotrophs (Figure 1.3) [491-495]. GHRH-mediated GH 1134 
synthesis during high SRIF tone is believed to allow GH accumulation in somatotrophs 1135 
which potentiates release of GH pulses when SRIF input is withdrawn and GHRH 1136 
levels are high [407, 496]. Furthermore, acyl-ghrelin can act directly on the 1137 
somatotrophs or stimulate GHRH neuronal activity in the hypothalamus to enhance GH 1138 
pulse amplitude [497-500].  1139 
The pattern and abundance of GH secretion is crucial for its biological activity. In 1140 
hypophysectomised rats, the lack endogenous GH secretion, greater bone growth and 1141 
weight gain is observed when the same dose of GH given in pulses compared to 1142 
continuous administration [501, 502]. In children, growth rates and circulating plasma 1143 
IGF1 concentrations correlate positively with peak, but not basal GH concentrations 1144 
[503-505].  1145 
Both the pattern and magnitude of GH release differ between males and females in a 1146 
species-dependent manner [513]. In humans, males secrete GH in high amplitude 1147 
bursts at regular intervals, separated by periods of very low or undetectable GH 1148 
concentrations, whereas females exhibit more frequent, irregular and lower GH 1149 
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secretory pulses and have higher baseline GH concentrations [495, 510, 514-516]. In 1150 
contrast to humans, mean GH concentrations and GH pulse amplitude in blood are 1151 
higher in male compared to female rats [506, 517-521]. However, female rats have 1152 
higher interpulse plasma GH concentrations and exhibit a higher irregularity in pulsatile 1153 
GH secretion compared to male rats [517-519, 522, 523]. Although mean and basal 1154 
plasma GH concentrations as well as pulse amplitude are also greater in rams (intact 1155 
males) than ewes (intact females), GH pulse frequency does not differ between the 1156 
sexes in sheep [524].  1157 
The sexual dimorphism in circulating GH likely reflects both acute responses to sex 1158 
steroids and persistent effects of the steroid hormone environment during early 1159 
development on the hypothalamo-pituitary axis, which result in sex-specific differences 1160 
in the number of GHRH neurons and somatotrophs and their sensitivity to post pubertal 1161 
steroids (reviewed by [525]). Acute changes in circulating steroids likely underlie 1162 
changes in GH patterns throughout the menstrual cycle in women, where pulsatile GH 1163 
release doubles during the late follicular stage of the menstrual cycle compared to early 1164 
follicular phase [509]. Sex steroids regulate circulating GH through multiple pathways. 1165 
For example, oestrogen administration in women increases circulating GH peak 1166 
amplitude via suppressing GH negative feedback on hypothalamic GHRH secretion, 1167 
enhancing SRIF withdrawal-induced GH release, reducing pituitary responsiveness to 1168 
SRIF and increasing potency to exogenous GHRH [526-529].  1169 
1.6.5.1 GH signalling 1170 
Once released into the circulation, GH binds to GH binding protein (GHBP), which is 1171 
produced through the proteolytic cleavage of the extracellular domain of the GHR, and 1172 
stabilises the hormone and prolongs its bioavailability [530, 531]. GH must be released 1173 
from GHBP in order to bind to membrane-bound full-length GHR. Binding of GH to a 1174 
pre-formed GHR homodimer causes rotation of an internal section of the receptor and 1175 
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repositions the catalytic domain of the associated JAK2 tyrosine kinase [532]. This 1176 
allows JAK2 to phosphorylate the cytoplasmic regions of the GHR and creates a 1177 
binding site for Src homology 2 (SHC2) domain-containing proteins. These proteins 1178 
include the signal transducers and activators of transcription (STAT)1, 3, 5a and 5b 1179 
proteins, which are phosphorylated by JAK2 and are critical signalling components 1180 
involved in mediating GH action [404]. The phosphorylated STAT proteins dimerise and 1181 
are subsequently translocated to the nucleus where they regulate transcription of GH 1182 
target proteins [533]. Stat5b is the major regulator of GH actions and upregulates 1183 
transcription of IGF1. IGF1 mediates many growth-promoting actions of GH by binding 1184 
to the IGF1-receptor (IGFR) which stimulates growth in tissues including bone and 1185 
muscle [534-536].  1186 
1.6.5.2 GH target tissues 1187 
GH acts on multiple tissues to promote longitudinal growth and regulate metabolism of 1188 
carbohydrates, lipids and proteins. The liver is a major site of GH action, including 1189 
promotion of IGF1 secretion [537], and hepatic glucose output through glycogenolysis 1190 
and gluconeogenesis [538-540]. GH also promotes lipolysis in adipose tissues, in part 1191 
by upregulating lipase activity and downregulating the expression of glucose 1192 
transporters in adipocytes [541-545]. While this can reduce adiposity, particularly 1193 
visceral adiposity, it increases circulating free fatty acid concentrations, which 1194 
enhances uptake of free fatty acids by skeletal muscle and liver and can contribute 1195 
towards impaired insulin signalling and ultimately, development of insulin resistance 1196 
[546-550]. GH also acts directly via GHR in skeletal muscle to promote net protein 1197 
anabolism by stimulating protein synthesis [551], as well as indirectly via IGF1, which 1198 
decreases protein degradation [552, 553]. Both GH and IGF1 promote bone formation 1199 
through the stimulation of osteoblast proliferation and activity [554-557] and bone 1200 
resorption by inducing osteoclast differentiation and activity [558]. Together, these 1201 
50 
actions increase the rate of bone remodelling and ultimately promote bone 1202 
accumulation [554]. 1203 
1.6.6 Insulin-like growth factors (IGFs) 1204 
IGF1 and IGF2 are peptide growth factors that stimulate growth and development of 1205 
vertebrates through metabolic, mitogenic, anti-apoptotic and differentiating effects on a 1206 
wide range of cell types [559]. The endocrine, paracrine and autocrine actions of the 1207 
IGFs are typically exerted through interactions with two different receptors, IGF type 1 1208 
(IGF1R) and type 2 (IGF2R) receptors. Additionally, IGFs can also bind to the insulin 1209 
receptor (IR) and IGF1R/IR hybrid receptors [560-563]. IGF1R has high binding affinity 1210 
for IGF1, lower affinity for IGF2 and little to no affinity for insulin. Binding of IGF1 to 1211 
IGF1R activates the phosphatidylinositol 3-kinase (PI3K)- protein kinase B (PKB/AKT) 1212 
and mitogen activated protein kinase (MAPK) signalling pathways [563-565], whereas 1213 
binding of IGF2 to IGF2R can either activate G-protein-coupled signalling pathways or 1214 
result in IGF2 degradation [566].  1215 
The bioavailability and actions of the IGFs in circulation is regulated by the family of six 1216 
insulin-like growth factor-binding proteins (IGFBPs). The majority of serum IGFs are 1217 
bound to IGFBP-3 in a heterotrimeric complex with acid-labile subunit (ALS), which can 1218 
also form with IGFBP-5, but not other members of the IGFBP family. These ternary 1219 
complexes are mainly restricted to the vasculature, and extend the half-life of the IGFs 1220 
to approximately 15 h, compared to ~10 min for “free” IGF1 not complexed to IGFBP 1221 
[567, 568]. Most remaining serum IGFBPs are found in binary complexes, which can 1222 
exit the circulation rapidly but still extend half-life of the IGFs by approximately 20-30 1223 
min [567]. Depending on the IGFBP and cell types, IGFBPs either block or promote 1224 
binding of IGFs to their receptors [569]. IGFBP proteases, on the other hand, can 1225 
degrade IGFBPs to release IGFs and increase their availability at their receptors [570, 1226 
571]. The IGFBPs also have additional roles, including inhibition of insulin-stimulate 1227 
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glucose uptake in adipocytes (IGFBP-3) [572] and supporting bone tissue growth 1228 
(IGFBP-5) [573], as reviewed previously [569, 574].  1229 
Postnatally, GH is one of the main promotors of hepatic IGF1 synthesis. However, 1230 
energy status and protein intake are also important regulating factors, and fasting 1231 
decreases serum IGF1 concentrations [575-578]. During human intrauterine 1232 
development, the IGFs appear to be less dependent on GH, as congenital GH 1233 
deficiency is associated with postnatal growth failure, rather than reduced intrauterine 1234 
growth [579, 580]. IGF1 is more important for fetal growth and loss-of-function IGF1 1235 
gene mutations are associated with severe intrauterine growth restriction [581, 582]. In 1236 
humans, circulating IGF1 levels are low at birth and rise gradually during childhood, 1237 
peak at puberty, and then gradually decline with age [559, 583]. IGF2 is less well 1238 
studied but its levels have been reported to increase from birth to puberty and then 1239 
remain stable [559]. 1240 
IGF1 mediates the majority of GH’s effects on skeletal metabolism, including 1241 
stimulation of amino acid transport, but can also directly stimulate protein synthesis and 1242 
is an important inhibitor of protein breakdown [584]. In skeletal muscle, IGF1 acts as a 1243 
potent stimulator of free fatty acid uptake and oxidation and, together with IGF2, plays 1244 
a crucial role in skeletal muscle differentiation [585, 586]. Although IGF1 can stimulate 1245 
pre-adipocyte differentiation, at physiological concentrations its actions on lipid 1246 
synthesis, lipolysis and glucose transport in mature adipose tissue appear to be limited 1247 
[587, 588].  IGF1 may also be involved in regulation of carbohydrate metabolism 1248 
through inhibition of GH secretion and through its insulin-sensitising effects [589]. IGF1 1249 
suppresses GH secretion and also enhances insulin suppression of hepatic 1250 
gluconeogenesis [590, 591]. IGF1 also promotes chondrogenesis and increases bone 1251 
formation by regulating function of the differentiated osteoblasts [592]. 1252 
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There is substantial evidence that both IGFs play a crucial role in placental and fetal 1253 
development. Several in vitro studies have also shown that these growth factors 1254 
promote cell differentiation and growth [593-597]. More specific to fetal growth, and 1255 
discussed in more detail in section 1.7.3 data from in vivo studies suggests that 1256 
maternal IGFs promote fetal growth in part by increasing materno-fetal transfer of 1257 
nutrients throughout gestation [598-600].  1258 
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1.7 The GH/IGF axis in pregnancy 1259 
 1260 
Figure 1.6 The GH axis during pregnancy (A) Humans: Late in the first trimester, 1261 
continuous placental secretion of growth hormone variant (GH-V), increases basal 1262 
maternal GH concentrations. By early in the second trimester, placental GH-V 1263 
production suppresses pituitary GH secretion, and results in a pattern of elevated, non-1264 
pulsatile maternal circulating GH which persists for the remainder of pregnancy. (B) 1265 
Rodents: Circulating maternal GH concentrations also increase significantly during 1266 
pregnancy in rodents. Unlike humans, rodents do not express GH-V and maternal 1267 
circulating GH remains pulsatile and pituitary-derived throughout pregnancy. The 1268 
pregnancy-associated increase in maternal GH is likely induced by an unidentified 1269 
placental signal, which acts on the maternal pituitary and/or hypothalamus to enhance 1270 
GH secretion. Figure based on information from [120, 121, 123] 1271 
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1.7.1 Changes in GH and IGFs during normal pregnancy  1272 
The GH/IGF axis undergoes substantial changes during pregnancy in humans (Figure 1273 
1.6A) and most mammalian species studied to date, including rodents (Figure 1.6B). 1274 
These changes facilitate maternal adaptation to pregnancy in addition to promoting 1275 
fetal and placental growth and function. During early human pregnancy, pulses of 1276 
pituitary-derived GH are superimposed on elevated basal GH as a result of continuous 1277 
release of GH-V, which can be detected by late in the first trimester (Figure 1.7A) [120, 1278 
121]. In early pregnancy, at 11 weeks of gestation, circulating GH remains pulsatile and 1279 
is largely pituitary-derived, whilst pituitary GH secretion becomes suppressed by 1280 
negative feedback due to placental GH production before mid-pregnancy at around 15-1281 
17 weeks of gestation (Figure 1.7A) [120]. Unlike the pulsatile pattern of pituitary-1282 
derived GH secretion, placental GH secretion is continuous, resulting in elevated and 1283 
non-pulsatile maternal circulating GH in the second half of human pregnancy (Figure 1284 
1.7A) [120], Circulating GH patterns during pregnancy have also been characterised in 1285 
rodents (Figures 1.7B and 1.7C). In contrast to humans, circulating GH profiles remain 1286 
pulsatile throughout pregnancy in rats (Figure 1.7B) [122, 601], as well as mice (Figure 1287 
1.7C ) [123]. In these species, the increase in average circulating GH concentrations 1288 
reflects elevated basal GH secretion [122, 123], while the number and magnitude of 1289 
pulsatile GH secretion remain unchanged throughout murine pregnancy, they decrease 1290 
in regularity [123, 602]. Despite the importance of GH during pregnancy in many 1291 
mammalian species, the mechanism driving increased maternal GH in non-human 1292 
species is not yet completely understood.  1293 
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Figure 1.7 GH secretory profiles in non-pregnant and early, mid and late pregnant 1295 
humans (A), rats (B) and mice (C). In human pregnancy (A), pulses of pituitary-derived 1296 
GH are super-imposed on elevated basal GH derived from placental expression of a 1297 
GH variant (GH-V) by late in the first trimester. Unlike the secretory pattern of pituitary 1298 
derived GH, GH-V secretion is non-pulsatile and continuous and becomes the main 1299 
form of circulating GH by mid-pregnancy. In rats (B) and mice (C), total and basal GH 1300 
concentrations are also elevated by early-mid pregnancy but unlike humans, GH is only 1301 
produced by the pituitary and GH profiles remain pulsatile throughout the course of 1302 
pregnancy. Hatched area in A indicates detection limit of the assay used to detect 1303 
circulating pituitary GH in humans. Shaded areas in C (mouse) indicate sampling 1304 
during dark period. Profiles have been generated using data from [120, 122, 123].  1305 
 1306 
Changes in circulating maternal IGF concentrations during pregnancy are highly 1307 
variable across species [603]. In humans, reported maternal IGF1 concentrations 1308 
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during the first two trimesters are inconsistent, with some studies reporting a modest or 1309 
gradual rise in concentrations but others finding no change or decreased 1310 
concentrations compared to pre-pregnancy levels [604-612]. During the third trimester, 1311 
however, the majority of studies have reported substantially (45-200%) higher maternal 1312 
circulating IGF1 concentrations compared with levels in non-pregnant women [604]. In 1313 
rodents, IGF1 concentrations gradually decrease throughout pregnancy, falling below 1314 
non-pregnant levels by late pregnancy [613, 614]. In rabbits and guinea pigs, on the 1315 
other hand, maternal IGF1 gradually rises during the first half of pregnancy, followed by 1316 
a rapid decline after mid-pregnancy [615, 616], while circulating IGF1 concentrations 1317 
do not change during pregnancy in sheep and cattle [617-619]. In humans, proteolysis 1318 
of IGFBPs increases around ~6-8 weeks of gestation [620-624]. Similarly, in rats, most 1319 
IGFBPs in serum are significantly reduced in the latter half of rat pregnancy, and this 1320 
likely contributes to faster clearance of maternal IGF1 [614]. 1321 
In contrast, maternal IGF2 concentrations increase throughout pregnancy in most 1322 
species, and are higher than circulating concentrations of IGF1 [605, 615, 616, 618, 1323 
625]. The placenta is a major source of IGF2 in animals with a haemochorial placenta, 1324 
where IGF2 is produced by the syncytiotrophoblast layer in direct contact with maternal 1325 
blood [626-629]. Consistent with the majority of IGF2 being placentally-derived, IGF2 is 1326 
high in pregnancy but almost undetectable in plasma in non-pregnant rodents 1327 
postnatally [630, 631]. Although placental IGF1 expression is minimal, other hormones 1328 
produced by the placenta (like GH-V in humans or placental lactogen) may still 1329 
influence maternal IGF1 concentrations and actions [629].  1330 
1.7.1.1 Potential drivers of increased maternal growth hormone during pregnancy  1331 
The GH gene cluster consists of five structurally similar genes, including the pituitary 1332 
GH variant GH-N/ GH-1, placental growth hormone (GH-V), chorionic 1333 
somatomammotropin hormone 1 (CSH1/ hCS-A), chorionic somatomammotropin 1334 
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hormone 2 (CSH2/ hCS-B), and a pseudogene known as chorionic 1335 
somatomammotropin-like hormone. A related protein, human prolactin (PRL), is also 1336 
included in the GH gene family [632, 633]. As discussed in earlier sections, placental 1337 
production of GH-V is responsible for the change in maternal GH secretory pattern 1338 
during human pregnancy (Figure 1.6 and 1.7A). Most other mammalian species, 1339 
however, do not produce placental GH [634]. The increases in circulating GH 1340 
concentration and basal GH secretion in pregnant mice [123] coincide with the 1341 
formation of the chorioallantoic placenta and initiation of placental blood flow [635]. 1342 
This suggests, therefore, that the pregnancy-associated increase in GH secretion 1343 
observed in species like rats (Figure 1.7B) and mice (Figure 1.7C) is driven by another 1344 
placentally-derived factor [123]. A number of candidate placental products might 1345 
contribute to the increase in GH section. Although lacking the GH-V, endocrine, 1346 
trophoblast giant cells of the mouse placenta express 22 placental-specific genes 1347 
related to prolactin (Prl) [110, 636, 637]. A number of these prolactin related peptides, 1348 
including Prl3d1 and Prl3b1, can bind to the Prl receptor and contribute to the 1349 
increasing maternal glucose concentrations in murine pregnancy [638, 639]. Other 1350 
potential candidates expressed by the murine placenta include two factors important for 1351 
endogenous GH secretion, GHRH and ghrelin [640, 641]. Although no studies to date 1352 
have assessed whether MBOAT4 is expressed in the rodent placenta, GHSR-1a gene 1353 
and protein expression has been identified in the placenta of rats [642]. It is therefore 1354 
possible that the increase in basal GH secretion in rodent pregnancy, in the absence of 1355 
GH-V, may be mediated via placental production and activation of ghrelin, which in turn 1356 
promotes pituitary GH production throughout pregnancy [123]. However, the 1357 
relationship between changes in maternal ghrelin and GH production during pregnancy 1358 
are not clearly understood.  1359 
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1.7.2 Responses to maternal GH/IGF treatment in normal pregnancy 1360 
Maternal treatment with GH during pregnancy increases fetal growth in a number of 1361 
species, provided maternal nutrient intake is not limited. The response is also 1362 
dependent on the pattern of administration. Continuous GH administration does not 1363 
alter maternal IGF1 concentrations, fetal or placental weights in rats [643], whereas 1364 
intermittent (once or twice daily) GH administration significantly increases fetal growth 1365 
[644-646]. The mechanisms underlying differential effects of intermittent and 1366 
continuous GH administration on pregnancy outcomes in rats are unclear, but are 1367 
consistent with pattern-dependent responses to GH in non-pregnant animals and 1368 
humans (see section 1.6.5 above). In pigs, maternal GH administration via daily 1369 
injections from early to mid-pregnancy in increased fetal growth and birth weight if the 1370 
treatment was continued for the majority of gestation [380, 647]. Birth weight was not 1371 
increased when pigs were treated with GH only in early-mid pregnancy [648], even 1372 
though fetuses were heavier immediately following treatment [649]. In sheep, sustained 1373 
release GH administration during the periconceptional or breeding period improved 1374 
birth weight by approximately 10% [650, 651]. Although some have reported a similar 1375 
increase in fetal weight with intermittent GH administration to ewes during late 1376 
gestation, others found an improvement in placental diffusion capacity without any 1377 
changes in progeny weight [652, 653].  1378 
In other studies, exogenous maternal IGF1 treatment alters resource allocation 1379 
between maternal tissues and the developing conceptus but results vary according to 1380 
species and gestational age. In rats, maternal IGF1 administration in the second half of 1381 
pregnancy does not alter fetal or placental weight but increases maternal weight [643, 1382 
654, 655]. In guinea pigs, early-mid pregnancy treatment with IGF1 or IGF2 increases 1383 
fetal and placental weight [656] and improves placental function around mid-late 1384 
gestation [626]. However, only treatment with IGF1, and not IGF2, decreases maternal 1385 
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fat mass in this species, supporting the suggestion that IGF1 acts to divert nutrients 1386 
from the mother to the conceptus, thereby promoting fetal growth at the expense of the 1387 
mother [626].    1388 
1.7.3 Placental responses to GH and IGF1 function  1389 
Growth-promoting effects of GH may be mediated by the placenta, since maternal GH 1390 
treatment also increases placental growth and promotes placental function in a number 1391 
of species [646, 649, 652, 657, 658]. In pigs, maternal GH administration during early-1392 
mid pregnancy increases placental weight and surface area [657, 659] with increased 1393 
protein expression of glucose and amino acid transporters GLUT1 (SLC2A1) and 1394 
SNAT2 (SLC38A2) in the fetal-facing placental membrane [658] which would be 1395 
expected to enhance fetal nutrient supply. In sheep, short-term (10 day) maternal GH 1396 
administration during mid-late pregnancy increases placental capacity for simple and 1397 
facilitated diffusion (responsible for glucose transport), compared to saline-treated 1398 
controls [652]. The increase in simple diffusion in this study was greater compared to 1399 
the effect on facilitated diffusion, suggesting that the improved placental transport 1400 
capacity was likely the result of increased placental surface area or reduced placental 1401 
barrier thickness, rather than increased activity of placental nutrient transporters [652].  1402 
Maternal treatment with IGF1 and IGF2 during pregnancy also promote fetal growth by 1403 
enhancing placental growth, fetal nutrient availability and uptake [119, 603, 660, 661]. 1404 
In guinea pigs, maternal IGF1 infusion during early pregnancy increases placental 1405 
uptake and transfer of glucose and amino acids at mid pregnancy [661]. This is likely to 1406 
be mediated in part by increased placental gene expression of Slc38a2, suggesting 1407 
early pregnancy maternal IGF1 concentrations play a role in enhancing mid-gestation 1408 
fetal nutrient supply and growth [661]. In another guinea pig study, maternal IGF2 1409 
treatment increased the volume and surface area of the labyrinth zone in the near term 1410 
placenta, which is likely to enhance placental capacity for materno-fetal nutrient and 1411 
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gas exchange during this crucial growth stage [662]. The importance of IGF2 is further 1412 
highlighted in mouse studies where deletion of the placental-specific P0 Igf2 promoter, 1413 
which blocks placental labyrinth-specific Igf2 production and causes IUGR due to a 1414 
reduced placental nutrient transfer capacity as discussed in more detail in section 1415 
1.5.7.6 [370, 371, 373]. This leads to a 50% reduction in surface area, 28% increase in 1416 
barrier thickness and a decrease in the overall placental capacity to transport system A 1417 
transporter substrates, which constributes to 20-25% reduction in fetal weight 1418 
compared to wild type controls.   1419 
The role of IGFs in enhancing placental function is further supported by in vitro findings 1420 
that both IGF1 and 2 promote proliferation, invasion/migration and exhibit anti-apoptotic 1421 
properties in trophoblast cell lines from humans, pigs and mice, and are therefore likely 1422 
to promote implantation and overall placental growth [593-597]. The IGFs also enhance 1423 
the endocrine capacity of trophoblasts in culture, such that the secretion of 1424 
progesterone, hCG, and placental lactogen by human trophoblasts increases after 1425 
IGF1 treatment [663, 664]. In mice, IGF2 stimulates the differentiation of ectoplacental 1426 
cone cells into endocrine trophoblast giant cells, and in ovine trophectoderm cells, 1427 
IGF2 regulates signalling pathways, suggesting its role in conceptus growth and 1428 
differentiation [593, 594]. Therefore, the results of both in vitro and experimental animal 1429 
in vivo studies support the suggestion that stimulation of the GH/IGF axis can promote 1430 
fetal and placental growth, as well as enhance hormonal secretion and nutrient 1431 
transport capacity of the placenta [665]. 1432 
1.7.4 Responses to GH and IGF1 treatment in IUGR pregnancy  1433 
Given its effects on growth in normal pregnancies, a number of studies have 1434 
investigated whether administration of maternal GH or IGF1 can rescue fetal growth in 1435 
growth-restricted pregnancies. Pigs provide a natural model of IUGR pregnancies, as 1436 
fetal size and birth weight are constrained by adolescent first pregnancy, limited uterine 1437 
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capacity, large litter size and limited maternal nutrition [666-669]. Gatford and 1438 
colleagues previously reported that average piglet weight at birth correlates negatively 1439 
with litter size in adolescent first pregnancy [380]. However, the impact of maternal 1440 
constraint and a large litter size on the average progeny birth weight was less 1441 
pronounced if the mother was treated with GH throughout early to late pregnancy [380]. 1442 
Similarly, in pregnant sheep with IUGR induced via placental embolisation, twice-daily 1443 
maternal GH administration increased fetal growth in terms of fetal weight and length 1444 
[670].  1445 
These fetal growth-promoting effects could be mediated by GH acting directly on 1446 
tissues via its own receptors or indirectly, via increased secretion of IGF1. In rodents 1447 
increased maternal plasma IGF1 concentrations, either endogenously or exogenously, 1448 
reduce the impact of maternal constraint induced by litter size on fetal growth [379]. 1449 
Thus, in both normal dams and dams selected from a low plasma IGF1 line, IGF1 1450 
treatment from days 1-19 of pregnancy abolishes the usual negative relationship 1451 
between fetal weight and litter size in late gestation [379].   1452 
1.7.5 Limitations to clinical treatment with GH or IGF1 1453 
Despite the clear evidence that GH and IGF1 promote fetal growth and placental 1454 
function, the potential for clinical application of GH or IGF1 administration in humans is 1455 
limited. This is largely due to the fact that these proteins are not orally active and 1456 
therefore need to be delivered by injection or infusion. Interventions delivered orally are 1457 
more acceptable to patients compared to injections, even in pregnancy [671]. 1458 
Therefore, in this current project, we aim to identify orally active interventions that act 1459 
directly or indirectly to increase maternal circulating GH, and hence IGF1, to improve 1460 
fetal growth in IUGR pregnancies. One potential approach to do this is through 1461 
increasing circulating levels of the acyl-ghrelin, either by direct administration or 1462 
through a specific dietary intervention. 1463 
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1.7.6 Ghrelin and its potential role in pregnancy  1464 
Although limited studies have investigated changes in the ghrelin axis during 1465 
pregnancy, the available evidence suggests that it has a potential role in facilitating 1466 
maternal adaptation to pregnancy and promoting fetal growth. Treatment with acyl-1467 
ghrelin promotes GH secretion in multiple species [401, 457, 672, 673], while ghrelin 1468 
administration during pregnancy promotes growth of progeny in rodents [674-676]. 1469 
Intramuscular administration of acyl-ghrelin to pregnant sheep for the last 10 days of 1470 
gestation resulted in higher serum GH concentrations compared to non-treated controls 1471 
[672]. Furthermore, administering acyl-ghrelin 3 times a day, from GD14 until delivery 1472 
to pregnant rats increased fetal growth by ~10%, while suppressing maternal acyl-1473 
ghrelin levels via passive immunisation had the opposite effect [674]. Interestingly, 1474 
maternal administration of total ghrelin during early pregnancy (GD3 to GD7) alone, 1475 
reduces birth weight in rats [677], while administration of acyl-ghrelin during the first-1476 
half of pregnancy (GD1 to GD11) reduces litter size without altering birthweight [675]. 1477 
These results suggest that the timing of exogenous elevation in maternal circulating 1478 
ghrelin may be important for ghrelin’s growth-promoting effects. Although not assessed 1479 
in pregnant animals, it is known that acyl-ghrelin, but not des-acyl ghrelin, can act 1480 
centrally to stimulate food intake in rodents [476, 678]. Acyl-ghrelin also plays an 1481 
important role in metabolic adaptations to maintain circulating glucose in response to 1482 
calorie restriction, particularly in pregnancy [679]. Treatment with acyl-ghrelin might 1483 
therefore potentially increase fetal growth through direct action on the placenta, by 1484 
increasing maternal GH and/or by stimulating maternal food intake. 1485 
Changes in maternal circulating ghrelin concentrations during gestation occur in a 1486 
number of mammalian species, albeit not all in the same direction. Total ghrelin 1487 
concentrations have been reported as lower in pregnant than non-pregnant women and 1488 
as lower or unchanged in pregnant than non-pregnant rats [642, 680-683]. Variable 1489 
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evidence exists regarding changes in acyl-ghrelin, with elevated or lower 1490 
concentrations during pregnancy reported in different studies in women [681, 684], and 1491 
increased concentrations during late pregnancy in a single study in rats [685]. Although 1492 
responses to exogenous ghrelin during pregnancy have been previously investigated, 1493 
the role of endogenous ghrelin during pregnancy remains unclear. Pregnant mice 1494 
lacking the Mboat4 gene, which consequently cannot convert ghrelin to acyl-ghrelin 1495 
[686], still undergo a similar increase in GH during late pregnancy as wild-type mice 1496 
[686], suggesting that acyl-ghrelin is not required to increase GH during pregnancy. 1497 
However, compared to wild-type mice, there was a trend for lower median GH 1498 
concentrations in the knockout mice. Furthermore, in this study GH was only measured 1499 
in a single maternal blood sample collected at the time of post-mortem which does not 1500 
provide a precise representation of GH’s secretory pattern overtime. Therefore, it is 1501 
unclear whether a lack of acyl-ghrelin alters the circulating patterns of GH during 1502 
pregnancy [686]. 1503 
1.7.7 Acyl-ghrelin levels can be increased by feeding dietary C8 fatty acids or 1504 
triglycerides 1505 
The finding that increased acylation of ghrelin can be achieved by a nutritional 1506 
approach [453, 468, 687] offers great translational potential as a method to increase 1507 
circulating GH. Feeding mice a diet enriched with the C8 medium chain fatty acid, 1508 
octanoic acid (C8-MCFA), or the triglyceride containing this fatty acid, glyceryl 1509 
trioctanoate, increases octanoylation of ghrelin in the stomach and the abundance of 1510 
circulating acyl-ghrelin [453, 468, 687]. Circulating acyl-ghrelin concentrations as well 1511 
as plasma GH concentrations in blood pooled from samples collected at 15-minute 1512 
intervals across a 4-h period, also increased in pigs that were fed a diet enriched with 1513 
mixed medium chain fatty acids [688]. To date, there has only been one study that has 1514 
assessed effects of feeding octanoic acid in humans. Enteral feeding of a single meal, 1515 
64 
containing 2.8 g of octanoic acid, over a period of 3 h, increased plasma acyl-ghrelin 1516 
concentrations by more than 30% [689]. Together, these studies provide evidence that 1517 
dietary C8-MCFA supplementation increases circulating acyl-ghrelin levels in pigs, 1518 
rodents and humans and that this increases circulating GH, at least in pigs.  1519 
In a pilot study conducted in the Gatford lab in 2015-2016 (n=3 mice), dietary 1520 
supplementation with C8-MCFA increased circulating GH abundance in non-pregnant 1521 
female mice. Standard lab chow supplemented with 5% octanoic acid increased basal 1522 
GH secretion >20-fold compared to mice fed a non-supplemented standard chow diet. 1523 
The pattern of GH secretion remained pulsatile in both groups. This approach to 1524 
increase maternal circulating GH (which does not require injections or infusions) could 1525 
be adapted during pregnancy to stimulate placental growth and function and hence, 1526 
provide a potential pathway for clinical translation. However, no study to date has 1527 
determined whether, and to what extent dietary C8-MCFA supplementation regulates 1528 
activation of ghrelin and pulsatile GH profiles in either normal or IUGR pregnancy.  1529 
 1530 
1.8 Hypotheses and aims of thesis 1531 
Given the capacity of GH to promote placental and fetal growth, and evidence that 1532 
dietary C8-MCFA supplementation increases acyl-ghrelin and GH concentrations, two 1533 
hypotheses were developed to be tested in this project: 1534 
1. Feeding C8-MCFA will increase circulating acyl-ghrelin and GH levels in the 1535 
non-pregnant and pregnant female mouse; and 1536 
2. Elevated acyl-ghrelin throughout IUGR murine pregnancy will increase 1537 
placental growth and/or improve placental function and hence reduce fetal 1538 
growth constraint associated with IUGR pregnancies.  1539 
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These hypotheses were tested in the following aims, described in the following three 1540 
chapters: 1541 
1. Determine effects of feeding C8-MCFA on circulating total and acyl-ghrelin and 1542 
GH profiles in non-pregnant and pregnant mice (chapter 2);  1543 
2. Develop methodology to measure placental function in mice using fluorescent 1544 
tracers (chapter 3); and  1545 
3. In order to test potential interventions, develop a mouse model of IUGR (chapter 1546 
4);  1547 
4. Determine effects of feeding C8-MCFA on circulating total and acyl-ghrelin, fetal 1548 
and placental growth and function in IUGR mouse pregnancy using the model 1549 
developed in aim 3. 1550 
However, because C8-MCFA supplementation did not increase acyl-ghrelin in non-1551 
pregnant mice or in normal pregnant mice, the experiment corresponding to the final 1552 
aim (aim 4) was not conducted in this thesis.  1553 
  1554 
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Chapter 2 Pregnancy, but not dietary octanoic acid 1555 
supplementation, stimulates the ghrelin-pituitary growth 1556 
hormone axis in mice 1557 
 1558 
2.1 Overview  1559 
The work described in this chapter corresponds to the first aim of this thesis. In this 1560 
study, we characterised and compared the GH-ghrelin axis in non-pregnant and 1561 
pregnant mice, and determined the effect of dietary octanoic acid supplementation on 1562 
this axis in both pregnant and non-pregnant animals.  1563 
This chapter has been published in the Journal of Endocrinology [602] and has been 1564 
reproduced exactly as published, with the exception of formatting, which has been 1565 
modified to be consistent with the rest of this thesis.  1566 
 1567 
  1568 
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 1569 
  1570 
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 1571 
  1572 
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 1573 
  1574 
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 1575 
  1576 
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2.2 Abstract  1577 
Circulating growth hormone (GH) concentrations increase during pregnancy in mice and 1578 
remain pituitary-derived. Whether abundance or activation of the GH secretagogue 1579 
ghrelin increase during pregnancy, or in response to dietary octanoic acid 1580 
supplementation, is unclear. We therefore measured circulating GH profiles in late 1581 
pregnant C57BL/6J mice and in aged-matched non-pregnant females, fed standard 1582 
laboratory chow supplemented with 5% octanoic or palmitic (control) acid (n=4-1583 
13/group). Serum total and acyl-ghrelin concentrations, stomach and placenta ghrelin 1584 
mRNA and protein expression, Pcsk1 (encoding prohormone convertase 1/3) and 1585 
Mboat4 (membrane bound O-acyl transferase 4) mRNA were determined at Zeitgeber 1586 
(ZT) 13 and ZT23. Total and basal GH secretion were higher in late pregnant than non-1587 
pregnant mice (P<0.001), regardless of diet. At ZT13, serum concentrations of total 1588 
(P=0.004), but not acyl-ghrelin, and the density of ghrelin-positive cells in the gastric 1589 
antrum (P=0.019) were higher, and gastric Mboat4 and Pcsk1 mRNA expression were 1590 
lower in pregnant than non-pregnant mice at ZT23. In the placenta, ghrelin protein was 1591 
localised mostly to labyrinthine trophoblast cells. Serum acyl-, but not total, ghrelin was 1592 
lower at mid-pregnancy than in non-pregnant mice, but not different at early or late 1593 
pregnancy. In conclusion, dietary supplementation with 5% octanoic acid did not 1594 
increase activation of ghrelin in female mice. Our results further suggest that increases 1595 
in maternal GH secretion throughout murine pregnancy are not due to circulating acyl-1596 
ghrelin acting at the pituitary. Nevertheless, time-dependent increased circulating total 1597 
ghrelin could potentially increase ghrelin action in tissues that express the acylating 1598 
enzyme and receptor. 1599 
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2.3 Introduction  1601 
Successful pregnancy requires substantial maternal physiological adaptations, 1602 
including increases in food intake, to maintain maternal health and allow optimal growth 1603 
of the feto-placental unit to term. Growth hormone (GH) is a key endocrine regulator of 1604 
growth and metabolism in a range of mammalian species and its secretion changes 1605 
markedly during pregnancy. In humans, placental synthesis of variant GH in the 1606 
syncytiotrophoblast increases circulating GH concentrations and progressively 1607 
suppresses pulsatile pituitary secretion from mid-pregnancy onwards [120]. Although 1608 
the placentas of most other mammalian species, including rodents, do not produce GH 1609 
[634], circulating GH does increase during pregnancy in the majority of species 1610 
investigated to date. In contrast to humans, circulating GH profiles remain pulsatile 1611 
throughout pregnancy in mice and rats [122, 123, 601]. In these species, the increase 1612 
in average circulating GH concentration and secretion reflect elevated basal GH 1613 
secretion, while the number and amplitude of GH pulses remains unchanged [122, 123, 1614 
601]. In addition to driving maternal metabolic adaptation to pregnancy, including 1615 
insulin resistance [119, 690-693], GH likely promotes fetal growth through other 1616 
mechanisms. Provided maternal nutrition is adequate, intermittent maternal treatment 1617 
with exogenous GH increases fetal growth in non-human species including rats, pigs 1618 
and sheep, [380, 646, 649, 652, 657, 658, 670], likely through enhanced placental 1619 
growth and/or function [646, 649, 652, 657, 658]. Despite the importance of GH during 1620 
pregnancy in many mammals, the mechanism driving increased maternal GH in non-1621 
human species remains less well-known. 1622 
The increases in circulating GH concentration and basal GH secretion in pregnant mice 1623 
[123] coincide with the formation of the chorioallantoic placenta and initiation of 1624 
maternal blood flow through the placenta [635]. This suggests that placentally-secreted 1625 
factors are likely to be responsible, either indirectly or directly, for driving the increased 1626 
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pituitary GH secretion during rodent pregnancy. Ghrelin, a gastric peptide hormone that 1627 
acts in conjunction with hypothalamic growth hormone-releasing hormone (GHRH) and 1628 
somatostatin to generate pulsatile GH secretion from the anterior pituitary, is one 1629 
possible candidate. In mouse stomach, the endoproteolytic processing of the ghrelin 1630 
molecule from its precursor (proghrelin) into mature ghrelin is facilitated by the enzyme 1631 
prohormone convertase 1/3 (PC1/3, encoded by proprotein convertase, Pcks1) [426]. 1632 
Ghrelin is secreted in its des-acyl form and requires activation by acylation of the 1633 
peptide’s serine 3 residue with an 8-carbon octanoyl group [401]. This modification is 1634 
mediated by the enzyme membrane bound O-acyl transferase (Mboat4, also known as 1635 
GOAT), and allows the activated acyl-ghrelin to bind to the GH-secretagogue receptor 1636 
[GHSR, 401, 453], stimulating GH secretion. Intravenous administration of exogenous 1637 
acyl-ghrelin induces GH pulses in humans and rodents [401, 673] whilst mice deficient 1638 
in ghrelin or Mboat4 have lower amplitude GH pulses than littermate controls [456, 1639 
694]. Acyl-ghrelin, but not des-acyl ghrelin, also acts centrally to stimulate food intake 1640 
[476, 678], and acyl-ghrelin plays an important role in metabolic adaptations to 1641 
maintain circulating glucose in response to calorie restriction, particularly in pregnancy 1642 
[679]. Although ghrelin and Mboat4 are predominantly expressed in the stomach [401], 1643 
ghrelin, Mboat4 and GHSR expression are also detected in the human [449, 695] and 1644 
rodent [642, 696] placenta. Furthermore, maternal administration of exogenous acyl-1645 
ghrelin promotes fetal growth in rats [674]. This raises the possibility that ghrelin could 1646 
be synthesised by, and act directly on, the placenta, as well as through central actions, 1647 
to stimulate maternal GH secretion, food intake and fetal growth. 1648 
The potential role of ghrelin in pregnancy is supported by evidence that there are 1649 
changes in maternal circulating ghrelin during pregnancy in a number of mammalian 1650 
species. However, the reported changes in circulating total and acyl-ghrelin during 1651 
pregnancy vary between studies. Total ghrelin concentration has been reported as 1652 
lower compared to non-pregnant levels in humans and as lower or unchanged in 1653 
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pregnant rats [642, 680-683]. Conflicting evidence is likewise available regarding 1654 
changes in acyl-ghrelin, with either elevated or lower concentrations during pregnancy 1655 
in women [681, 684], and elevated during late pregnancy in a single study in rats [685]. 1656 
Although responses to exogenous ghrelin demonstrate its functional activity during 1657 
pregnancy, the role of endogenous ghrelin during pregnancy remains unclear. 1658 
Pregnant mice lacking the Mboat4 gene, which consequently cannot convert ghrelin to 1659 
acyl-ghrelin [686], still undergo a similar increase in GH during late pregnancy [686], 1660 
suggesting that acyl-ghrelin is not required to increase GH during pregnancy. However, 1661 
in this study GH was only measured in maternal blood collected at post-mortem and, 1662 
therefore, it is unknown whether the lack of acyl-ghrelin altered the circulating patterns 1663 
of GH during pregnancy [686]. These pulsatile patterns of circulating GH during 1664 
pregnancy are important since intermittent, but not continuous, GH administration, 1665 
improves placental function and increases fetal growth in a number of animal species 1666 
[643-646]. 1667 
The finding that increased acylation of ghrelin can be achieved by a nutritional 1668 
approach [453, 468, 687] offers great translational potential as an approach to increase 1669 
circulating GH. Oral supplementation with the C8 medium chain fatty acid, octanoic 1670 
acid, or with the triglyceride containing this fatty acid, glyceryl trioctanoate, induced 1671 
octanoylation of ghrelin in the stomach and increased abundance of circulating acyl-1672 
ghrelin in mice [453, 468, 687]. Similarly, enteral feeding with octanoic-acid enriched 1673 
formula increased circulating acyl-ghrelin in humans [689]. Further, dietary 1674 
supplementation with a medium chain triglyceride mixture containing 65-75% octanoic 1675 
acid increased circulating levels of acyl-ghrelin in pigs [688]. 1676 
Therefore, the aims of the present study were: (i) to characterise and compare the GH-1677 
ghrelin axis in non-pregnant and pregnant mice, and (ii) to determine the effect of 1678 
dietary octanoic acid supplementation on this axis in both pregnant and non-pregnant 1679 
animals. We hypothesised that the GH-ghrelin axis would be upregulated during 1680 
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pregnancy, and that dietary octanoic acid supplementation would increase circulating 1681 
acyl-ghrelin and GH, and pulsatile GH secretion, in both non-pregnant and pregnant 1682 
mice. 1683 
 1684 
2.4 Methods  1685 
2.4.1 Ethical approval  1686 
Experimental procedures were approved by The University of Adelaide Animal Ethics 1687 
Committee (studies one and two, M-2016-186), or South Australian Health and Medical 1688 
Research Institute (SAHMRI) Animal Ethics Committee (study three, SAM395.19) and 1689 
carried out in accordance with the Australian code of practice for the care and use of 1690 
animals for scientific purposes [697]. 1691 
2.4.2 Animals and experimental design  1692 
Study one: Virgin female C57Bl/6J 10-week-old female mice were obtained from the 1693 
Animal Resource Centre, Perth and CBAF1 males were obtained from Laboratory 1694 
Animal Services, The University of Adelaide. All animals were acclimatised to the 1695 
facility for at least 7 d prior to commencement of cycle tracking; with estrus cycles 1696 
tracked for at least 8 d prior to mating. All mice were housed at ~23°C with 12-h:12-h 1697 
light:dark cycle (lights on at 06:00 h or zeitgeber (ZT0), with ad libitum access to water 1698 
and meat-free rat and mouse diet (14.0 MJ/kg, 20% protein, Speciality Feeds, Glen 1699 
Forrest, Australia), except when fed experimental diets as detailed below. Female mice 1700 
were weighed daily throughout the experiment. Estrus stage in females was classified 1701 
daily by observation of cell types collected by gently flushing the vagina with 10 μL of 1702 
saline [698]. To generate timed pregnancies, a male was placed in the females’ cage 1703 
overnight when one or both females were in diestrus-to-proestrus transition or 1704 
proestrus. The presence of a vaginal plug on the following morning was taken as 1705 
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confirmation of successful mating and designated as 0.5 d of pregnancy (GD0.5). 1706 
Pregnancy was subsequently confirmed by weight gain and at post-mortem. 1707 
The experimental diets were based on prior observations that adding 5 mg/mL octanoic 1708 
acid to drinking water or feeding a diet supplemented with 5% glyceryl trioctanoate, 1709 
increased stomach acyl-ghrelin content in mice, whilst dietary tripalmitate did not alter 1710 
ghrelin activation [468]. The experimental diets were therefore generated by adding  1711 
5% (wt/wt) of either octanoic acid or palmitic acid to ground meat-free rat and mouse 1712 
diet (Speciality Feeds, Glen Forrest, Australia), which was then re-formed into pellets 1713 
and baked for 4 h at 60 °C prior to feeding. Experimental diets were fed ad libitum 1714 
throughout the remainder of the experiment, commencing at GD0.5 in mated groups 1715 
and from the same day in age-matched controls, including the day of sampling. To 1716 
confirm the fatty acid content, samples of each diet were ground, extracted into 1717 
chloroform and analysed for fatty acid composition as described below. 1718 
Samples were collected from pregnant mice (n=8 palmitic acid diet, n=7 octanoic acid 1719 
diet) at 17.5 d after mating (term is ~19.3 d after mating in this strain [32], and from 1720 
non-pregnant mice (n=9 palmitic acid diet, n=10 octanoic acid diet) when mice were in 1721 
diestrus and between 15.5 and 19.5 d after commencing experimental diets. Additional 1722 
non-pregnant mice (n=2 palmitic acid diet, n=3 octanoic acid diet) did not enter diestrus 1723 
between 15.5 and 19.5 d after commencing experimental diets and were thus not 1724 
sampled for GH since secretion patterns change throughout the estrus cycle (Chen 1725 
Chen, pers. comm.). All other samples were collected from these animals. To minimise 1726 
stress, all females were handled daily for ~5 min per mouse for ≥14 days before 1727 
sampling. GH samples were collected from each animal over a continuous 6 h period 1728 
to allow patterns of GH in the circulation and of GH secretion to be determined. From 1729 
13:00 h, ZT7 (lights on at 06:00 h, lights off at 18:00 h, ZT12), 36 sequential tail-tip 1730 
blood samples (each 2 μL) were collected at 10-min intervals from each mouse, 1731 
processed and stored at −80°C for later analysis as previously described [123, 699]. 1732 
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Shortly after collection of the final sample (19:00 h to 19:30 h), mice were terminally 1733 
anaesthetised by i.p injection of Avertin (2,2,2-tribromoethanol and tert-amyl alcohol; 1734 
Sigma-Aldrich, Missouri, United States) and 0.5 to 1.0 mL of venous blood was 1735 
collected via retro-orbital puncture. Whole blood (30 µL) from each individual mouse 1736 
was spotted onto customised PUFAcoat™ collection cards and air-dried for later 1737 
analysis of free fatty acids [700]. The remaining blood was collected into Eppendorf 1738 
tubes containing 4-(2-aminoethyl) benzenesulphonyl fluoride (AEBSF; at a final 1739 
concentration of 2 mg AEBSF per mL whole blood) allowed to clot at room temperature 1740 
for 30 minutes before centrifugation, and plasma acidified to a final concentration of 1741 
0.05M HCl to minimise breakdown of acyl-ghrelin [701]. Following blood collection, 1742 
mice were humanely killed by cervical dislocation. The uterus was removed from 1743 
pregnant mice, and the stomach was rapidly collected for processing as described 1744 
below. The stomach was opened along the greater curvature and rinsed in saline prior 1745 
to dissection, along the lesser curvature, into two pieces. Mucosal scrapings from the 1746 
corpus and antrum, the glandular regions of the stomach, were collected from one half 1747 
of the stomach, snap-frozen in liquid nitrogen and stored at -80°C until further analysis. 1748 
For the immunohistochemistry experiments, the other half of the stomach was pinned 1749 
out flat in 4% paraformaldehyde dissolved in 0.1 M phosphate buffer (PFA-PB) and 1750 
rocked at room temperature for 3 hours before cryoprotection in 30% sucrose-PB 1751 
solution overnight. The stomachs were then embedded in optimal cutting temperature 1752 
compound (Tissue-Tek, ProSciTech, Queensland Australia), frozen and stored at -80 1753 
°C until sectioning [702]. The numbers of implantations, fetuses and resorption sites 1754 
were counted and each fetus and placenta was dissected and weighed. Placentas 1755 
were alternately snap-frozen in liquid nitrogen or fixed for histological analysis as 1756 
described below. Complete suppression of GH secretion was observed in two pregnant 1757 
mice, who had normal litter size and foetal weights at post-mortem. Data for these 1758 
animals were excluded from all analyses, because a loss of GH secretion occurs 1759 
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acutely in stressed mice [703], and these two animals were therefore not considered to 1760 
reflect the normal physiology of pregnancy. 1761 
Study Two: In study one, plasma samples were collected from animals at the 1762 
completion of GH sampling, when most animals had not eaten. Upon analysis, we 1763 
found no difference in the circulating plasma acyl-ghrelin concentrations between 1764 
groups. Given the rapid turnover of acyl-ghrelin in circulation [701], we considered it 1765 
possible that any effects of diet on ghrelin production and release may only have been 1766 
evident close to the time of feeding. Therefore, in order to determine whether there was 1767 
an increase in basal circulating plasma acyl-ghrelin levels in mice that had undisturbed 1768 
access to food overnight, we conducted a second study, with the same interventions, 1769 
but with samples collected late in the active feeding period (dark phase) for mice [704], 1770 
and without serial sampling for GH, to minimise disruption to feeding. Animal 1771 
management, breeding and diets were as described for study one. Animals were 1772 
humanely killed at 07:30 to 08:00 h (lights on at 09:00 h, lights off at 21:00 h), and 1773 
blood and tissue samples were collected as described above.  1774 
Study three: Since circulating ghrelin was not consistently different between non- and 1775 
late-pregnant mice in the first two studies, we collected plasma from a third cohort of 1776 
mice to assess changes in ghrelin abundance throughout pregnancy. Mice were sampled 1777 
shortly after lights on, at a time when they have recently eaten [705]. Female C57Bl/6J 1778 
10-12 week-old female mice were obtained from SAHMRI Bioresources. All mice were 1779 
housed at ~22°C with 12-h:12-h light:dark cycle (lights on at 07:00 h, with ad libitum 1780 
access to water and standard rodent diet (18.6% protein, 6.2% fat, 44.2% carbohydrate, 1781 
Teklad standard diet, Envigo, Cambridgeshire, United Kingdom). For timed mating, 1782 
female mice were pair-housed with a C57BL/6J male at 17:00 h, and pregnancy was 1783 
confirmed by the presence of a vaginal plug at 07:00 h (assigned as day 0.5 of 1784 
pregnancy) before being returned to individual cages. Plugged females were randomly 1785 
assigned to either early (6.5 days, n=8), mid (12.5 days, n=8) or late (18.5 days, n=8) 1786 
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stage pregnancy end points. Age-matched females that were not housed with a male for 1787 
mating were used as non-pregnant controls (n=8). Mice were anaesthetised at ZT0-ZT1 1788 
by isoflurane inhalation (5% in oxygen) and venous blood was collected from the inferior 1789 
vena cava and processed as described above to obtain plasma for ghrelin assays. Mice 1790 
were then humanely killed via decapitation.  1791 
2.4.3 Analysis of fatty acids in feed and blood 1792 
The fatty acid composition of blood and feed samples was assessed as previously 1793 
described [700, 706]. Briefly, whole dried blood spots from the PUFAcoat™ cards and 1794 
extracted feed samples were trans-esterified with 2 ml of 1% H2SO4 in methanol at 70 1795 
°C for 3 h. After adding distilled water and heptane to the vial, the samples were 1796 
shaken using a vortex. Samples were then left standing and the top heptane layer 1797 
containing fatty acid methyl esters was extracted and analysed using gas 1798 
chromatography [700]. Abundance of each fatty acid is expressed as a percentage of 1799 
total fatty acids in the sample. 1800 
2.4.4 Hormone analyses 1801 
Serum concentrations of acyl-ghrelin and total ghrelin were determined by commercial 1802 
enzyme-linked immuno-absorbent assay (ELISA) kits [EZRGRA-90K, Rat/mouse 1803 
Ghrelin (Active) ELISA and EZRGRT-91K, Rat/mouse Ghrelin (Total) ELISA 1804 
respectively; R&D Systems, Minneapolis, MN, USA], in accordance with the 1805 
manufacturer’s instructions. A single ELISA plate was used to measure all samples from 1806 
each study. Within-assay coefficients of variation were each <10% (study one: total 1807 
ghrelin: 4.1%, acyl-ghrelin: 7.4%; study two: total ghrelin: 5.8%, acyl-ghrelin: 3.8%). 1808 
Analysis for GH was performed using an in-house mouse GH ELISA as described and 1809 
validated previously [699]. Within- and between-assay coefficients of variation were 2.0 1810 
% and 16.8 % respectively for a mouse plasma QC sample containing 27.7 ng/mL (n =16 1811 
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assays). All samples from a single mouse (serial samples for analysis of secretion 1812 
pattern) were analysed on the same ELISA plate. Kinetics and secretory patterns of 1813 
pulsatile GH secretion were determined by deconvolution analysis following parameters 1814 
established previously for GH secretion in mouse [699, 703]. The orderliness and 1815 
regularity of serial GH serum concentrations were calculated by approximate entropy 1816 
(ApEn) analysis as described previously; a higher absolute ApEn denotes greater 1817 
irregularity and indicates a loss in stability of feedback of GH regulation [707]. 1818 
2.4.5 Ghrelin and Mboat4 gene expression in stomach and placenta 1819 
Total RNA from snap frozen placenta and gastric mucosal scrapings was extracted using 1820 
PureLink RNA Mini Kit (12183018A; Invitrogen, Carlsbad, CA, USA), and quantified 1821 
using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). 1822 
Quantitative real-time PCR reactions (qPCR) were performed using a 7500 Fast Real-1823 
time PCR System (Life Technologies, Carlsbad, CA, USA) and Express One-Step 1824 
SuperScript qRT-PCR Kit (11781-200, Invitrogen). Predesigned Taqman gene 1825 
expression assays (4331182, Life technologies) that target Ghrelin (Mm00445450_m1), 1826 
Mboat4 (Mm01200389_m1), Pcsk1 (encodes for PC 1/3; Mm00479023_m1) were used. 1827 
B2m (Mm00437762_m1), Hprt (Mm01545399_m1) and Ppia (Mm02342429_g1) with an 1828 
expression stability value of 0.035 were used as reference genes for the gastric mucosa, 1829 
while Polr2a (Mm00839502_m1) and Ubc (Mm01198158_m1) were identified as suitable 1830 
reference genes in the mouse placenta [708]. qPCR reactions were carried out under 1831 
the following conditions: reverse transcription, 50 °C for 15 minutes; initial PCR 1832 
activation, 95 °C for 20 seconds; PCR cycles 95 °C for 3 seconds, 60 °C for 30 seconds 1833 
repeated for 40 cycles. Each assay was run in triplicate. Control PCRs were carried out 1834 
substituting RNase-free water for template RNA. Relative RNA levels were calculated 1835 
using the delta CT method as described previously [709]. 1836 
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2.4.6 Immunohistochemistry and histology 1837 
Stomach ghrelin localisation: Stomach tissue was sectioned (10 μm), air dried at RT 1838 
before being rinsed in PBS + 0.2% Triton X-100 (PBS-TX; Sigma-Aldrich) and blocked 1839 
with 10% donkey serum at room temperature. To detect ghrelin immunoreactivity, 1840 
sections were then incubated with rabbit-anti-ghrelin primary antibody (1 in 800 dilution 1841 
in PBS-TX; Abcam Cat# ab129383, RRID:AB_11159267ab129383, Abcam, Cambridge, 1842 
United Kingdom) for 20 h at 4 °C and donkey-anti-rabbit 488 secondary antibody (1 in 1843 
200 in PBS-TX, Cat# A-21206, RRID:AB_2535792 Thermo Fisher Scientific) for 1 h at 1844 
RT. The slides were mounted using ProLong Antifade (Life technologies). Slides where 1845 
primary antibody was omitted showed no labelling and served as negative controls. Slide 1846 
sections were visualised using an epifluorescence microscope (BX-51, Olympus, Tokyo, 1847 
Japan) equipped with filters for Alexa Fluor® 488, with images acquired using a 1848 
CoolSnapfx monochrome digital camera (Roper Scientific, Tuscon, AZ, USA). Ghrelin-1849 
positive cells were counted manually on images taken at 10 X magnification by two 1850 
people blind to treatment. Ten stomach tissue sections were randomly chosen from each 1851 
mouse. In each section, ghrelin-positive cells were counted in an area of 400 µm × 400 1852 
µm in both proximal corpus and distal antrum. The number of ghrelin positive cells in 1853 
corpus or antrum from each mouse was averaged from the 10 selected sections. 1854 
Placental morphology: Histological analyses were performed on two placentae from 1855 
each dam (palmitic acid n=14 placentas, octanoic acid n=12 placentas). One dam from 1856 
the palmitic acid group was excluded from this analysis due to a small litter size (a single 1857 
fetus), however, the placenta was collected and frozen for gene expression analysis. 1858 
Bisected placentae were fixed in 4% paraformaldehyde (PFA), washed in 1 X PBS over 1859 
48 h and stored in 70% ethanol prior to being paraffin embedded. Full-faced placental 1860 
sections cut to 5 µm thickness were stained with Masson’s Trichrome following standard 1861 
protocols [710]. Areas of junctional zone and placental labyrinth for each placental 1862 
82 
section were visualised and measured with NDP.view 2 software (Hamamatsu 1863 
Photonics, Shizuoka, Japan). Total cross-sectional area and the proportion of junctional 1864 
zone to placental labyrinth were calculated.  1865 
Placental ghrelin localisation: Full-faced sections cut to 5 μm thickness were 1866 
deparaffinised and rehydrated, using the same placentas as above (palmitic acid n=14 1867 
placentas, octanoic acid n=12 placentas). Antigen retrieval was performed by 1868 
microwaving slides in citrate buffer (0.2% citric acid in distilled water) for 10 min at 150 1869 
W. In order to quench endogenous peroxidase, sections were incubated in 3% H2O2 in 1870 
1 X PBS for 10 min. Non-specific binding was blocked by incubation with 10% goat 1871 
serum in 1 X PBS for 30 min before addition of rabbit anti-ghrelin antibody (1 in 250 1872 
dilution, Abcam Cat# ab129383, RRID:AB_11159267ab129383) and incubated 1873 
overnight at RT. Bound antibody was detected using biotinylated goat anti-rabbit IgG (1 1874 
in 200 dilution, Agilent Cat# E0432, RRID:AB_2313609, DAKO, Carpinteria, CA, USA) 1875 
for 1 h, followed by streptavidin-conjugated horseradish peroxidase (1 in 500 dilution, 1876 
Cat# P0397, DAKO) for 1 h, both at RT. Immunolabelling was visualised by incubating 1877 
sections with diaminobenzidine (Cat# K346811-2, DAKO) and by counterstaining with 1878 
hematoxylin before mounting in DPX (Sigma-Aldrich). Areas of ghrelin staining were 1879 
visualised with NDP.view 2 software (Hamamatsu Photonics). 1880 
2.4.7 Statistical analyses 1881 
For studies one and two, effects of diet (palmitic acid supplemented cf. octanoic acid 1882 
supplemented) and pregnancy status (non-pregnant cf. pregnant) on maternal 1883 
outcomes were analysed by 2-way ANOVA. For study three, effects of pregnancy 1884 
stage (non-, early-, mid- and late-pregnant) were analysed by 1-way ANOVA. Where 1885 
outcomes differed between pregnancy stages, post-hoc analyses were performed 1886 
using the Bonferroni correction. Effects of diet on fetal and placental outcomes was 1887 
analysed using repeated measures ANOVA, treating each fetus or placenta as a 1888 
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repeated measure on the dam. GH secretion data were natural log-transformed to 1889 
achieve equal variances before analysis. Data are presented as mean ± SEM and 1890 
P<0.05 was considered statistically significant. 1891 
 1892 
2.5 Results  1893 
2.5.1 Pregnancy outcomes were unaffected by maternal diet 1894 
Maternal weight gain during the study, body and liver weights at post-mortem (Table 1895 
2.1) and absolute and relative organ weights (liver, kidneys and spleen, data not 1896 
shown) were higher in pregnant than non-pregnant mice, and unaffected by diet. 1897 
Pregnancy outcomes including litter size, fetal weight and placental gross structure 1898 
were also unaffected by maternal diet (Table 2.1). 1899 
2.5.2 Circulating fatty acid profiles were altered by diet and pregnancy 1900 
As expected, the content of C16:0 (palmitic acid) was higher in the palmitic acid-1901 
supplemented feed (4.1 g/100 g feed) than in the octanoic acid-supplemented feed (0.5 1902 
g/100 g feed). Similarly, the content of C8:0 (octanoic acid) was higher in the octanoic 1903 
acid-supplemented feed (1.5 g/100 g feed) than in the palmitic acid-supplemented feed 1904 
(0.07 g/100 g feed). 1905 
Study one: In mice sampled at ZT13, total saturated fatty acid levels were higher in mice 1906 
fed the palmitic acid than the octanoic acid diet (P=0.014) and higher in pregnant than 1907 
non-pregnant mice (P<0.001, Table 2.2). Conversely, total monounsaturated fatty acid 1908 
levels were higher in the blood of mice fed the octanoic acid diet (P=0.006) and in 1909 
pregnant compared to non-pregnant mice (P=0.046, Table 2.2). Octanoic acid was 1910 
undetectable in blood, regardless of diet or pregnancy status (data not shown). 1911 
Circulating palmitic acid (C16:0) comprised a higher percentage of total lipids in mice fed  1912 
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Table 2.1 Maternal and pregnancy characteristics (study one ZT13). 1913 
 Non pregnant Pregnant P value 
 Palmitic acid Octanoic acid Palmitic acid Octanoic acid Diet Pregnancy D*P 
Number of dams 11 13 8 6    
Final body weight (g) 21.3 ± 0.1 21.9 ± 0.3 34.5 ± 1.3 34.0 ± 1.5 0.953 <0.001 0.542 
Weight gain (g/d) 0.05 ± 0.01 0.05 ± 0.02 0.83 ± 0.07 0.78 ± 0.10 0.488 <0.001 0.593 
Liver (g) 0.75 ± 0.03 0.76 ± 0.02 1.30 ± 0.08 1.20 ± 0.16 0.550 <0.001 0.431 
Liver (% of body weight) 2.5 ± 0.5 3.2 ± 0.3 3.8 ± 0.2 3.6 ± 0.6 0.563 0.073 0.306 
Litter size   6.4 ± 0.8 7.3 ± 0.8 0.432   
Average fetal weight (g)   1.2 ± 0.1 1.1 ± 0.1 0.626   
Average placental weight (g)   0.1 ± 0.1 0.1 ± 0.1 0.276   
Average junctional zone area 
(mm2) 
  2.5 ± 0.2 2.5 ± 0.1 0.938   
Average labyrinth zone area 
(mm2) 
  5.2 ± 0.2 4.7 ± 0.2 0.158   
Maternal data were analysed using two-way ANOVA and data for fetal outcomes were analysed using 1-way ANOVA. Data are presented 1914 
as mean ± SEM.  Abbreviations: D*P, diet*pregnancy interaction; FA, fatty acid1915 
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Table 2.2 Circulating maternal fatty acid concentrations. 1916 
Fatty acids were measured by GCMS in blood collected from non-pregnant and pregnant mice, fed chow supplemented with either 5% 1917 
palmitic acid or 5% octanoic acid. Mice in study one were sampled between 1 and 2 h after lights off, and mice in study two were sampled 1918 
between 1 and 0 hours before lights on, at the end of the natural feeding period. Data were analysed by two-way ANOVA and are 1919 
presented as mean ± SEM. Abbreviations: D*P, diet*pregnancy interaction; FA, fatty acids. 1920 
 1921 









Diet  Pregnancy  D*P 
Study one 
n animals 11 13 8 6    
Total saturated FA (% of total lipids) 42.0 ± 0.2 40.6 ± 0.4 44.1 ± 0.5 43.3 ± 0.5 0.014 <0.001 0.466 
16:0 (% of total lipids) 24.7 ± 0.3 22.1 ± 0.2 26.4 ± 0.3 24.3 ± 0.3 <0.001 <0.001 0.307 
Total trans-esterified FA (% of total 
lipids) 
0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.674 0.978 0.593 
Total monosaturated FA (% of total 
lipids) 
16.2 ± 0.3 17.8 ± 0.2 17.5 ± 0.5 17.9 ± 0.3 0.006 0.046 0.092 
Study two 
n animals 13 9 5 6    
Total saturated FA (% of total lipids) 44.3 ± 0.3 43.4 ± 0.5 45.1 ± 0.5 46.5 ± 0.5 0.680 0.000 0.022 
16:0 (% of total lipids) 28.2 ± 0.2 25.6 ± 0.4 28.3 ± 0.2 28.4 ± 0.5 0.004 0.001 0.002 
Total trans-esterified FA (% of total 
lipids) 
0.3 ± 0.02 0.2 ± 0.02 0.3 ± 0.03 0.3 ± 0.02 0.949 0.191 0.485 
Total monosaturated FA (% of total 
lipids) 
14.9 ± 0.6 15.1 ± 0.2 14.4 ± 0.4 15.9 ± 0.4 0.141 0.830 0.279 
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the palmitic acid diet, compared to those fed an octanoic acid diet (P<0.001) and were 1922 
also higher in pregnant than non-pregnant mice overall (P<0.001, Table 2.2). 1923 
Study two: In mice sampled at ZT23, effects of diet on total saturated fatty acids differed 1924 
between non-pregnant and pregnant groups (interaction P=0.022, Table 2.2). Thus, in 1925 
mice fed the palmitic acid-supplemented diet, the concentration of total saturated fatty 1926 
acids was similar between non-pregnant and pregnant mice. However, within mice fed 1927 
the octanoic acid-supplemented diet, the concentration of total saturated fatty acids was 1928 
7% higher in pregnant than non-pregnant mice. Circulating total saturated fatty acid 1929 
concentrations did not differ between diets within either non-pregnant or pregnant 1930 
groups. Total trans-esterified and monounsaturated fatty acid concentrations were 1931 
similar between groups (P>0.05, Table 2.2). 1932 
2.5.3 Circulating GH was higher in pregnant than non-pregnant mice but was 1933 
unaffected by diet 1934 
Circulating GH was pulsatile in all mice and mean plasma GH concentrations increased 1935 
during pregnancy (study one, Figure 2.1, Table 2.3). Total and basal GH secretion rates 1936 
were significantly higher in pregnant mice (P<0.001, Table 2.3) compared to non-1937 
pregnant mice, irrespective of diet. The irregularity of GH pulses (approximate entropy; 1938 
P=0.033) and mode of secretion (P=0.001) were also higher in pregnant mice compared 1939 
to non-pregnant mice and unaffected by diet (Table 2.3). Pulse frequency, mass of GH 1940 
released per burst and pulsatile GH secretion rate were similar between dietary groups 1941 




Table 2.3 Circulating maternal growth hormone (GH) and parameters of pulsatile GH secretion following deconvolution and 1945 
approximate entropy (ApEn) analysis. 1946 
 Non pregnant Pregnant P value 
 




Palmitic    
acid 
Octanoic    
acid 
Diet Pregnancy D*P 
n samples 7 10 8 4    
Mean circulating GH (ng/mL) 3.9 ± 1.0 6.1 ± 1.3 11.4 ± 2.7 18.5 ± 9.2 0.155 0.004 0.433 
Total GH secretion rate (ng/mL 6h) 169.2 ± 43.0 247.7 ± 58.3 491.6 ± 118.1 819.1 ± 409.1 0.159 <0.001 0.382 
Basal GH secretion rate (ng/mL 6h) 18.0 ± 11.3 68.6 ± 24.8 312.2 ± 85.4 404.6 ± 187.3 0.344 <0.001 0.780 
Interval between bursts 19.9 ± 10.0 24.3 ± 8.0 26.0 ± 6.7 28.0 ± 10.3 0.343 0.151 0.724 
Number of GH pulses/6h 4.1 ± 0.8 4.2 ± 0.6 5.4 ± 0.7 5.8 ± 0.9 0.773 0.073 0.832 
Mode of secretory bursts (min) 15.0 ± 2.0 11.3 ± 0.5 7.6 ± 1.2 8.7 ± 1.4 0.353 0.001 0.096 
ApEn 0.8 ± 0.1 0.9 ± 0. 04 1.0 ± 0.1 1.0 ± 0.1 0.573 0.033 0.528 
Mass of GH secreted/burst (ng/mL) 34.5 ± 8.5 47.8 ± 9.9 39.3 ± 11.0 62.8 ± 31.0 0.187 0.472 0.709 
Pulsatile GH  secretion rate (ng/mL 
6h) 
151.2 ± 44.7 179.1 ± 40.0 179.4 ± 40.5 414.5 ± 262.2 0.130 0.130 0.230 
Data were analysed by two-way ANOVA and are presented as mean ± SEM. Abbreviations: D*P, diet*pregnancy interaction1947 
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 1948 
Figure 2.1 Representative circulating GH profiles in non-pregnant females fed palmitic 1949 
acid diet; n=7 (A) or octanoic acid diet; n=10 (B), in mice at GD17.5 or age-matched 1950 
diestrus controls after 15±5 days of eating experimental diets, and in pregnant mice fed 1951 
palmitic acid diet; n=8 (C) or octanoic acid diet; n=4 (D) at GD17.5. Shading indicates 1952 
dark period. 1953 
 1954 
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2.5.4 Total but not acyl-ghrelin is higher in pregnant than non-pregnant mice, 1955 
depending on time of day 1956 
In mice sampled at ZT13 (study one), serum total ghrelin levels were significantly higher 1957 
in pregnant than non-pregnant mice (P=0.004, Figure 2.2), and were unaffected by diet, 1958 
while serum acyl-ghrelin concentrations were similar irrespective of diet or pregnancy 1959 
status. In mice sampled at ZT23 (study two), total and acyl-ghrelin levels in mice were 1960 
similar between dietary groups and between pregnant and non-pregnant animals (Figure 1961 
2.2).  1962 
 1963 
Figure 2.2 Circulating maternal serum total (A, C) and acyl (B, D) ghrelin in non-1964 
pregnant and pregnant mice fed palmitic acid diet (white bars) or octanoic acid diet 1965 
(grey bars), sampled at ZT13 (study one, A, B) or ZT23 (study two, C, D), in mice at 1966 
GD17.5 or age matched controls. Data were analysed by two-way ANOVA and are 1967 
presented as mean ± SEM. Animal numbers are indicated by numerals within bars. 1968 
 1969 
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When assessing changes in ghrelin abundance across pregnancy (study three), serum 1970 
total ghrelin did not differ between pregnancy stages (P=0.059, Figure 2.3A). In contrast, 1971 
serum acyl-ghrelin concentrations changed with pregnancy stage (P=0.008, Figure 1972 
2.3B). Acyl-ghrelin concentrations were lower in mid-pregnant compared to non-1973 
pregnant mice (P=0.007), and did not differ between other pregnancy stages (Figure 1974 
2.3B).  1975 
 1976 
Figure 2.3 Circulating maternal plasma total (A) and acyl (B) ghrelin throughout 1977 
pregnancy in non-pregnant (white bars), early, mid and late pregnant (grey bars) mice 1978 
sampled at ZT0-1 (study three).Data were analysed by 1-way ANOVA and are 1979 
presented as mean ± SEM. Animal numbers are indicated by numerals within bars. 1980 
  1981 
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2.5.5 Stomach and placental ghrelin expression may explain higher total but not 1982 
acyl-ghrelin in pregnancy 1983 
Gastric ghrelin, Mboat4 and Pcsk1 mRNA levels were similar in all groups at ZT13 (study 1984 
one, Table 2.4). Gastric ghrelin mRNA expression was unaffected by pregnancy or diet 1985 
at ZT23 (study two, Table 2.4). However, the gastric mRNA expression of Mboat4 and 1986 
Pcsk1 was lower in pregnant compared to non-pregnant mice at ZT23 (Table 2.4).  1987 
 1988 
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Table 2.4 Stomach ghrelin, Mboat4 and Pcsk1 mRNA expression. 1989 
 Non- pregnant  Pregnant  P value 
 Palmitic acid Octanoic acid Palmitic acid Octanoic acid Diet Pregnancy D*P 
Study one (ZT13) 
n samples 5 5 5 5    
Ghrelin 5.4 ± 0.3 4.9 ± 0.3 4.9 ± 0.2 4.4 ± 0.2 0.090 0.070 0.976 
Mboat4 0.0059 ± 0.0007 0.0061 ± 0.0004 0.0059 ± 0.0002 0.0060 ± 0.0004 0.716 0.927 0.794 
 
Pcsk1 0.015 ± 0.001 0.017 ± 0.001 0.016 ± 0.001 0.015 ± 0.001 0.553 0.829 0.167 
Study two (ZT23) 
Ghrelin 3.8 ± 1.0 3.2 ± 0.9 2.7 ± 0.6 2.4 ± 0.6 0.587 0.243 0.825 
Mboat4 0.0074 ± 0.0006 0.0067 ± 0.0009 0.0052 ± 0.0004 0.0051 ± 0.0005 0.553 0.007 0.599 
Pcsk1 0.021 ± 0.003 0.018 ± 0.002 0.015 ± 0.001 0.016 ± 0.002 0.644 0.049 0.378 
Gene expression was quantified using qRT-PCR and is expressed relative to reference genes. Gene expression data were 1990 
analysed by two-way ANOVA. Data are presented as mean ± SEM. Abbreviations: D*P, diet*pregnancy interaction; Mboat4, 1991 
membrane bound O-acyltransferase, Pcsk1, proprotein convertase  1992 
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At ZT13 (study one), the effects of pregnancy on the density of ghrelin-positive cells in 1993 
the corpus region of the stomach differed between diets (interaction, P=0.003, Figure 1994 
2.4C). In mice fed the palmitic acid diet, the density of ghrelin-positive cells in the 1995 
stomach corpus was higher in pregnant than non-pregnant mice (P<0.001, Figure 2.4). 1996 
Pregnancy status did not affect the density of ghrelin-positive cells in the corpus of mice 1997 
fed the octanoic acid diet. 1998 
In pregnant mice, the density of ghrelin-positive cells in the corpus was higher in mice 1999 
fed the palmitic acid compared to mice fed the octanoic acid diet (P=0.012, Figure 2.4). 2000 
There was no effect of diet on the density of ghrelin-positive cells in the corpus in non-2001 
pregnant mice. In the antrum region, the density of ghrelin-positive cells was higher in 2002 
pregnant mice than non-pregnant mice (P=0.019), irrespective of diet (Figure 2.4E).  2003 
At ZT23 (study two), the density of ghrelin-positive cells in the corpus region was higher 2004 
in pregnant mice than non-pregnant mice (P=0.023), irrespective of diet (Figure 2.4D). 2005 
However, the density of ghrelin-positive cells in the antrum region of the stomach at this 2006 




Figure 2.4 Immunohistochemistry for ghrelin positive cells in the corpus of non-2010 
pregnant (A) and pregnant (B) mice. Arrows indicate ghrelin-positive cells, L and M 2011 
indicate lumen and mucosal regions respectively, scale bar = 100 μm. Effects of 2012 
pregnancy and diet on the density of ghrelin-positive cells in the corpus (C, D) and 2013 
antrum (E, F) regions of the stomach in mice fed palmitic acid diet (white bars) or 2014 
octanoic acid diet (grey bars). Samples were collected at ZT13 (study one, C, E) or 2015 
ZT23 (study two, D, F), in mice at GD17.5 or age-matched controls. Data were 2016 
analysed by two-way ANOVA and are presented as mean ± SEM. Animal numbers are 2017 
indicated by numerals within bars.  2018 
 2019 
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Table 2.5 Placental ghrelin and Mboat4 mRNA expression. 2020 
Gene expression was quantified using qRT-PCR and is expressed relative to reference 2021 
genes. Gene expression data were analysed by 1-way ANOVA. Data are presented as 2022 
mean ± SEM. Abbreviations: Mboat4, membrane bound O-acyltransferase 2023 
 2024 
Placental ghrelin and Mboat4 mRNA levels were measured in pregnant animals and 2025 
were unaffected by diet in both studies (Table 2.5). In the placenta, cytoplasmic ghrelin 2026 
immunostaining was mostly localised to labyrinthine trophoblast, and nuclear 2027 
immunostaining was present in both labyrinth and junctional zones (Figure 2.5). 2028 
Localisation was unaffected by diet. 2029 
 2030 
 Palmitic acid Octanoic acid P value 
Study one (ZT13) 
n samples 5 5  
Ghrelin  0.0021 ± 0.0001 0.0023 ± 0.0001 0.258 
Mboat4  0.0007 ± 0.0002 0.0011 ± 0.0003 0.292 
Study two (ZT23) 
n samples 5 6  
Ghrelin  0.0022 ± 0.0001 0.0023 ± 0.0002 0.922 
Mboat4 0.0021 ± 0.0005 0.0013 ± 0.0004 0.216 
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 2031 
Figure 2.5 Immunohistochemistry for ghrelin localisation in GD17.5 murine placentas 2032 
from dams fed palmitic acid (A) and octanoic acid (B) diet. L and J indicate labyrinthine 2033 
and junctional zones respectively. Scale bar = 100 μm 2034 
 2035 
2.6 Discussion  2036 
In the present study, circulating basal and total GH, as well as total, but not acyl, ghrelin 2037 
concentrations were significantly higher in pregnant compared to non-pregnant mice. 2038 
Contrary to our hypothesis, dietary supplementation with octanoic acid did not increase 2039 
acyl-ghrelin, circulating GH concentration or pulsatile GH secretion in either pregnant or 2040 
non-pregnant mice. 2041 
The increased circulating levels of GH we observed during late pregnancy are consistent 2042 
with previous studies in mice [123] as well as rats [122, 601]. This further confirms that 2043 
maternal GH is elevated in multiple species during pregnancy [120, 122, 123, 601] 2044 
despite the lack of a placentally-expressed GH variant gene in rodents and most other 2045 
non-primate species [711]. Interestingly, GH was elevated in pregnant mice despite the 2046 
fact that maternal acyl-ghrelin levels were similar in late pregnant and non-pregnant 2047 
mice, and actually lower at mid-pregnancy than in non-pregnant females. These 2048 
observations are consistent with the findings of Trivedi and colleagues, who 2049 
demonstrated that circulating GH, measured in single samples at post-mortem, was 2050 
97 
similarly higher in late pregnant than non-pregnant animals in both Mboat4-knockout and 2051 
wild-type mice [686]. Together, these findings imply that endogenous circulating acyl-2052 
ghrelin is not an important regulator of changes in GH during pregnancy.   2053 
Total serum ghrelin concentrations were higher in pregnant than in non-pregnant mice, 2054 
however this was only observed in mice that were sampled at the end of the light phase 2055 
(study one), and not in those sampled at the end of the dark phase (study two) or early 2056 
in the light phase (study three). Ghrelin secretion undergoes a pre-prandial increase and 2057 
a postprandial decline in humans, reflecting its function in stimulating hunger and 2058 
initiation of meals [450, 451]. Besides the stimulation of food intake, ghrelin decreases 2059 
energy expenditure in rodents and promotes the storage of fatty acids in adipocytes [712, 2060 
713]. The difference in effects of pregnancy on total ghrelin abundance in the light and 2061 
dark phases might therefore reflect greater diurnal ghrelin variation in pregnancy, 2062 
possible due to greater nutrient demand and appetite drive [714]. Consistent with food 2063 
intake patterns in non-pregnant female and male mice [715, 716], the majority of food 2064 
intake occurs during the dark phase in pregnant mice [3]. Lower acyl-ghrelin 2065 
concentrations in fed mice at mid-pregnancy (study three) might be a consequence of 2066 
increasing food intake during pregnancy [3], since postprandial suppression of plasma 2067 
ghrelin is proportional to the amount of calories ingested [717]. Additional studies are 2068 
needed to characterise the circadian rhythm in ghrelin and determine whether these 2069 
change in pregnancy. 2070 
The higher circulating total ghrelin concentrations in pregnant than in non-pregnant mice 2071 
in study one might be explained by greater ghrelin production in the stomach, as well as 2072 
potentially by placental production. Specific cells in the stomach, particularly X/A-like 2073 
enteroendocrine cells, are the main site of ghrelin production and acylation in non-2074 
pregnant animals [434], and in male mice preproghrelin mRNA expression is 2075 
substantially higher in the stomach than in other tissues [454]. Although ghrelin mRNA 2076 
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expression was detected in placenta, its abundance was >1000-fold lower than in 2077 
stomach, suggesting its contribution to circulating ghrelin is relatively minor, although 2078 
abundant ghrelin was evident in placentas stained for ghrelin protein. Gene expression 2079 
of ghrelin in the stomach was not different in pregnant and non-pregnant mice in either 2080 
study, consistent with similar stomach, hypothalamic and pituitary ghrelin expression in 2081 
pregnant and non-pregnant mice reported previously [679]. However, the 1.5-fold greater 2082 
density of ghrelin-positive cells in the stomach antrum of pregnant than non-pregnant 2083 
mice sampled at ZT13 (study one) suggests a greater capacity to secrete ghrelin, 2084 
although this was not seen at ZT23 (study two). We saw a similar pattern for the stomach 2085 
corpus, with greater ghrelin-positive cell density in pregnant than non-pregnant mice at 2086 
ZT23, although at ZT13 the effect of pregnancy was only significant within the subset fed 2087 
the palmitic acid diet. The discrepancy between ghrelin gene expression levels and 2088 
number of ghrelin positive cells in the stomach may be because gene expression was 2089 
measured from the entire gastric mucosa, whereas ghrelin positive cell count was carried 2090 
out in specific sections of the stomach. Given the variability within groups and relatively 2091 
low sample size, we suggest that this is probably a chance finding and not likely to reflect 2092 
diet-specific outcomes. An increased density of ghrelin-expressing cells is consistent 2093 
with a recent report in rats, where the density of ghrelin immunopositive cells in the 2094 
stomach mucosa is increased by ~10% at mid-pregnancy compared to non-pregnant 2095 
animals, and increases by a further ~30% by the day of birth [683]. We also characterised 2096 
ghrelin protein expression in the murine placenta. Cytoplasmic expression was primarily 2097 
localised to the labyrinth (nutrient exchange) region, whilst nuclear expression was 2098 
evident in both labyrinth and junctional (endocrine crosstalk) regions. This is the first 2099 
report of ghrelin protein localisation in the rodent placenta, and its presence is consistent 2100 
with prior reports of ghrelin mRNA expression in placenta of rats and humans [642].  2101 
Despite greater circulating total ghrelin in pregnancy, we did not detect greater 2102 
circulating acyl-ghrelin in pregnant mice, with a lower acyl:total ghrelin ratio in pregnant 2103 
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compared to non-pregnant mice, and lower circulating acyl-ghrelin at mid-pregnancy. 2104 
The decreased ratio of acyl to total ghrelin we observed in mice are broadly consistent 2105 
with those of Tham and co-authors in women, who reported markedly lower maternal 2106 
acylated ghrelin concentrations during pregnancy than postpartum [681]. These 2107 
authors suggested that lower acyl-ghrelin during human pregnancy probably reflected 2108 
decreased acylation, since they found lower rather than higher activity of the key de-2109 
acylating enzyme butylcholinesterase in the pregnant group [681]. We observed 2110 
comparatively lower gastric mRNA expression of Mboat4 and Pcsk1 in pregnant mice 2111 
compared to non-pregnant mice at ZT23. Although the acylation of ghrelin is 2112 
independent of processing by PC 1/3 [426], lower gastric gene expression of Mboat4 at 2113 
ZT23 may explain the lack of subsequent increase in circulating serum acyl-ghrelin 2114 
concentrations despite higher total ghrelin concentrations in pregnant compared to 2115 
non-pregnant mice sampled at ZT13. Further experiments are required to determine 2116 
whether the lower acyl:total ghrelin ratio reflects slower acylation or more rapid 2117 
deacylation in pregnancy. Despite the lack of elevation of circulating acyl-ghrelin in 2118 
pregnancy, it is possible that the higher total ghrelin seen before substantial feeding 2119 
might lead to increased local ghrelin action in tissues expressing both Mboat4 and the 2120 
ghrelin-receptor, such as the pancreas, placenta and hypothalamus [454, 679]. 2121 
Consistent with a potential role for elevated ghrelin during pregnancy, ghrelin receptor 2122 
mRNA expression increased in hypothalamus and pituitary during rat pregnancy [685]. 2123 
It is also possible that non-acylated ghrelin has a functional role in pregnancy, since 2124 
growing evidence suggests that des-acyl ghrelin has GHSR1a independent roles in 2125 
energy and glucose metabolism [484, 679, 718]. We did not measure des-acyl ghrelin 2126 
in the present study, but post-test meal concentrations of des-acyl (but not acyl) ghrelin 2127 
were higher in women with gestational diabetes during late pregnancy and postpartum 2128 
compared to normal pregnant women [681], suggesting it either regulates or responds 2129 
to maternal metabolism.   2130 
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Contrary to our hypothesis, dietary supplementation with octanoic acid did not alter 2131 
circulating GH or ghrelin concentrations regardless of whether the mice had a full or 2132 
empty stomach. Although we were able to confirm the presence of octanoic acid in our 2133 
supplemented diet, we were not able to confirm its presence in the circulation, despite 2134 
the fact that abundance of other circulating fatty acids were altered in response to the 2135 
experimental diets. Similarly, Lemarié and co-authors could not detect C8 fatty acids in 2136 
rat plasma in response to C8-supplementation with 0, 8 or 21% of total fatty acids [719]. 2137 
This could possibly be due to rapid gastrointestinal hydrolysis and absorption of medium 2138 
chain-fatty acids, specific transport through the portal vein and rapid beta-oxidation in 2139 
the liver [720]. The lack of increase in acyl-ghrelin was surprising given that previous 2140 
studies in mice found increased stomach acyl-ghrelin in male mice using similar dose 2141 
regimens used in the present study [468]. Furthermore, dietary supplementation with 2142 
octanoic acid increased circulating acyl-ghrelin concentrations in studies conducted in 2143 
humans, mice and cattle [687, 689, 721]. However, in other studies, dietary 2144 
supplementation with octanoic acid increased stomach acyl-ghrelin of mice [468] and 2145 
stomach octanoic acid content in rats [719] without any changes in circulating acyl-2146 
ghrelin secretion. Interestingly, dietary supplementation with medium chain triglycerides 2147 
(MCT) increased circulating acyl-ghrelin in humans and pigs of both sexes and 2148 
circulating growth hormone concentrations in pigs [688, 722], suggesting a possible 2149 
alternate dietary approach to increase circulating acyl-ghrelin abundance. In addition, we 2150 
did not see any differences in circulating GH patterns in response to diet. Although the 2151 
current study utilised the established method of characterising patterns of pulsatile GH 2152 
secretion in mice [699], it was necessary to exclude data from two pregnant animals 2153 
where pulsatile GH secretion was lost, indicative of an acute response. Pulsatile GH 2154 
secretion was evident in the majority of mice, indicating that the acclimatisation and 2155 
sampling protocol were mostly successful in preventing stress responses [703]. Loss of 2156 
GH secretion in two pregnant mice but no non-pregnant mice on the present study, and 2157 
from one late pregnant mouse and no non-, early- of mid-pregnant mice in our previous 2158 
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study [123], suggests that pregnancy may increase susceptibility to handling-induced 2159 
stress, despite extensive acclimatisation. Together with the need for consistency in the 2160 
estrous cycle stage of non-pregnant mice, this resulted in a limited sampling size for GH 2161 
measurements. Therefore, we cannot exclude the possibility of a diet effect on GH based 2162 
only on the present study. Maternal and fetal weights did not differ with diet, which was 2163 
not unexpected given that we did not anticipate any restriction of fetal growth in this 2164 
model of normal pregnancy. Although mice ate both experimental diets readily, we 2165 
cannot exclude the possibility that food intake may differ between diets and suggest this 2166 
should be measured in subsequent studies. Future studies may find it beneficial to adapt 2167 
a dietary approach based on dietary supplementation with medium chain triglycerides 2168 
containing up to 65-75% of octanoic acid, which has been shown to increase circulating 2169 
levels of acyl-ghrelin as well as average plasma GH levels in pigs [688]. 2170 
Overall, increased total and basal GH during murine pregnancy does not appear to be 2171 
regulated by maternal circulating acyl-ghrelin. Maternal total ghrelin secretion in 2172 
pregnancy may follow an altered diurnal pattern, possibly due to the pregnancy-2173 
associated changes in nutrient demand and energy intake. A higher number of gastric 2174 
ghrelin expressing cells in pregnant mice may explain the time-dependent higher 2175 
concentrations of circulating total ghrelin compared to non-pregnant mice. Interestingly, 2176 
despite elevated total ghrelin, acyl-ghrelin concentrations were not elevated in 2177 
pregnancy or by dietary supplementation with octanoic acid at the concentrations used 2178 
in the present study. Our results confirm upregulation of the GH-ghrelin axis in 2179 
pregnancy, but the mechanisms underlying increases in circulating GH in murine 2180 
pregnancy remain to be explained. 2181 
 2182 
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Chapter 3 Validation studies of a fluorescent method to 2205 
measure placental glucose transport in mice 2206 
 2207 
3.1 Overview  2208 
 2209 
The work in this chapter corresponds to the second aim of this thesis. In this study, we 2210 
developed and validated a fluorescence-based method to measure placental perfusion 2211 
in mice using the IRDye 800CW 2-DG, a commercially available glucose analog 2212 
designed to measure cellular GLUT transporter activity.  2213 
This chapter has been published in Placenta [723] and has been reproduced exactly as 2214 
published, with the exception of formatting, which has been modified to be consistent 2215 






3.2 Abstract  2219 
Proper placental function is essential for optimal fetal growth in utero. Placental transfer 2220 
of nutrients to the fetus can be measured using radiolabelled tracers, but non-radioactive 2221 
methods have potential advantages. This study aimed to develop a fluorescence-based 2222 
method to measure placental glucose transport in mice. Time course and localisation of 2223 
the IRDye 800CW 2-deoxyglucose were recorded (Lumina IVIS Live Imaging System) 2224 
following tail vein injection into anaesthetised late pregnant mice. Fluorescent signals in 2225 
placental and fetal tissues were assessed after injecting conscious dams with 10 nmol 2226 
IRDye 800CW 2-deoxyglucose (3, 30, 60, 120 min) or vehicle. Specificity of dye uptake 2227 
was determined by comparing uptake of IRDye 800CW conjugated to 2-deoxyglucose 2228 
or carboxylate, at 2 and 24 h. Finally, we assessed relationships of fetal size and 2229 
umbilical blood flow velocities with relative dye uptake. In late pregnant mice, uterine 2230 
fluorescent signal localised rapidly over placentas and remained consistent for >1 h. 2231 
Signal intensity in whole and homogenised tissues was increased in fetuses and 2232 
decreased in placentas after 3 minutes and stabilised by 30 min post-injection. Relative 2233 
fetal dye uptake at 2 and 24 h was greater in littermates with the highest compared to 2234 
lowest placental efficiency; signals were similar for 2-deoxyglucose- or carboxylate-2235 
conjugated dyes. Relative fetal dye uptake correlated positively with fetal weight and 2236 
placental efficiency and negatively with umbilical artery resistance indices. Fetal uptake 2237 
of IRDye 800CW correlates with markers of placental blood flow and fetal growth, but 2238 
does not specifically measure placental glucose transport.   2239 
107 
3.3 Introduction 2240 
One of the major determinants of intrauterine growth is the placental supply of nutrients 2241 
to the fetus, which occurs primarily by diffusion and transporter-mediated transfer [724]. 2242 
The capacity of the placenta to facilitate this nutrient exchange depends on its size, 2243 
morphology and blood flow as well as the abundance and activity of nutrient transporters 2244 
[725, 726]. There is now considerable evidence that poor placental function is a major 2245 
contributor to restricted fetal growth [150]. Although the placenta can adapt 2246 
morphologically and functionally to fetal signals of nutrient demand [727-729], 2247 
inadequate placental function can result in intrauterine growth restriction (IUGR) wherein 2248 
the fetus fails to reach its genetically pre-determined growth potential [213, 730]. Low 2249 
birthweight (LBW, <2.5 kg) and IUGR fetuses are at a higher risk of fetal mortality and 2250 
morbidity, both perinatally and later in life [731-735].  2251 
One of the most widely used methods of assessing placental efficiency is the 2252 
measurement of placental nutrient transporter expression and activity. Isolated placental 2253 
vesicles from human pregnancies complicated by IUGR typically exhibit decreased 2254 
placental activity of system A amino acid transporters [736]. While not differentially 2255 
expressed in placentas from human IUGR and normally-grown fetuses [208], placental 2256 
protein abundance of the facilitated glucose transporter solute carrier family 2 member 2257 
1 (Slc2a1, previously known as GLUT1) is lower in experimentally-induced rat IUGR 2258 
pregnancies at late gestation compared to sham controls [737]. Conversely, in non-2259 
manipulated murine pregnancy, small placentas are able to support fetal growth by 2260 
increasing the expression of nutrient transporters when compared with larger placentas 2261 
[727]. Near term, at 19 days after mating (e19; GD19.5), although not at e16 (GD15.5), 2262 
the lightest placentas had 20-40% higher expression of Slc2a1 and the placental solute 2263 
carrier family 38, member 2 (Slc38a2/SNAT2), an isoform of the System A amino acid 2264 
transporter, compared to the heaviest placentas within the litter [727]. Compared with 2265 
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the heaviest placenta, active transfer of [14C] methyl aminoisobutyric acid (MeAIB) per 2266 
gram of placenta was ~40-50% greater in the lightest placentas of the litter, at both e16 2267 
and e19, when mouse fetuses are growing most rapidly in absolute terms [727]. 2268 
However, despite greater transported expression of Slc2a1, materno-fetal transfer of 2269 
[14C] glucose per gram placenta did not differ between the lightest and heaviest placentas 2270 
in the litter [727]. Along with alterations in placental morphology, such changes in 2271 
placental function are considered to be adaptations that aim to match nutrient delivery to 2272 
fetal demand. As a result of these alterations, around 30% more fetus is produced per 2273 
gram of placenta by the lightest than the heaviest placenta in the litter in a normal mouse 2274 
litter [727]. Consequently, the fetal:placental weight (FW:PW) ratio is used as a marker 2275 
of placental efficiency [727, 738, 739].   2276 
While measuring protein levels can provide an indication of transport capacity, direct 2277 
assessment of nutrient transfer requires the use of labelled substrates. Alterations in the 2278 
passive and active placental transport of solutes in experimental models of IUGR has 2279 
been demonstrated by quantifying the maternofetal transfer of radiolabelled tracers 2280 
including [14C] inulin, [3H] methyl-D-glucose (MG) and [14C] amino-isobutyric acid (AIB) 2281 
[93, 661, 729]. An alternative approach to this use of radiolabelled substrates is to use 2282 
fluorescently labelled compounds. These offer a number of potential advantages over 2283 
radioisotopes, including fewer constraints on handling and disposal, and the availability 2284 
of many emission spectra and therefore ability to measure greater numbers of substrates 2285 
simultaneously [740]. Additionally, live course imaging can be performed by tracking the 2286 
movement of the label in real-time as well as obtaining better signal localisation and 2287 
stability [741]. One such commercially available fluorescently labelled substrate is IRDye 2288 
800CW 2-DG Optical Probe (LI-COR Biosciences, Lincoln, NE, Lincoln, NE). The 2289 
fluorescent dye is conjugated to 2-deoxyglucose (2-DG), which is a non-metabolisable 2290 
glucose analogue that remains within cells after phosphorylation [742]. Uptake of IRDye 2291 
800CW 2-DG in human tumour cell lines with high and low metabolic rates and in mouse 2292 
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adipocytes is dose-dependent and can be blocked by incubation with unlabelled glucose, 2293 
2-DG or monoclonal antibodies raised against Slc2a1 [743]. This probe has been 2294 
previously used to study in vitro and in vivo glucose uptake in cancer research, including 2295 
in rodents [743, 744]. To date, there are no non-radioactive methods available to study 2296 
placental transport. Therefore, the current study aimed to develop and validate a 2297 
fluorescence-based method to measure placental glucose transport in mice using the 2298 
IRDye 800CW 2-DG.  2299 
 2300 
3.4 Methods  2301 
3.4.1 Ethics and animal management 2302 
Experiments One and Two: Experimental procedures were approved by the University 2303 
of Adelaide Animal Ethics Committee (M-2014-168) and carried out in accordance with 2304 
the Australian code of practice for the care and use of animals for scientific purposes 2305 
[745]. C57BL/6J virgin female mice aged 10 weeks were obtained from the Animal 2306 
Resource Centre, Perth and housed at ~23°C with 12 h:12 h light:dark lighting cycle 2307 
(lights on 06:00 h). Access to water and meat-free rat and mouse diet (14.0 MJ/kg, 20% 2308 
protein, Speciality Feeds, Glen Forrest, Australia) was ad libitum and mice were weighed 2309 
daily throughout the experiment. Estrous cycle stages were confirmed by daily 2310 
monitoring of vaginal cell types collected by gently flushing the vagina with 10 µL of saline 2311 
[698]. To generate timed pregnancies, females in either proestrus or early estrus were 2312 
placed overnight with a mature adult CBAF1 male. Pregnancy was determined by the 2313 
presence of a vaginal plug (day 0.5 after mating, GD0.5) and/or weight gain, and 2314 
confirmed at post-mortem.  2315 
Experiment Three: CBAF1 virgin female mice aged 10-12 weeks were obtained from the 2316 
Animal Resource Centre, Perth and housed at ~23°C on a 12 h:12 h light:dark lighting 2317 
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cycle (lights on 0700 h), with ad libitum access to Teklad global soy protein-free extruded 2318 
rodent diet (irradiated; 13 MJ/kg, 18.4% protein, Envigo, Huntingdon, UK). Mice were 2319 
weighed daily throughout the experiment. Timed pregnancies were generated and 2320 
confirmed as described above, with commencement of breeding delayed until ~17-20 2321 
weeks of age due to a shift of animal facilities. 2322 
Experiment Four: CBAF1 virgin female mice aged 10-12 weeks were obtained from the 2323 
Animal Resource Centre, Perth and housed and bred under the same conditions as 2324 
those described above for experiment three. 2325 
3.4.2 Experiment 1 – Live imaged time course  2326 
In order to confirm our ability to detect fluorescent signals over the conceptus regions 2327 
and the timeframe for the appearance of signals, pregnant mice aged 15-18 weeks at 2328 
GD17.5 were anaesthetised by intra-peritoneal injection of 20 mg/mL Avertin (2,2,2-2329 
tribromoethanol and tert-amyl alcohol; Sigma-Aldrich, Missouri, United States) 2330 
immediately after being injected with 10 or 20 nmol of fluorescently-labelled 2-DG (LI-2331 
COR Biosciences) dye (n=2/dose) diluted in a total volume of 50-100 µL phosphate 2332 
buffered saline (PBS), intravenously into the tail vein. This was followed by uterine 2333 
exteriorisation to allow serial live imaging at 3-5 minute intervals under isofluorane 2334 
anaesthesia for approximately 1 h post-injection using the IVIS imaging system 2335 
(wavelengths: Ex 760 nm/Ex 790 nm, IVIS Lumina XRMS system, Perkin Elmer). An 2336 
additional animal was imaged without dye injection to confirm the absence of non-2337 
specific signal. Dams were then humanely killed by cervical dislocation. Fluorescent 2338 
emission signals in a region encompassing the middle conceptus of each horn were 2339 
measured in each animal throughout each time course. Background signal was 2340 
measured in an area adjacent to each mouse and was subtracted from the signal 2341 
measured over the conceptus. 2342 
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3.4.3 Experiment 2 – Time course of placental and fetal dye uptake in 2343 
conscious mice 2344 
In order to determine the time course for placental and fetal uptake of IRDye 800CW 2-2345 
DG following maternal tail-vein injection, 16-25 week old dams pregnant at GD17.5 were 2346 
injected with 10 nmol of IRDye 800CW 2-DG in 50 µL PBS (intravenous, tail vein 2347 
injection). Injected mice were returned to their home cage for 3, 30, 60 or 120 min (n=2-2348 
3/group) before being anaesthetised with Avertin and humanely killed by cervical 2349 
dislocation. Individual fetuses and placentas were dissected, weighed and imaged using 2350 
the IVIS imaging system, using settings as described above. Background signal 2351 
measured in an area adjacent to each tissue was subtracted from tissue fluorescent 2352 
signals. Immediately after being imaged, all fetuses were snap-frozen in liquid nitrogen, 2353 
while placentas were alternately snap-frozen or fixed in 4% paraformaldehyde with 2.5% 2354 
polyvinylpyrrolidone-40 in 70 mM phosphate buffer for 24 h. Samples were subsequently 2355 
washed in four changes of 1 X PBS over 48 h, incubated in 30% sucrose solution for 2 2356 
h before being embedded in Optimum Cutting Temperature compound (OCT, Tissue-2357 
Tek, Sakura Finetek Japan Co. Ltd., Tokyo, Japan).   2358 
To develop a method to measure fluorescent signals in stored tissues, frozen placentas 2359 
and fetuses were homogenised in radioimmunoprecipitation assay (RIPA) buffer (20 mM 2360 
Tris (pH 8.0), 150 mM NaCl, 1% octylphenoxypolyethoxyethanol (IGEPAL), 0.5% sodium 2361 
deoxycholate, 5 mM Ethylenediaminetetraacetic acid (EDTA) and 0.1% sodium dodecyl 2362 
sulfate) using the PowerLyzer 24 (Mo Bio Laboratories, Inc. Carlsbad, CA). The 2363 
placentas were homogenised for 3 cycles of 15 seconds duration each, at 3500 rpm with 2364 
pause/dwell time of 30 seconds. The fetuses were homogenised using the same 2365 
settings, except that the cycle number was increased to 10. For each sample, 50 µL of 2366 
homogenate and RIPA buffer was pipetted in triplicate into an opaque 96-well plate, 2367 
before being imaged with the Odyssey CLx Infrared Imaging System (LI-COR 2368 
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Biosciences, Lincoln, NE) using the 800 nm channel at 42 µm resolution and a 4.0 mm 2369 
focus offset. Background values were measured in wells containing only RIPA buffer. 2370 
Images were analysed using Image StudioTM Lite (LI-COR Biosciences, Lincoln, NE) 2371 
image processing software. The triplicate fluorescence emission values (minus 2372 
background values) from each respective fetus and placenta were averaged and 2373 
expressed as signal intensity per fetus or placenta. Fetal signals were also expressed 2374 
relative to placental weight. Relationships between signals obtained using the IVIS 2375 
imaging system on whole tissues and signals obtained using the Odyssey CLx Infrared 2376 
Imaging System on homogenised tissues were evaluated by Pearson’s correlation. 2377 
3.4.4 Experiment 3 – Specificity of dye uptake 2378 
In order to test the specificity of dye uptake, we compared fetal and placental fluorescent 2379 
signals after maternal tail vein injection with 0.2 nmol/g body weight of IRDye 800CW 2-2380 
DG or IRDye 800CW carboxylate dye (LI-COR Biosciences, Lincoln, NE) in PBS (total 2381 
volume 50-100 µL) in mice aged 20-21 weeks at GD17.5-GD18.5 of pregnancy. IRDye 2382 
800CW carboxylate contains the fluorophore conjugated to carboxylate and is  by the 2383 
manufacturer as a negative control to the IRDye 800CW 2-DG [741, 746]. When injected 2384 
into tumour-bearing mice, fluorescent signals 18-72 hours post-injection were ~3-fold 2385 
higher for IRDye 800CW 2-DG than for IRDye 800CW carboxylate, and IRDye 800CW 2386 
carboxylate is completely cleared from non-tumour-bearing mice within 48 h post-2387 
injection [746]. Dams were humanely killed at 2 h post-maternal injection (n=3/group), 2388 
based on the results of our previous experiments, and at 24 h post-maternal injection (2-2389 
DG: n=6; carboxylate: n=4), based on data collection times used in previous in vivo 2390 
studies using this probe [746]. Fetal and placental tissues were dissected, weighed and 2391 
snap-frozen for subsequent homogenisation and tissue from the fetuses with the highest 2392 
and lowest placental efficiency (FW:PW ratio) of each litter was imaging using the 2393 
Odyssey CLx Infrared Imaging System as described above. Data from fetuses within a 2394 
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litter were treated as repeated measures of the dam. A repeated measures ANOVA was 2395 
performed to compare fetal dye uptake (fetal fluorescent signal per gram placenta) 2396 
between dyes and between the littermates with the highest and lowest placental 2397 
efficiency of each litter (within litter factor), separately for litters collected at 2 and 24 2398 
hours. 2399 
3.4.5 Experiment 4 – Relationship between fetal dye uptake and fetal blood flow  2400 
To assess the relationship between fetal dye uptake and indices of fetal blood supply, 2401 
CBAF1 dams at 14-18 weeks of age were injected (tail vein) with 0.2 nmol/g body weight 2402 
of IRDye 800CW 2-DG at GD17.5. Approximately 24 h after maternal-dye injection, 2403 
umbilical artery blood flow velocities were assessed by Doppler ultrasound, using the 2404 
Vevo 3100 Ultrasound Biomicroscope (FUJIFILM VisualSonics, Toronto, Ontario, 2405 
Canada) with a 32-55 MHz transducer probe, as described previously [747]. Mice were 2406 
anaesthetized with isoflurane (5% induction, 1.5% maintenance, in medical air). Doppler 2407 
ultrasound recordings were taken from the umbilical arteries of at least two, and where 2408 
possible, four fetuses per dam. Recordings were analysed for peak systolic velocity 2409 
(PSV), time-averaged velocity (TAV), end diastolic velocity (EDV), and fetal heart rate 2410 
from 3 consecutive cardiac cycles (Figure 3.1) [748]. Resistance index 2411 
(RI = [PSV − EDV]/PSV) and pulsatility index (PI = [PSV − EDV]/time averaged velocity 2412 
[TAV]) were calculated for each fetus. Following Doppler imaging, dams were humanely 2413 
killed by cervical dislocation, and fetuses and placentas dissected and weighed. Fetal 2414 
size (abdominal circumference, crown to rump length, and head width) was also 2415 
measured, prior to snap-freezing of fetal and placental tissues for subsequent 2416 
homogenisation and imaging using the Odyssey CLx Infrared Imaging System as 2417 
described above. Relationships of fetal dye uptake (fetal signal per gram placenta) with 2418 
umbilical blood flow parameters and fetal weight and size were assessed by Pearson’s 2419 
Correlation analysis using data for each individual fetus.  2420 
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 2421 
Figure 3.1 Umbilical blood flow characteristics at GD18.5 in naturally-mated CBAF1 2422 
dams were characterised for 3-4 individual fetuses per litter. 2423 
 2424 
3.5 Results  2425 
3.5.1 Experiment 1 – Live imaged time course  2426 
In the uterine region of anaesthetised GD17.5 pregnant C57Bl6/J mice, fluorescent 2427 
signal localised rapidly to the placenta after maternal tail vein injection with IRDye 2428 
800CW 2-DG (Figure 3.2). Fluorescent signals could be readily detected in the 2429 
conceptus regions of mice injected with 10 or 20 nmol dye and signal intensity remained 2430 
stable in individual animals for > 1 h (Supplementary Figure 3.1).  2431 
 2432 
 2433 
Figure 3.2 Fluorescent signal detected by the Lumina IVIS Live Imaging System (ex 2434 
760 nm/em 790 nm) in anaesthetised C57Bl6/J mice on day GD17.5 of pregnancy at 8 2435 
(A), 38 (B) and 68 (C) min after tail vein injection with IR Dye 800CW 2-DG. 2436 
 2437 
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3.5.2 Experiment 2 – Time course of experimental and fetal dye uptake in 2438 
conscious mice 2439 
Signal intensity from whole fetuses by IVIS imaging was initially low and placental 2440 
signals were high at 3 min and then remained stable between 30 and 120 min following 2441 
maternal tail vein injection (Figures 3.3A and 3.3B). Fluorescence emission measured 2442 
in homogenised fetuses and placentas followed a similar pattern over time (Figures 2443 
3.3C and 3.3D). Fluorescence signals obtained from the same tissues using the two 2444 
approaches were strongly positively correlated (fetal tissues: P<0.001; R=0.662; 2445 
placental tissues: P<0.001; R=0.813). 2446 
 2447 
Figure 3.3 Fluorescent signal was measured by IVIS in whole fetuses (A) and 2448 
placentas (B) and in homogenised fetuses (C) and placentas (D) by Odyssey CLx (B). 2449 
At GD17.5 of pregnancy, C57Bl6/J mice were injected with 10 nmol IR Dye 800CW 2-2450 
DG via the tail vein and humanely killed at 3 to 120 minutes after injection. Each cluster 2451 
of symbols represents a separate litter. Filled symbols show litter averages, unfilled 2452 
symbols show individual fetal and placental data within each litter and the black oval 2453 
indicates a litter where dye was inadvertently injected into tail sheath (n=2-3 dams and 2454 
litters for each time point). NEG indicates control animals injected with PBS. Placental 2455 
fluorescence data from Odyssey measures (D) was only available for frozen placentas 2456 
from each litter. 2457 
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3.5.3 Experiment 3 – Specificity of dye uptake  2458 
Fluorescent signals were higher in the highest compared to lowest placental efficiency 2459 
littermates regardless of dye type at 2 h (Figure 3.4A) and 24 h post-maternal injection 2460 
(Figure 3.4B). Signal intensities were similar in fetuses from dams injected with 2-DG- or 2461 
carboxylate-conjugated IRDye 800CW at each time point (Figures 3.4A and 3.4B). 2462 
Differences in signal intensity between lowest and highest placental efficiency littermates 2463 
did not differ between dye types at either time point (Figures 3.4A and 3.4B). 2464 
 2465 
Figure 3.4 Fluorescent signals (A, B) measured by Odyssey CLx Infrared Imaging 2466 
System (800 nm channel), in fetuses (from CBAF1 dams at GD17.5-18.5) that had 2467 
highest and lowest placental efficiency (PE; defined as FW:PW ratio) within the litter. 2468 
Dams were tail vein-injected with IRDye 800CW 2-DG (black symbols) or IRDye 2469 
800CW carboxylate negative control dye (white symbols), and fetuses collected either 2470 
2 h (A, C) or 24 h (B, D) post-maternal injection. Panels C and D show corresponding 2471 
data for placental efficiency – the pairs of littermates on panels A and C and panels B 2472 
and D share the same symbols. Results are presented as individual data, littermates 2473 
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3.5.4 Experiment 4 – Relationship between fetal dye uptake and fetal blood flow  2475 
Fetal dye signal relative to placental weight correlated positively with fetal weight (Figure 2476 
3.5A) and FW:PW ratio (Figure 3.5B), fetal head width (P<0.001, R=0.533) abdominal 2477 
circumference (R=0.514, P<0.001) and crown to rump length (P<0.001, R=0.582), and 2478 
negatively with umbilical pulsatility indices (Figure 3.5C) and umbilical resistance (Figure 2479 
3.5D) at GD18.5 of gestation. Additionally, relative fetal dye uptake correlated positively 2480 
with umbilical end-diastolic velocity (P=0.005, R=0.475) and fetal heart rate (P=0.003, 2481 
R=0.515), but was not correlated with peak systolic velocity (P=0.112, R=0.282).  2482 
 2483 
Figure 3.5 Correlations between fetal dye signal per gram of placental weight and fetal 2484 
weight (A), fetal:placental weight ratio (B), and umbilical artery pulsatility (C) and 2485 
resistance (D) indices. Symbols show data from individual fetuses derived from nine 2486 
independent litters; fetal and placental weight data was available for all 56 viable 2487 
fetuses and umbilical artery Doppler ultrasound data was obtained in 33 fetuses.   2488 
 2489 
3.6 Discussion  2490 
This is the first study to test the use of a fluorescently-labelled dye for measuring 2491 
placental nutrient transport. As originally aimed, we developed a method to quantify feto-2492 
placental uptake of the near-infrared IRDye 800CW 2-DG dye in term mice. Consistent 2493 
with reported within-litter differences in uptake of radiolabelled glucose in mice [93, 727], 2494 
fetal uptake of IRDye 800CW 2-DG relative to placental weight was greater in littermates 2495 
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with high compared to low placental efficiency, and correlated positively with fetal size. 2496 
Fetal uptake of dye relative to placental weight also correlated negatively with markers 2497 
of impaired placental function, including umbilical blood flow resistance indices. Although 2498 
these data suggested that uptake of IRDye 800CW 2-DG provides a proxy measure of 2499 
placental function, signals were similar whether the fluorophore was conjugated with 2500 
carboxylate (negative control) or glucose, implying that uptake is at least in part via other 2501 
mechanisms than glucose transporters. 2502 
Placental efficiency, commonly defined as the ratio of fetal to placenta weight (FW:PW 2503 
ratio), acts as a proxy measure of placental function up to that stage of gestation [727, 2504 
738, 739]. The characteristics of a highly efficient placenta include a large surface area 2505 
for exchange and appropriate expression and activity of nutrient transporting proteins to 2506 
ensure optimum nutrient delivery to the fetus [306, 725, 738]. In the present study, we 2507 
observed differences in fetal uptake of IRDye 800CW 2-DG based on the relative 2508 
placental efficiency of littermates within near-term mouse litters. Consistent with the 2509 
results of radioisotope tracer studies [93, 727], the uptake of the 2-DG dye was 2510 
significantly higher in the fetuses with the highest compared to the lowest placental 2511 
efficiencies within the litter. Furthermore, we found that fetal accumulation of the dye 2512 
relative to its placental weight, was positively correlated with fetal biometric parameters 2513 
at birth, including birthweight, head width, abdominal circumference and crown to rump 2514 
length. Together, these data imply that the uptake of the fluorescent 2-DG dye provides 2515 
an indirect measure of nutrient delivery to the fetus. Ultrasonography is often used in 2516 
clinical practice to monitor placental function by assessing the resistance to blood flow 2517 
in the feto-placental unit. In normal pregnancies, low impedance in the umbilical artery 2518 
allows continuous and stable forward flow throughout the cardiac cycle [749]. Maternal, 2519 
placental or environmental conditions that negatively influence uterine blood flow are 2520 
often detected by abnormal umbilical artery Doppler velocimetry, and are associated with 2521 
pregnancy complications including IUGR and preeclampsia [750, 751]. In these 2522 
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complications, fetal delivery of nutrients that cross the placenta by diffusion is often 2523 
reduced due to low uterine blood flow [752, 753]. Hence, as part of the current study, we 2524 
recorded and analysed fetal umbilical arterial waveforms in late gestation (GD18.5) in 2525 
our final experiment. Even though our investigations focussed on normal mouse 2526 
pregnancy, and did not include studies of experimental IUGR, we found that lower 2527 
resistance indices in the feto-placental unit were associated with higher fetal uptake of 2528 
IRDye 800CW 2-DG per gram of placenta.  2529 
Although IRDye 800CW 2-DG uptake was greater in high than low placental efficiency 2530 
littermates and correlated positively with markers of fetal growth and negatively with 2531 
umbilical resistance indices, total and differential uptake of the fluorophore were similar 2532 
regardless of whether it was conjugated to 2-DG or carboxylate. This was unexpected, 2533 
since in non-pregnant mice, uptake and retention of IRDye 800CW 2-DG 24 h post-2534 
injection is ~3–4-fold higher than that of IRDye 800CW carboxylate in kidneys, muscle 2535 
and liver [743]. Similarly, uptake and retention of these dyes differ in murine cancer. In 2536 
mice with unilateral brain tumours, fluorescent signals imaged in anaesthetised animals 2537 
24 h after injection with IRDye 800CW 2-DG were also ~3-fold greater in the tumour 2538 
region than in the contralateral brain region, thought to reflect higher glucose metabolic 2539 
demand within the tumour [741]. Fluorescent signals after injection with IRDye 800CW 2540 
carboxylate were ~3-fold lower than those in mice injected with the 2-DG-conjugated 2541 
dye, and were not different in tumour and non-tumour sides of the brain [741]. In our 2542 
initial live imaging studies, we observed high fluorescence intensity in the bladder area 2543 
of dams injected with the 2-DG dye (data not shown), suggesting rapid renal clearance. 2544 
Although the renal threshold for glucose in mice has not been clearly stated in literature, 2545 
the available data suggest that in rodents, glucose excretion through urine only occurs 2546 
at concentrations >22.2 mmol/L (400 mg/dL) [754]. The maximum amount of the dye 2547 
injected to dams in this study was 20 nmol, which in a blood volume of approximately 2 2548 
mL in a heavily pregnant 35 g mouse should increase circulating glucose by 2549 
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approximately 0.01 mmol/L. Therefore the dye administration itself is not expected to 2550 
have caused the mice to reach the renal clearance threshold. When measuring the tissue 2551 
distribution of the IRDye 800CW carboxylate in male and female rats, the highest degree 2552 
of uptake occurred in the kidneys, regardless of sex [755], also suggesting renal 2553 
clearance of the fluorophore. In the same study, uptake of the IRDye 800CW carboxylate 2554 
was markedly higher in the ovaries compared to the testes [755]. SLC2A1 transporter-2555 
dependent uptake of IRDye 800CW 2-DG has been previously validated in vitro, where 2556 
it can be inhibited by addition of antibodies raised against SLC2A1, as well as by addition 2557 
of unlabelled glucose or 2-DG [743]. This is interesting, given that IRDye 800CW 2-DG 2558 
is estimated to be too large to pass through the predicted three-dimensional model of 2559 
the SLC2A1 channel [756]. Given these data, and the findings of the current study, it is 2560 
possible that IRDye 800CW 2-DG is taken up by transporters that are not glucose-2561 
specific, and that are co-expressed in the kidneys and the female reproductive tract in 2562 
rodents. However, further cell assays will need to be performed in order to investigate 2563 
the mechanisms involved in the cellular uptake of the IRDye, including the placenta. 2564 
Confirmation that placental IRDye 800CW 2-DG transport is glucose transporter-2565 
independent requires inhibition studies using unlabelled glucose or 2-DG or antibodies 2566 
to glucose transporters in placental cells or cell lines, similar to previous studies in tumour 2567 
cells [743]. 2568 
In conclusion, the lack of differential uptake between 2-DG- and carboxylate-2569 
conjugated dyes indicate that the IRDye 800CW 2-DG is not able to specifically 2570 
measure placental glucose uptake via glucose transporters in mice. The use of radio-2571 
labelled tracers therefore remains the optimal method to measure placental transport of 2572 
specific nutrients. However, in term mice, IRDye 800CW 2-DG signals can differentiate 2573 
between littermates of high and low placental efficiencies, and its relative fetal uptake 2574 
correlates positively with fetal growth parameters and negatively with markers of 2575 
impaired placental function. This establishes a fluorescence-based method to indirectly 2576 
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measure overall placental function and nutrient supply to the fetus in murine 2577 
pregnancy.  2578 
 2579 
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 2599 
Figure 3.6 (Supplementary) Fluorescent signal detected by the Lumina IVIS Live 2600 
Imaging System (ex 760 nm/em 790 nm) in individual anaesthetised C57Bl6/J mice on 2601 
day GD17.5 of pregnancy after tail vein injection with IR Dye 800CW 2-DG. Y axis 2602 
shows fluorescence signal measured in the regions over the middle left and middle 2603 
right conceptus of each uterine horn. X axis shows minutes after dye injection. All data 2604 
points for each animal were taken under the same imaging settings (missing points for 2605 
animals F62 and F64 were from images taken at different settings or reflect technical 2606 
problems). Due to varying imaging settings used for different animals during these pilot 2607 
studies, signal intensity should not be directly compared between animals. 2608 
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Chapter 4 A sexually-dimorphic murine model of IUGR induced 2610 
by embryo transfer  2611 
4.1 Overview  2612 
The work described in this chapter corresponds to the final aim of this thesis. In this 2613 
study, we established and characterised a model of variable fetal constraint due to 2614 
increasing litter size induced through embryo transfer, in which to test intervention 2615 
strategies to prevent or treat IUGR in multiple pregnancies. We also assessed whether 2616 
responses to increasing litter size in our experimental model were sex-specific. 2617 
This chapter has been submitted to Reproduction (manuscript number: REP-20-0209) 2618 
and a revised version is currently under review. The chapter included in this thesis is 2619 
the resubmitted version, with additional edits made in response to suggestions of the 2620 
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4.2 Abstract 2625 
Animal models are needed to develop interventions to prevent or treat intrauterine growth 2626 
restriction (IUGR). Fetal growth rates and effects of in utero exposures differ between 2627 
sexes, but little is known about sex-specific effects of increasing litter size. We 2628 
established a murine IUGR model using pregnancies generated by multiple embryo 2629 
transfers, and evaluated sex-specific responses to increasing litter size. CBAF1 embryos 2630 
were collected at gestational day 0.5 (GD0.5) and 6, 8, 10 or 12 embryos were 2631 
transferred into each uterine horn of pseudo-pregnant female CD1 mice (n=32). Fetal 2632 
and placental outcomes were measured at GD18.5. In the main experiment fetuses were 2633 
genotyped (Sry) for analysis of sex-specific outcomes. The number of implantation sites 2634 
(P=0.004, P=0.003, respectively) and litter size (P=0.058, P=0.001, respectively) 2635 
correlated positively with number of embryos transferred, while placental weight 2636 
correlated negatively with litter size (both P<0.01). The relationship between viable litter 2637 
size and fetal weight differed between sexes (interaction P=0.002), such that fetal 2638 
weights of males (P=0.002), but not females (P=0.233), correlated negatively with litter 2639 
size. Placental weight decreased with increasing litter size (P<0.001) and was lower in 2640 
females than males (P=0.020). Our results suggest that male fetuses grow as fast as 2641 
permitted by nutrient supply, whereas the female maintains placental reserve capacity. 2642 
This strategy reflecting sex-specific gene expression is likely to place the male fetus at 2643 
greater risk of death in the event of a “second hit”. 2644 
2645 
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4.3 Introduction 2646 
Intrauterine growth restriction (IUGR), where a suboptimal fetal environment prevents 2647 
the fetus from attaining its genetically determined growth potential, affects 6-12% of 2648 
pregnancies in developed countries [150]. Babies born from IUGR pregnancies often 2649 
have a low birth weight (LBW, <2.5 kg), although this can also result from prematurity 2650 
without IUGR [152]. In developed countries, one the most common causes of IUGR is 2651 
placental insufficiency [150]. This typically affects the fetus in the later stages of 2652 
gestation (>32 weeks) and results in an asymmetric reduction in fetal biometric 2653 
parameters like abdominal circumference, while the growth of the fetal brain is 2654 
relatively preserved [757]. LBW is associated with increased risks of both neonatal 2655 
complications, including still birth, and persistent impacts on health, including ~20-30% 2656 
increased risks for cardio-metabolic diseases [153, 154, 188, 263]. There is currently 2657 
no cure or prevention for IUGR and robust animal models are needed to develop and 2658 
test interventions. 2659 
In humans, the risk of LBW increases in multiple births; 5.2% of singletons, 55% of 2660 
twins and 99% of higher-order multiples in Australia were LBW in 2017 [188]. In mice, 2661 
as in other litter-bearing species such as pig, placental and fetal weights decrease as 2662 
litter size increases [378-381]. Seminal studies demonstrated restricted fetal growth 2663 
due to maternal constraint in the context of cross-breeding of horses [758] and, embryo 2664 
transfer experiments in horses [759, 760] and pigs [761] that remove confounding 2665 
effects of imprinting. More recently, the embryo transfer technique was also used in 2666 
rabbits to demonstrate that fetal size is larger in smaller litters [762]. These studies 2667 
clearly show that fetal growth is limited by maternal size, despite evidence of some 2668 
compensatory adaptations to placental size and structure [759]. The mechanisms for 2669 
constrained fetal growth due to increasing litter size is likely to differ somewhat from 2670 
those seen in singleton pregnancies. However, larger litters are subject to  both 2671 
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reduced placental growth and function and competition for maternal nutrients, since 2672 
reducing litter size from twin to singleton post-implantation only partially restores fetal 2673 
growth in sheep [386].  2674 
Litter size increases as a greater number of embryos are transferred to pseudo-2675 
pregnant mice [763], producing a range of litter sizes independent of these maternal 2676 
confounders, although fetal and placental growth have not been reported in this model 2677 
Our primary aim was therefore to establish and characterise a model of variable fetal 2678 
constraint due to increasing litter size induced through embryo transfer. In human 2679 
pregnancies, median weights of male fetuses are higher than female fetuses at all 2680 
gestational ages up to term [36, 38]. Their rapid growth strategy is believed to put male 2681 
infants at a higher risk of preterm birth and neonatal mortality compared to female 2682 
infants, and fetal and placental responses to an adverse environment also differ 2683 
between sexes in humans and experimental animal models [54, 55, 764-766]. 2684 
Therefore, our secondary aim was to assess sex-specific responses to increasing litter 2685 
size in our experimental model. We hypothesised that within our model, as litter size 2686 
increased, there would be a decrease in fetal and placental weights. Furthermore, we 2687 
expected the degree of growth restriction to be more pronounced in male compared to 2688 
female fetuses near term. 2689 
 2690 
4.4 Materials and methods 2691 
4.4.1 Ethics and experimental design  2692 
Experimental procedures were approved by the University of Adelaide Animal Ethics 2693 
Committee (M-2016-186) and carried out in accordance with the Australian Code of 2694 
Practice for the Care and Use of Animals for Scientific Purposes [697]. Mice used in 2695 
this study were housed at ~23 °C with 12-h:12-h light:dark cycle (lights on 06:00 h), 2696 
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with ad libitum access to water and meat-free rat and mouse diet (14.0 MJ/kg, 20% 2697 
protein, Speciality Feeds, Glen Forrest, Australia).  2698 
4.4.2 Animal experiments 2699 
Fetal and placental outcomes were assessed in recipient dams that received between 2700 
12 and 24 embryos to induce variable litter sizes (Figure 4.1). Virgin female CBAF1 2701 
mice at 21-25 d old were purchased from the University of Adelaide breeding colony. 2702 
Mice aged approximately 4-5 weeks old were super-ovulated by intraperitoneal (i.p.) 2703 
injection of pregnant mare’s serum gonadotropin (Folligon, 5 IU; Intervet Australia, 2704 
Victoria, Australia), followed 46-48 h later by an i.p. injection of human chorionic 2705 
gonadotropin (hCG, Chorulon, 5 IU, Intervet Australia) to induce ovulation. These mice 2706 
were then housed 1:1 with proven fertile CBAF1 males, and 1-cell embryos were 2707 
collected by humanely killing the mouse and flushing the tract, 23 h after hCG injection. 2708 
Embryos were vitrified, thawed and transferred to pseudo-pregnant CD1 females [767] 2709 
in the South Australian Health and Medical Research Institute (SAHMRI) facility. All 2710 
transfers were conducted by the same operator. 2711 
To induce pseudo-pregnancy, mature (7-10 week old) CD1 female mice purchased 2712 
from SAHMRI breeding colony (selected due to their availability as well as the wide use 2713 
of this strain as recipients in embryo transfer protocols) were mated at estrus to 2714 
vasectomised male CBAF1 mice by housing two females with a male overnight. The 2715 
following morning, females with a vaginal plug were anaesthetised using gas 2716 
anaesthesia (isofluorane, 2% O2 at 2 L per minute) and analgesia (single dose of 0.1 2717 
mL Buprenorphine (Temgesic) administered subcutaneously at the rate of 0.05-0.1 2718 
mg/Kg). To access each uterine horn, a small cut was made in the skin and muscle 2719 
wall, and the upper part of the reproductive tract was gently exteriorised. Either 6, 8, 10  2720 
or 12  embryos were transferred to the ampulla of each uterine horn using a fine 2721 
pipette, resulting in transfer of a total of 12, 16, 20 and 24 embryos per dam, 2722 
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respectively (n = 8 dams per group, n = 32 dams in total). The reproductive tract was 2723 
then returned to the abdominal cavity and the skin closed with surgical clips. Females 2724 
were pair-housed after recovery and wound clips were removed 7-10 d post-surgery 2725 
[767]. Transfer was noted as unsuccessful during the procedure in one mouse 2726 
receiving 6 embryos per horn, and data from this animal was excluded from analyses 2727 
of the relationship between number of embryos transferred and litter size. 2728 
 2729 
Figure 4.1 Experimental design  2730 
 2731 
At GD17.5, 0.2 nmol/g body weight of IRDye 800CW 2-deoxyglucose (IRDye 800CW 2732 
2-DG) was injected via the tail vein of each pregnant mouse [723], which were then 2733 
returned to pair-housing (Figure 4.1). Fetal uptake of IRDye 800CW 2-DG correlates 2734 
positively with placental efficiency, and fetal growth parameters. However, the fetal 2735 
fluorescence signal is similar for fluorophore conjugated to glucose or carboxylate 2736 
(negative control), so should be interpreted as a measure of overall placental function 2737 
and nutrient supply to the fetus in murine pregnancy, not as a marker of fetal glucose 2738 
accumulation [723].   2739 
Approximately 24 h later, at GD18.5 (Figure 4.1),, the mice were anaesthetised with 2740 
isoflurane (5% induction, 1.5% maintenance, in medical air). Blood flow velocities of the 2741 
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uterine artery (n=30 dams) and from the umbilical arteries of at least two, and where 2742 
possible, four fetuses per dam (n=66 male fetuses; n=49 female fetuses) were 2743 
assessed in vivo using an ultrasound biomicroscope (Vevo 3100, VisualSonics®, ON, 2744 
Canada) as described previously [747, 768]. These measurements were 2745 
transabdominal, and therefore Doppler ultrasound of umbilical vessels could only be 2746 
performed for fetuses located adjacent to the maternal ventral surface. Fetal location 2747 
was marked on the skin of the anaesthetised dam using permanent texta during 2748 
ultrasound. At post-mortem, conducted immediately after ultrasound of anaesthetised 2749 
dams, the maternal abdomen wall was opened carefully without moving the uterus, and 2750 
marks were made on the uterus to indicate the studied fetuses. The fetuses located at 2751 
these positions were dissected and weighed before other fetuses to ensure accurate 2752 
identification. Peak systolic velocity (PSV), end diastolic velocity (EDV), time-averaged 2753 
velocity (TAV) and heart rate averages were obtained from a minimum of three 2754 
consecutive cardiac cycles. Resistance index (RI = [PSV − EDV]/PSV) and pulsatility 2755 
index (PI = [PSV − EDV]/TAV) were calculated. Following Doppler imaging, dams were 2756 
humanely killed by cervical dislocation, and fetuses and placentas were dissected and 2757 
weighed. Placental and fetal weight (n=157 males; n=141 females) were measured for 2758 
all pregnancies. Every alternate placenta per dam was fixed as described above. 2759 
Additional fetal size measures (abdominal circumference, crown to rump length, and 2760 
head width) were made on all individual fetuses by a single researcher using cotton 2761 
thread and Vernier callipers in all pregnancies after the initial 10 post-mortems (n=22 2762 
dams; n=105 male fetuses; n=100 female fetuses). After completion of fetal size 2763 
measures, anaesthetised fetuses were killed by decapitation, and fetuses and fetal tails 2764 
were snap-frozen. 2765 
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4.4.3 Determination of fetal sex 2766 
DNA was extracted from fetal tails using QuickExtract DNA Extraction Solution 2767 
(Epicentre, Madison, Wisconsin, USA). PCR reactions for Sry were made up of 20 μL 2768 
mastermix containing 0.2 μL Taq polymerase (Platinum™ Taq DNA Polymerase, 2769 
Invitrogen), 10 μL FailSafe™ PCR Enzyme and 2X PreMix Buffer D (Epicentre) and 10 2770 
μM Sry primers (Forward: 5’ AACAACTGGGCTTTGCACATTG 3’, reverse: 5’ 2771 
GTTTATCAGGGTTTCTCTCTAGC 3’ (final concentration 0.5 nM) and samples were 2772 
run for 33 cycles (94 °C 1 minute, 60 °C 1 minute, 72 °C 72 seconds) followed by 9 2773 
minutes at 72 °C on a GeneAmp® PCR system 9700 (Applied Biosystems, Waltham, 2774 
Massachusetts, USA). Male fetuses were determined by the presence of Sry. Female 2775 
fetuses were defined by a negative Sry reaction, together with the presence of intact 2776 
DNA, confirmed by a positive reaction for Myogenin, assessed using the same protocol 2777 
and using forward and reverse primers for Myogenin (Forward: 5' 2778 
TTACGTCCATCGTGGACAGC 3', reverse: 5' TGGGCTGGGTGTTAGTCTTA 3’) [769]. 2779 
DNA was re-extracted and PCR repeated for any sample where Myogenin was not 2780 
detected. Outcomes of the PCR were validated by gel electrophoresis on a 2% 2781 
agarose gel. 2782 
4.4.4 Placental morphology and function 2783 
Frozen fetuses were homogenised and fluorescence-imaged at 800 nm using the 2784 
Odyssey CLx Infrared Imaging System [723]. An index of placental transfer of IRDye 2785 
800CW 2-DG, which correlates positively with placental efficiency and negatively with 2786 
umbilical cord resistance index, was calculated as total fetal fluorescence at 800 nm 2787 
divided by placental weight [n=154 males, n=140 females, 723]. 2788 
Bisected placentas (n=2-6 per dam) were fixed in 4% paraformaldehyde (PFA), washed 2789 
in 1 X PBS over a 48 h period and stored in 70% ethanol prior to being paraffin 2790 
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embedded. Full-faced mid-sagittal placental sections cut to 5 µm thickness were stained 2791 
with Masson’s Trichrome following standard protocols [710]. Areas of junctional zone 2792 
and placental labyrinth for each placental section were visualised and measured with 2793 
NDP.view 2 software (Hamamatsu Photonics, Shizuoka, Japan). Total cross-sectional 2794 
area and the proportion of junctional zone to placental labyrinth were calculated for each 2795 
placenta. 2796 
4.4.5 Statistical analyses 2797 
Relationships between numbers of embryos transferred and numbers of implantation 2798 
sites and fetuses in each experiment were assessed by Pearson’s correlation. Effects 2799 
of fetal sex (fixed factor) and litter size (covariate) on maternal, fetal and placental 2800 
outcomes were analysed using the mixed models procedure in SPSS (version 24.0, 2801 
IBM, New York, US) and including dam as a random variable to account for the 2802 
common maternal environment. Fetal dye uptake data was not normally distributed and 2803 
was log transformed for analysis but non-transformed data is presented in Figure 4.3 2804 
for ease of interpretation. Previous studies have reported that murine fetuses at either 2805 
end of the uterine horns are heavier than those located near the middle of the uterine 2806 
horns [770]. In preliminary analyses we therefore also added fetal position within the 2807 
uterine horn as a covariate; this was not significant and was removed from final 2808 
models. Because effects of litter size on fetal weight differed between males and 2809 
females, fetal morphometric data was also analysed separately within each sex. 2810 
Relationships between fetal dye uptake and umbilical blood flow parameters and fetal 2811 
weight and size were assessed by Pearson’s Correlation analysis using data for each 2812 
individual fetus. Figures show points for individual litters or fetuses/placentae, except 2813 
for Figure 4.4, where data are presented as mean ± SEM, and P<0.05 was considered 2814 
significant for all analysis. 2815 
 2816 
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4.5 Results  2817 
 2818 
Figure 4.2 The numbers of viable implantation sites in pilot study (A) correlated 2819 
positively with the number of embryos transferred in mice. Total number of viable 2820 
fetuses in the litter (B) also increased with the number of embryos transferred. P and R 2821 
values are derived from Pearson’s correlation analysis; n=31 litters.    2822 
 2823 
4.5.1 Increased litter size induces sex-specific fetal IUGR 2824 
Both the number of implantation sites (P=0.033, R=0.38, Figure 4.2A) and litter size 2825 
(P=0.008, R=0.47, Figure 4.2B) correlated positively with number of embryos 2826 
transferred. 2827 
The relationship between litter size and fetal weight differed between males and 2828 
females (interaction P=0.002), such that fetal weight was negatively correlated with 2829 
litter size in male (P<0.001; Figure 4.3A), but not female (P=0.25; Figure 4.3B) fetuses. 2830 
In contrast, abdominal circumference, fetal head width and crown to rump length did 2831 
not differ between sexes (all P>0.05). As litter size increased, fetal abdominal 2832 
circumference decreased overall (P=0.003), within males (P=0.003; Figure 4.3C and 2833 
within females (P=0.035; Figure 4.3D). Crown to rump length and fetal head width were 2834 
not related to litter size overall (P>0.1, Figures 4.3E, F and 4.3G, H), respectively), or 2835 
within each sex. Markers of IUGR were observed in fetuses from larger litters. 2836 
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Specifically, as litter size increased, fetal weight to crown rump length ratio decreased 2837 
overall (P=0.012), and in males (P=0.007; Figure 4.3I) but not females (Figure 4.3J). 2838 
Similarly, with increasing litter size fetal head width to abdominal circumference tended 2839 
to increase overall (P=0.0634), and increased in males (P=0.026; Figure 4.3K) but not 2840 




Figure 4.3 Effects of litter size on fetal weight differed between sexes in mice. Weights 2843 
of males (A), but not females (B), correlated negatively with litter size. Abdominal 2844 
circumference (C, D) decreased with litter size but crown to rump length (E, F) and 2845 
head width (G, H) were unchanged, regardless of fetal sex. With increasing litter size, 2846 
all fetuses were thinner (I, J) with evidence of brain sparing (K, L). P values are derived 2847 
from mixed model analyses of individual fetal data (weight n=298, other size measures 2848 
n=205). Symbols show data from individual male (grey triangles; A, C, E, G and I) and 2849 
female (open circles; B, D, F, H and J) fetuses. Regression lines show correlations for 2850 
combined sexes (black solid lines for significant correlations, grey solid lines for non-2851 
significant correlations); where sex or sex*litter size interactions were significant, 2852 
correlations are shown separately for male (dotted line) and female (dashed line) 2853 
fetuses.  2854 
 2855 
4.5.2 Increased litter size impairs placental size and function similarly in both 2856 
sexes 2857 
Placental weight correlated negatively with litter size (P<0.001) and was lower in 2858 
females than males (P=0.022; (Figure 4.4B and 4.4A, respectively), but the effect of 2859 
litter size on placental weight did not differ between sexes. Placental efficiency tended 2860 
to correlate positively with litter size (P=0.055), and the effect of litter size on placental 2861 
efficiency was similar in males and females (P>0.4, Figure 4.4C, D). Similarly, fetal dye 2862 
uptake per gram of placenta correlated positively with litter size (P=0.005), and this 2863 
relationship was similar between sexes (P>0.9, Figure 4.4E, F). Placental labyrinth 2864 
(P=0.028) and junctional zone (P=0.017) areas correlated negatively with litter size, 2865 
regardless of fetal sex (interactions: all P>0.4) and did not differ between male and 2866 
female placentas (all P>0.2, Figures 4.4G, H and 4.4I, J, respectively). The ratio of 2867 
junctional to labyrinth zone areas was unaffected by litter size or sex (each P>0.7, 2868 
Figure 4.4K, L). Pulsatility and resistance indices for the umbilical artery did not change 2869 
with litter size (P>0.70 for both). Interestingly, the pulsatility index in the umbilical artery 2870 
was lower in female than male fetuses (P=0.043, Figure 4.5B), with a similar trend for 2871 
resistance index (P=0.054). Uterine artery resistance and pulsatility indices did not 2872 





Figure 4.4 Placental weight (n=298) decreased with increasing litter size and was 2876 
lower in females (B; open circles) compared to their male littermates (A; triangles), but 2877 
effects of litter size did not differ between sexes in mice. Placental efficiency 2878 
(fetal:placental weight; C, D; n=298) and perfusion (E, F; n=295) increased while both 2879 
junctional zone (G, H; n=108) and labyrinth zone (I, J; n=108) areas decreased with 2880 
litter size, irrespective of fetal sex. Ratio of junctional zone to labyrinth zone area (K, L; 2881 
n=108) was not affected by litter size or fetal sex. P values are derived from mixed 2882 
model analyses of individual placental data, and data for fetal fluorophore uptake per 2883 
gram placenta was log-transformed for analysis but non-transformed data is presented 2884 
for ease of interpretation. Symbols show data from individual (A, B, C, D, G, H, I, J, K 2885 
and L) or within sex litter averages (E and F) for male (grey triangles; A, C, E, G, I and 2886 
K) and female (open circles; B, D, F, H, J and L) fetuses. Regression lines show 2887 
correlations for combined sexes (black solid lines for significant correlations, grey solid 2888 
lines for non-significant correlations); where sex or sex*litter size interactions were 2889 
significant, correlations are shown separately for male (dotted line) and female (dashed 2890 




Figure 4.5 Umbilical artery resistance (A) and pulsatility (B) indices from male (grey 2895 
bars; n=66) and female (white bars; n=49) mouse fetuses at GD18.5. Data is 2896 
represented as mean ± SEM. P values are obtained from mixed model analysis of 2897 
individual umbilical artery measurements. 2898 
 2899 
4.6 Discussion  2900 
We have shown that litter size increases linearly as more embryos are transferred to 2901 
recipient female mice, at least up to a total of 24 embryos. Increasing litter size in this 2902 
model induces an IUGR phenotype, with thinner fetuses and evidence of brain sparing 2903 
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near term. Furthermore, we have shown for the first time that fetal responses to 2904 
increasing litter size are sex-specific, with constrained body weight, thinness and brain 2905 
sparing evident in male but not female fetuses as litter size increased. Male placentas 2906 
were heavier than female placentas, but the effects of increasing litter size on placental 2907 
weight and function did not differ between sexes. We have therefore developed a 2908 
model of variable fetal constraint independent of maternal confounders that affect 2909 
ovulation rate (including breed or size), which can now be utilised to evaluate 2910 
interventions. 2911 
In this present study, we report for the first time that increased litter size achieved by 2912 
increasing the number of embryos transferred in mice is associated with increasing 2913 
degree of fetal and placental weight reduction near term, independent of maternal 2914 
confounding factors. This adds to previous evidence that the litter size of mice could be 2915 
nearly doubled by transferring increasing number of zygotes into recipient mice, 2916 
although fetal and placental outcomes were not characterised in this study [763]. Also 2917 
consistent with our findings, Gluckman and colleagues reported a negative relationship 2918 
between litter size and fetal growth in mice [379]. In contrast to the present study, 2919 
authors transferred similar numbers of embryos into each dam, rather than generating 2920 
a range of litter size by differential transfer, and the range of litter size that they 2921 
observed may therefore potentially reflect maternal factors that alter implantation rate. 2922 
Consistent with the results of Johnson and co-authors, who transferred up to 25 2923 
embryos per dam [763], we did not see any evidence of increasing fetal deaths as we 2924 
transferred more embryos into each uterine horn. This implicates variable implantation 2925 
rate as the cause of variable litter sizes amongst dams that received the same number 2926 
of embryos within the present study. We predict that fetal deaths might increase if the 2927 
numbers of embryos were increased further to exceed the natural litter size range of 2928 
the recipient strain, resulting in more resorptions, but this requires further 2929 
experimentation.  2930 
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Our findings of restricted fetal growth with increasing litter size in mice are consistent 2931 
with observations in non-litter bearing species like humans and sheep, where the 2932 
occurrence of multiple gestations reduces fetal growth rate relative to that of singletons 2933 
[388-390]. The fetal growth trajectory of twins diverges from that of singletons around 8 2934 
weeks in humans, and a slower fetal growth in twins persists in late gestation in both 2935 
humans and sheep [388-391]. Similar to our results, fetal length in late gestation 2936 
decreased with increasing fetal number in rabbit pregnancies generated by embryo 2937 
transfer, although within a limited range of litter sizes that were all below those of 2938 
natural pregnancies (8-10 pups), since a maximum of 6 embryos were transferred to 2939 
each recipient [762]. Transfer of limited embryo numbers may explain the lack of 2940 
relationship between litter size and placental length in this rabbit study, since low litter 2941 
sizes would have resulted in limited competition for implantation area [771]. In contrast, 2942 
placental weight and litter size correlated negatively in embryo-transfer murine 2943 
pregnancies in both the present study and that of Gluckman and colleagues, where 2944 
larger ranges in litter size were generated [379].  Reduced birthweight in multiple 2945 
pregnancies is similarly accompanied by reduced placental weight in humans [772], 2946 
and sheep [387, 773].  2947 
A particularly interesting and novel finding of the present study was that the effect of an 2948 
increasing litter size on fetal growth was sex-specific. In smaller litters, male fetuses 2949 
weighed more than their female littermates in late gestation. It is now well established 2950 
in humans, sheep and rodents that the average weights of male fetuses are heavier 2951 
than females at an equivalent gestational age [36-39]. In the present study, as litter 2952 
size increased, the weight of male fetuses decreased while weights of female fetuses 2953 
remained stable. Other markers of asymmetric growth restriction, i.e. weight:crown-2954 
rump length (thinness) and fetal head width:abdominal circumference (brain sparing), 2955 
were also evident with increasing litter size in male fetuses but not their female 2956 
littermates. Two hypotheses may explain this sex-specific relationship. Firstly, growth 2957 
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strategies may differ between sexes, such that females maintain a reserve by not 2958 
growing to their full genetic capacity, even in smaller litters where competition for 2959 
nutrients is likely within a normal range. The maximal growth strategy in males may 2960 
mean their growth is limited by the available nutrient supply when either faced with an 2961 
external insult or limitations to supply. Although we did not observe sex differences in 2962 
fetal:placental weight ratio, which is considered a marker of placental efficiency [739], 2963 
we did not measure placental nutrient transport in our late gestation pregnancies, 2964 
which would provide a direct, stage-specific measure of placental function. Evaluating 2965 
these outcomes in male and female placentas under “normal” conditions and in 2966 
response to an in utero challenge might also provide useful insight. This hypothesis of 2967 
a female placental “reserve” capacity is also consistent with reports, that although 2968 
IUGR is more prevalent in females [48], males have higher rates of spontaneous 2969 
preterm birth and perinatal death if there is a perturbation in pregnancy [44, 49-2970 
53].Secondly, female fetuses (and placentas) may be better able to adapt to an in utero 2971 
environment where competition for nutrients is high, in order to maintain growth. This is 2972 
supported by human and animal studies which demonstrate that in response to 2973 
maternal undernutrition, female placentas undergo a higher number of changes in gene 2974 
expressions compared to male placentas [781]. These changes in placental gene 2975 
expression likely act as a buffer to protect the female against in utero perturbations and 2976 
possibly reduce the risk of adult onset of diseases [782]. 2977 
In addition to reduced fetal and placental weights, we found that increasing litter size in 2978 
mice induced asymmetric IUGR in a sex-specific manner. Male fetuses in larger litters 2979 
were thinner and showed evidence of brain sparing, regardless of sex. Skeletal growth, 2980 
measured as crown-rump length, was not reduced with increasing litter size in the 2981 
present study, suggesting that restriction in multi-fetal litters occurs later in gestation, 2982 
after the spine develops [783, 784]. Similarly, a previous study in humans reported no 2983 
differences in skeletal mass between asymmetrically growth restricted and AGA 2984 
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fetuses and neonates [783]. This could be in part due to compensatory mechanisms in 2985 
IUGR which favour the formation of mineralised bone, such as the downregulation of 2986 
Dickkopf-1 (DKK-1), a protein involved in the inhibition of osteoblast differentiation 2987 
[785]. However, the effects of IUGR become apparent during adulthood, as growth 2988 
restricted individuals are predisposed to reduced peak skeletal size and mineralisation 2989 
in later life [783]. In humans, asymmetrical IUGR is also common in twins [390, 391, 2990 
774] and characteristic of IUGR fetuses [775]. This growth pattern is often associated 2991 
with placental dysfunction, which impairs fetal oxygen and nutrient supply to the fetus, 2992 
especially during late gestation when absolute fetal growth is at its fastest [776]. In 2993 
these fetuses, cardiac output is redirected towards maintaining growth of vital organs 2994 
like the brain and heart, further impairing the growth of other organs including the liver 2995 
and kidneys, contributing to the disproportionate fetal growth [160]. Structural and 2996 
functional changes in the organs that accompany asymmetric growth restriction 2997 
underlie adverse health outcomes that emerge in adolescent and adult life, including 2998 
arterial hypertension and chronic renal failure [49, 777, 778]. Asymmetric fetal growth is 2999 
also observed in a number of animal models of IUGR, including maternal undernutrition 3000 
in rabbits, mid-late gestation uterine artery ligation in rats, and reduction of placental 3001 
exchange surface (through endometrial caruncle removal or repeated uteroplacental 3002 
embolisation) in sheep, which likewise restrict rapid fetal growth in late gestation [310, 3003 
331, 341, 780]. 3004 
An additional major finding of the present study was that sex-specific relationships 3005 
between litter size and fetal growth were not explained by sex-specific changes in 3006 
placental size or function. The overall increase in placental efficiency and function as 3007 
litter size increased in our study, is likely an adaptation aimed at optimising or 3008 
maintaining fetal growth in the face of limited nutrient supply [43, 725, 727, 786]. 3009 
Although in the present study placental size, efficiency and dye transfer (a marker of 3010 
perfusion) increased similarly in males and females, it is possible that transport of 3011 
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specific nutrients might be differentially affected and hence explain the sex-specific 3012 
constraint of fetal growth in large litters. Fetal susceptibility to adverse outcomes in a 3013 
number of pregnancy complications appears to be sex-dependent [53] and is largely 3014 
orchestrated by the placenta, which is genetically identical to the fetus [42]. A number 3015 
of different human and animal studies show that placentas may undergo sex-specific 3016 
adaptations to the same in utero stressors [787]. In males, placental adaptations 3017 
appear to promote continued growth while in females, these adaptations are focussed 3018 
on promoting placental development and fetal survival [54]. Although umbilical blood 3019 
flow measures were not related to litter size, we did see some evidence of greater 3020 
uteroplacental resistance in male compared to female fetuses near term. Although we 3021 
were unable to assess placental microstructure in the present study, it has been 3022 
suggested that greater vascular resistance at term in mice may reflect decreased 3023 
surface area of the maternal blood spaces in the labyrinth [788, 789]. Decreased area 3024 
for exchange might therefore contribute to IUGR in male fetuses. Variable structural 3025 
adaptations, including increased fetal villi length, placental surface density and volume 3026 
fraction have been reported in inter-breed embryo transfer pregnancies in horses, 3027 
which may partially compensate for decreased placental weight and enable partial 3028 
maintenance of fetal growth in the face of maternal constraint [759, 790]. However, 3029 
further studies will be needed to characterise placental adaptations to variable litter 3030 
size within our IUGR model. 3031 
An important strength of our study is analysis by fetal sex, shown here to be an 3032 
important determinant of fetal growth responses to variable maternal constraint. An 3033 
additional strength of our model is removal of maternal factors that occur in studies of 3034 
natural variation in litter size. In naturally-conceived pregnancies, the spontaneous 3035 
variation in litter size is dependent on maternal factors that determine ovulation rate, 3036 
which increases with maternal weight, parity and age [393-398]. Our approach of 3037 
transferring variable numbers of embryos removes factors that affect ovulation rate as 3038 
146 
confounders. This does, however, require the additional periconceptional exposures of 3039 
super-ovulation, embryo culture and vitrification, which may also affect fetal 3040 
development [791]. Whether these effects differ with litter size or between sexes is, 3041 
however, unknown.  3042 
In summary, we have generated a murine model of variable fetal constraint reflective of 3043 
multiple birth, with sex-specific fetal outcomes. Explanations for this must lie in the 3044 
genetic differences between males and females conferred by the sex chromosomes 3045 
and resultant hormonal differences. This model can be used to understand the 3046 
mechanisms associated with IUGR induced by multifetal pregnancies, as well as to test 3047 
possible interventions in future studies. Such analyses could compare the slope of the 3048 
relationships between fetal and placental outcomes and litter size, as used here to 3049 
compare sex-specific correlations, or could compare outcomes in larger and small 3050 
litters specifically. We suggest also, that potential therapies identified in the mouse 3051 
model should be validated in other models prior to translation in humans, given the 3052 
potential differences in fetal demand and placental signalling between twins or triplets 3053 
in humans compared to higher-order multiples in mice. The availability of animal 3054 
models of variable fetal constraint in which to evaluate interventions has substantial 3055 
clinical relevance, given the substantial increases in the risks of perinatal death and 3056 
lifelong adverse effects on health in IUGR infants and the current lack of effective 3057 
treatments or preventative therapies. 3058 
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Chapter 5 General discussion 3082 
IUGR increases risks of perinatal death >5-fold and has lifelong adverse effects on 3083 
health. There is currently no treatment to prevent or cure IUGR. Both GH, and its main 3084 
mediator, IGF1, play crucial roles in facilitating maternal adaptations to pregnancy and 3085 
their circulating concentrations change significantly during pregnancy in a number of 3086 
species. In normal, as well as IUGR pregnancies, exogenous maternal GH 3087 
administration in patterns replicating endogenous secretion has shown promising 3088 
effects for promoting fetal growth. Therefore, in this project, I tested a novel approach 3089 
to stimulate the mother’s own production of hormones that promote placental function 3090 
and fetal growth. This involved investigating whether diet-induced increases in acyl-3091 
ghrelin elevated circulating maternal GH levels and promoted fetal growth in normal 3092 
murine pregnancies (chapter 2). Novel tools to test the effectiveness of this potential 3093 
intervention were also established. We developed and validated a method to measure 3094 
placental uptake of nutrients via non-radioactive tracers (chapter 3). In the final 3095 
experiment, a murine model of IUGR was established with the use of embryo transfer 3096 
techniques. In this model, sex-specific impacts of varying degrees of litter size-induced 3097 
prenatal constraint on fetal and placental growth were (chapter 4).  3098 
 3099 
5.1 Summary of results  3100 
Contrary to our original hypotheses, dietary supplementation with octanoic acid at 3101 
concentrations used in this study did not elevate circulating acyl-ghrelin concentrations. 3102 
Furthermore, circulating maternal acyl-ghrelin concentrations did not increase during 3103 
pregnancy and were actually lower in mid-pregnant compared to non-pregnant mice, 3104 
suggesting that acyl ghrelin is unlikely to be the main mediator of elevated maternal GH 3105 
concentrations during murine pregnancy. However, the observed time-dependent 3106 
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increase in maternal circulating total ghrelin concentrations and gastric ghrelin 3107 
expression indicate possible involvement of ghrelin in the regulation of maternal energy 3108 
homeostasis and energy intake during pregnancy. 3109 
As per the second aim of this thesis (chapter 3), a method was developed to quantify 3110 
feto-placental uptake of the near-infrared IRDye 800CW 2-DG in late pregnant mice. 3111 
Fetal uptake of this fluorescent tracer correlated positively with markers of placental 3112 
blood flow and fetal growth, suggesting that it provides a proxy measure of placental 3113 
function. However, the signals obtained were similar whether the fluorophore was 3114 
conjugated with glucose or carboxylate (negative control), implying that the uptake 3115 
mechanism is not restricted to glucose transport. The methods established in this chapter 3116 
have the potential to provide a marker of overall placental perfusion and can be adapted 3117 
to test the suitability of other fluorescent tracers.  3118 
In chapter 4, in order to test potential interventions (aim 3), we established a murine 3119 
model of IUGR. In this model, embryo transfer-generated pregnancies were used to 3120 
create a range of litter sizes, and hence prenatal constraint, to replicate the intrauterine 3121 
environment in multi-fetal pregnancies. Interestingly, the relationship between litter size 3122 
and fetal weight was sex-specific, such that increasing litter size restricted the weight of 3123 
male, but not female, fetuses at term. This sex bias in fetal growth could not be explained 3124 
by the effects of increasing litter size on placental size and perfusion (measured using 3125 
methods established in chapter 3), suggesting that other sex-specific adaptations are 3126 
responsible for slowing the growth of female fetuses to increase their resilience to insults 3127 
later in gestation. Whether this sex-specific fetal growth response would lead to male-3128 
biased fetal deaths or growth restriction in males if litter size was increased further, 3129 
consistent with sex-specific effects of perinatal insults on human fetuses, remains to be 3130 
established. Additional work is also needed to define sex-specific impacts throughout 3131 
gestation and up to birth, since in other models, impacts of restricted placental function 3132 
[370] and maternal undernutrition [354] on fetal growth increase with gestational age. 3133 
150 
This chapter therefore describes a model of variable fetal constraint that is largely 3134 
independent of maternal confounding factors, reflective of growth restriction in multifetal 3135 
pregnancies, and with sex-specific fetal outcomes, which can be utilised to evaluate 3136 
potential interventions.  3137 
5.2 Strengths, limitations and future directions 3138 
Studies reported within this thesis are the first to describe a number of outcomes 3139 
related to the GH-ghrelin axis in murine pregnancy. These include quantifying 3140 
circulating abundance of total and acyl-ghrelin at several stages of the light-feeding 3141 
cycle and at multiple stages of the murine pregnancy. This is also the first report of 3142 
alterations in gastric ghrelin expression and placental ghrelin expression in murine 3143 
pregnancy. Ghrelin’s role in regulating food intake and energy homeostasis is well-3144 
established in non-pregnant humans and animals. Although not previously 3145 
investigated, the time-dependent alterations in ghrelin expression and secretion 3146 
observed in this study are suggestive of ghrelin’s potential role in the regulation of 3147 
maternal energy expenditure and food intake during pregnancy. Furthermore, as 3148 
ghrelin acts at the level of the hypothalamus and pituitary to increase GH secretion 3149 
[401, 446], measurements of ghrelin receptor expression and activation in these 3150 
regions would be a valuable addition to future work.  3151 
One of the main limitations we faced while assessing the effects of dietary 3152 
supplementation on changes in growth hormone profiles in non-pregnant and pregnant 3153 
mice was a small sample size. Suppression of GH secretion was observed in three 3154 
otherwise normal pregnant mice, likely due to the stress associated with the sampling 3155 
period [703]. Data from these animals could therefore not be included in our analysis, 3156 
reducing the sample size/power of the data and hence potentially masking any diet 3157 
effects on GH secretion. A further limitation is that while we were able to detect 3158 
octanoic acid in the feed using gas chromatography analysis, we were unable to detect 3159 
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octanoic acid in the circulation of the mice using this same method. It is possible that 3160 
this reflects the rapid metabolism of MCFAs [719, 792-794]. The lack of increase in 3161 
circulating acyl-ghrelin in response to octanoic acid supplementation in our studies 3162 
was, however, surprising given that published studies have reported increased 3163 
stomach acyl-ghrelin in male mice when fed similar concentrations of octanoic acid 3164 
[468]. Our work is the first to test this dietary approach in female mice. Given that 3165 
estrogen administration decreases the number of ghrelin-producing cells, gastric 3166 
ghrelin gene expression and plasma ghrelin levels in ovariectomised rats, further 3167 
investigation should be conducted to test whether steroid hormones can explain the 3168 
lack of changes in circulating acyl ghrelin observed in the female mice in our study in 3169 
response to dietary supplementation with octanoic acid. Furthermore, variable effects 3170 
of octanoic acid or octanoic-containing triglyceride supplementation on circulating acyl-3171 
ghrelin have been reported in recent literature. In a few studies, dietary octanoic acids 3172 
increased circulating acyl-ghrelin in humans, mice and cattle [687, 689, 721]. In other 3173 
studies, although dietary octanoic acid supplementation increased stomach acyl-ghrelin 3174 
in mice [468, 795] and stomach octanoic acid content in rats [719], an increase in 3175 
circulating acyl-ghrelin was not observed [468, 719, 795]. There are recent reports 3176 
show that dietary supplementation with medium chain triglycerides (MCT) increases 3177 
circulating acyl-ghrelin in humans and pigs of both sexes [688, 722], as well as growth 3178 
hormone in pigs [688] Thus, supplementation with MCTs is a potential strategy to 3179 
increase circulating maternal acyl-ghrelin concentrations. In the current study, the daily 3180 
consumption of food pellets by pair-housed mice allocated to the octanoic acid diet was 3181 
not noticeably different to those given the palmitic acid diet. However, in future, a more 3182 
precise quantification of the amount of food consumed by mice may also allow better 3183 
understanding of the relationship between dietary intake and circulating acyl and total 3184 
ghrelin concentrations at different time points.  3185 
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The study described in chapter 3 is the first to attempt to quantify placental and fetal 3186 
uptake of nutrients using a non-radiolabelled tracer, which can potentially be used to 3187 
measure placental function in response to an intervention. However, a major limitation 3188 
of this method was that, unlike radio-labelled tracers, the fluorophore tested in this 3189 
study did not reflect the specific uptake of glucose by placental and fetal tissues. The 3190 
lack of specificity of this probe for glucose transporters is likely influenced by the 3191 
molecular size of the probe (18-23Å), as it was probably too large to be taken up by the 3192 
GLUT1 transporters (with a predicted channel size of 15 Å × 8 Å) [743, 756]. Therefore, 3193 
in vitro cell assays will need to be performed in future studies in order to investigate the 3194 
specific mechanisms involved in the cellular uptake of the 2-DG dye, including in the 3195 
placenta. Confirmation that placental IRDye 800CW 2-DG transport is glucose 3196 
transporter-independent would also require inhibition studies using unlabelled glucose, 3197 
2-DG or antibodies to glucose transporters in placental cells or cell lines, similar to 3198 
previous studies in tumour cells [743]. 3199 
Finally, the IUGR model described in chapter 4 is the first to utilise embryo transfer 3200 
techniques to generate litter sizes larger than those observed in normal mouse litters 3201 
and to subsequently measure the effect of this prenatal constraint on fetal and 3202 
placental outcomes. A strength of this approach to generate variable litter size and 3203 
therefore constraint is the avoidance of maternal confounders that impact ovulation 3204 
rates and therefore variation in spontaneous litter size. Our protocol does however 3205 
require exposure of embryos to hormones required for maternal super-ovulation (in 3206 
donors), as well as to embryo culture. Although these exposures happen in all 3207 
pregnancies, it is possible that these induce some of the adverse effects observed in 3208 
human IVF pregnancies, including lower birthweight and differential methylation of 3209 
genes critical for growth [791]. This approach does not confound our analyses of litter 3210 
size effects, since all embryos are similarly exposed. However, we suggest that future 3211 
intervention studies should include a naturally-mated control group as a reference. The 3212 
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findings of this study also highlighted the importance for animal models of IUGR to 3213 
analyse data by fetal sex. Our observation of sex-specific fetal growth responses to the 3214 
constraint due to increasing litter size is consistent with evidence from humans, 3215 
indicating that males and females can respond differently to the same intrauterine 3216 
environment [44, 49-53], which in turn may influence the nature of clinical interventions. 3217 
For example, following antenatal betamethasone treatment, the activity of the 3218 
glucocorticoid metabolising enzyme 11 beta-hydroxysteroid dehydrogenase-2 3219 
(11βHSD2), is increased in female but not male placentas [796], whereas higher 3220 
placental production of radical oxygen species is observed in preterm males compared 3221 
to preterm females [797]. The resultant increase in cortisol inactivation in females may 3222 
protect them from the glucocorticoid-induced effects of reactive oxygen species 3223 
production [796, 797], which are associated with conditions like bronchopulmonary 3224 
dysplasia that are more prevalent in premature males than in females [798, 799]. The 3225 
mechanisms contributing to the sex-bias in fetal growth in our model are not clear but 3226 
are likely to involve sex-specific morphological and functional placental adaptations. 3227 
This study is the first to investigate sex-specific placental uptake of a non-3228 
metabolisable glucose analogue in growth restricted rodent pregnancies. However, no 3229 
study to date has investigated whether placental uptake of other nutrients, including 3230 
amino acids, differ between male and female growth restricted mouse fetuses. 3231 
Although not possible in the current study, it would also be ideal to also measure 3232 
changes in placental microstructure, as suboptimal placental structural development 3233 
may explain our observations of greater uteroplacental resistance in male fetuses at 3234 
term and, possibly, the greater growth restriction in this group. It would also be 3235 
interesting to further develop this model and test whether the growth restricted mice 3236 
undergo postnatal catch-up growth in a sex-specific manner and whether this is 3237 
accompanied by glucose intolerance and impaired β-cell function, similar to that 3238 
observed in human IUGR. However, it must be highlighted that models using litter-3239 
bearing species may not accurately reflect the environment of human multifetal 3240 
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pregnancies, as the greater number of placentas in mice may mean more signals to the 3241 
mother that induce maternal adaptations to pregnancy, although these were not 3242 
measured in this study. 3243 
 3244 
5.3 Conclusion 3245 
Although the dietary approach tested in this project did not provide the expected 3246 
results, evidence from recent literature suggests that dietary supplementation with 3247 
triglycerides or even direct acyl-ghrelin administration may be more successful at 3248 
promoting maternal circulating acyl-ghrelin and GH levels, and possibly fetal growth. 3249 
Through our IUGR model, we have established the means to test the effectiveness of 3250 
these, and other interventions or treatments aimed at promoting fetal growth, including 3251 
maternal melatonin administration and local VEGF overexpression in uterine arteries, 3252 
especially in the setting of IUGR in multifetal pregnancies. Effects of interventions on 3253 
fetal and placental responses to constraint can be assessed by comparing the slope of 3254 
the relationship between litter size and fetal growth in treated and untreated dams. 3255 
Additionally, we have also developed methods to measure the impact of these 3256 
interventions on placental function, a crucial determinant of fetal growth. This method 3257 
can be applied by other researchers who wish to measure the placental uptake of a 3258 
broad range of nutrients, but are not able to use radioactive tracers, for example due to 3259 
facility constraints. Together, the work described in this thesis provides the means to 3260 
test and develop potential interventions aimed at promoting placental function and fetal 3261 
growth in the setting of prenatal constraint and hence, minimise the risk of perinatal 3262 
death and lifelong effects on health in IUGR infants.   3263 
 3264 
  3265 
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